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Abstract 
 
Breast cancer is the most frequently diagnosed form of cancer and leading cause of 
cancer death in females. Current screening techniques, such as mammography, are 
inadequate. Screening reduces the number of deaths caused by breast cancer but 
also results in a large number of women with non-life threatening forms of the 
disease being treated unnecessarily. Initial screening can produce a false positive 
result, which causes much anxiety. Clearly there is a need for a more reliable 
approach; nuclear magnetic resonance (NMR)-based metabolomics has been used 
to this end. Plasma and urine from female patients with breast cancer or abnormal 
but non-cancerous breast state and extracts from tumour and adjacent normal 
tissue obtained from those afflicted with the disease have been analysed in an 
attempt to elucidate a biomarker of disease presence or tumour grade. 
 
Aqueous extracts of tumour tissue compared to healthy adjacent (normal) tissue 
revealed increased levels of lactate, alanine, creatine, glutamate, glutamine, 
glycerophosphocholine (GPC), glycerophospholipids, phosphocholine (PCho), 
taurine, uridine-5'-diphosphate-N-acetylgalactosamine, (UDP-GaINAc) and uridine-
5'-diphosphate-N-acetylglucosamine (UDP-GlcNAc) and decreased levels of glucose. 
Increased lactate and decreased glucose is in agreement with the Warburg effect 
whereby cancer cells predominantly produce energy by a high rate of glycolysis. 
Analysis of lipophilic extracts did not reveal a difference between tumour and 
normal samples. Metabolite levels did not indicate the tumour grade using either 
type of extracts. 
 
Singly, plasma and urine data did not identify changing metabolite levels with breast 
cancer or tumour grade but correlations between the two biofluids were 
established using statistical heterospectroscopy (SHY). Through an unidentified 
species it was implied that a negative correlation existed between glycerol and 
certain lipids for patients with breast cancer.  
 
These studies have provided useful insights into tumour metabolism and 
correlations of metabolites in different biofluids.  
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Chapter 1. Introduction 
 
1.1 Breast Cancer 
 
1.1.1 Prevalence of Breast Cancer  
 
Breast cancer caused over 450,000 deaths and was diagnosed in 1.38 million 
women worldwide in the latest year for which statistics are available (2008).(1) This 
equates to 14% of total female cancer deaths and 23% of female diagnoses.(1) Using 
the GLOBOCAN 2008 online tool(2) it is estimated that the number of cases 
diagnosed in the United Kingdom (UK) will rise from 46,000 in 2008 to 56,000 in 
2030 with deaths rising by 25% from 12,000 to 15,000. Worldwide figures are 
estimated to continue to rise with nearly 750,000 deaths and 2.15 million cases 
diagnosed in 2030.  
 
Although recorded incidences increased in many Westernised countries in the last 
two decades of the previous millennium, a substantial proportion will have been 
due to increased use of testing, e.g. through national breast screening programmes  
to identify the presence of breast cancer, therefore it is difficult to estimate any 
potential change to the prevalence in the population.(1) However, incidence and 
mortality rates continue to rise in many developing countries where screening is 
less common. In these areas the rises have been mainly attributed to changes in 
reproductive patterns, physical inactivity and obesity.(1)  
 
Increased risk of developing breast cancer has been linked with alcohol 
consumption and reproductive factors that include a long menstrual history, 
nulliparity, recent use of postmenopausal hormone therapy or oral contraceptives 
and late age at first birth.(1) Incidence rates have started to decrease in some 
Westernised countries in the last few years, largely due to reduced use of 
postmenopausal hormone therapy, but breast cancer remains a leading cause of 
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death in women.(1) This is why further studies and alternative strategies are needed 
in the attempt to reduce the burden of this worldwide disease.  
 
1.1.2 Types and Grade of Breast Cancer  
 
Breast cancer, like other cancers, occurs due to mutations in genes, which results in 
alterations to cell proliferation, differentiation and death.(3) Certain proteins 
enhance resistance of cells to apoptosis (programmed cell death).(4) Breast cancer is 
a multifaceted disease comprised of distinct biological subtypes that have varied 
clinical, pathologic and molecular features with different prognostic and 
therapeutic implications.(5) The female reproductive hormones, oestrogen and 
progesterone, have a major impact on breast cancer and control postnatal 
mammary gland development.(6)  
 
Oestrogen receptors (ER) are cellular proteins that bind to the most biologically 
active type of oestrogen. DNA synthesis, cell division and production of proteins 
including progesterone receptor (PR) proteins result from the interaction.(7) 
Approximately 50-80% of breast cancers have elevated levels of ER(7-9) compared to 
normal breasts for which the level is extremely low.(7) Presence of oestrogen or 
progesterone receptors results in breast cancers being referred to as ER+ or PR+, 
respectively, and similarly ER- and PR- refers to non-presence.  
 
Breast cancers that are hormone receptor positive (either ER or PR, or both) are 
receptive to treatment by endocrine (anti-oestrogen) therapies. For post-
menopausal women anti-aromatase agents can be administered that inhibit the 
final step of oestrogen synthesis(10) whereas tamoxifen, the primary treatment in 
pre-menopausal women, binds to the ER.(11) The anti-aromatase agents are 
designed to inactivate the aromatase in postmenopausal women, which is different 
to the prevalent aromatase form in premenopausal women.(9) Approximately 50-
60% of the patients with ER+ tumours respond to endocrine therapy.(11) 
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Approximately 25-30% of breast cancer cases have increased levels of human 
epidermal growth factor receptor 2 (HER2) and the associated protein is present in 
abnormally high levels in the cells.(11) Breast cancers that overexpress HER2 are 
more aggressive forms of the disease(12) but trastuzumab (Herceptin) binds to HER2 
and causes an increase in a protein that halts cell proliferation.(13) Triple negative 
breast cancers (ER-, PR- and HER2-) do not respond to endocrine therapy or other 
available targeted agents and chemotherapy is the current treatment therapy.(14) 
This form of the disease is associated with a lower survival rate.(14) The status of the 
three receptors can be combined to indicate breast cancer sub-types (luminal A, 
luminal B and basal like).(5) 
 
Presence of the different receptors can be determined by immunohistochemistry 
staining of biopsy samples whereby specific antibodies bind to the proteins of 
interest.(15,16) A common method of assessing this is the Allred method(17) where 
separate scores are assigned to the overall stain intensity (0-3) and the percentage 
of tissue that is stained (0-5). A score of 0 indicates undoubtedly that the receptor is 
not present whereas undoubtedly positive status is assigned for scores of 8 with 
scores in between indicating moderate positivity.(18,19) 
 
Breast cancer can be of an invasive or non-invasive nature. Ductal carcinoma is the 
most common invasive form and lobular carcinoma is the second most common 
form accounting for 4-15% of all breast cancers.(20) In addition to invasive breast 
cancer, non-invasive forms can manifest with ductal carcinoma in situ (DCIS) the 
most common type.(21) Lobular carcinoma in situ (LCIS) is less common than DCIS, 
approximate ratio 1:8, and is viewed as a marker of an increased risk of invasive 
breast cancer rather than as a true precursor lesion.(21) Carcinoma in situ can also 
be present for invasive breast cancers. 
 
A grade can be calculated for invasive breast cancers to indicate the severity. Rakha 
et al.(22) state that histologic grading is now part of the minimum data set for breast 
cancer pathology reporting produced by the United Kingdom Royal College of 
Pathologists and European Commission and is endorsed by the World Health 
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Organisation (WHO) and the College of American Pathologists. The Nottingham 
grading system(23) is the most widely used histologic grading system.(22) Pathologists 
assess three morphological criteria (tubule formation, mitotic count and nuclear 
polymorphism), which are given a score 1-3, with 3 the most severe, and combined 
to give an overall score. Scores of 3-5, 6-7 and 8-9 are classified as grade 1 (low), 2 
(intermediate) and 3 (high), respectively.(24) 
 
1.1.3 Cell Proliferation 
 
Given sufficient oxygen, most normal cells metabolise glucose via glycolysis into 
pyruvate that is oxidised in the tricarboxylic acid (TCA) cycle and CO2 is produced. 
Reduced nicotinamide adenine dinucleotide (NADH, the reduced form of NAD+) is 
produced in the TCA cycle, which fuels oxidative phosphorylation that allows 
adenosine 5´-triphosphate (ATP) production. NAD+ results from oxidative 
phosphorylation and 36 ATP molecules are produced per glucose molecule via this 
process.(25,26) When there is insufficient oxygen, i.e. under anaerobic conditions, 
oxidative phosphorylation is not possible so ATP and NAD+ cannot be produced. For 
glycolysis to proceed NAD+ is required and can only be formed when pyruvate is 
converted to lactate, hence the large amount of lactate that is produced through 
anaerobic glycolysis. This produces two molecules of ATP per glucose molecule.(25,26) 
Cancer cells convert most glucose to lactate with only approximately 5% of pyruvate 
directed to the TCA cycle resulting in four molecules of ATP per glucose molecule.(25) 
As first observed by Warburg, aerobic glycolysis proceeds irrespective of whether 
oxygen is present and is often referred to as the Warburg effect.(25,26) 
 
Through mutation, metabolism of cancer cells is adapted to facilitate the uptake and 
incorporation of nutrients, e.g. nucleotides, amino acids and lipids, for growth and 
to produce a new cell. Aerobic glycolysis, fatty acid synthesis and mitochondrial 
glutamine metabolism are three pathways that are considered important in cell 
growth and proliferation.(27) Glucose, glutamine and lipids are in near-constant 
supply and, unlike differentiated cells, there is no need to optimise ATP production 
for maximum energy so aerobic glycolysis can proceed. Lactate, produced by 
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aerobic glycolysis, may provide carbon, which is one of the components required for 
rapid cell division and some specialised non-proliferating cells could recycle lactate 
to glucose.(25) Glucose provides most of the carbon required for fatty acid synthesis, 
being initially converted to acetyl-coenzyme A (acetyl-CoA), which is used to 
produce citrate in the TCA cycle. Citrate production is also upheld by glutamine 
because it too supplies carbon.(28) Acetyl-CoA is also required for the biosynthesis of 
amino acids.(29) Changes to nutrient levels or usage pathways might predispose 
those with certain metabolic diseases, such as obesity, to cancer. Further knowledge 
of regulation of proliferating cell metabolism is required along with how tumour and 
whole body metabolisms interact to enhance cancer prevention strategies.(25) 
 
This can be investigated by metabolomic studies that incorporate nuclear magnetic 
resonance (NMR) spectroscopy as the data acquisition method and multivariate 
analysis (MVA) to determine whether differences exist in the levels of metabolites. 
Determination of whether metabolic changes occur due to presence of breast 
cancer or severity of the tumour will aid the information and knowledge required to 
reduce the effects of this disease.  
 
1.2  Nuclear Magnetic Resonance Spectroscopy 
  
1.2.1 Relaxation 
 
When a static magnetic field, B0, is applied individual nuclei precess around the z-
axis at the Larmor frequency. Together, the vectors for individual nuclei are 
represented by the bulk magnetisation vector, which at equilibrium is aligned along 
the +z-axis.(30,31) When a perpendicular radio frequency (RF) pulse is applied the 
populations of the nuclear spins are perturbed and the bulk magnetisation is 
rotated towards the x-y plane (Figure 1.1). If the RF pulse is applied for the correct 
length of time the bulk magnetisation will transfer 90o because the populations of α 
and β states of the nuclei that make up the bulk magnetisation are equalised.(30,31) 
Following this, through the process of relaxation, the system returns to equilibrium 
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through the spins dissipating energy, thus allowing the population of the energy 
levels to return to the Boltzmann distribution.(30,31) 
 
The dissipation of energy from the spins to the surrounding lattice and subsequent 
return of the bulk magnetisation to its equilibrium state on the +z-axis is known as 
longitudinal, or spin lattice, relaxation.(30,31) Oscillating magnetic fields at the correct 
Larmor frequency are not abundant but are required for excited nuclei to off-load 
energy and regain the ground state. The fields are produced by the motion of 
neighbouring nuclei and the process of regaining the ground state in this way is 
characterised by a time constant, T1, the longitudinal relaxation time. Despite 
longitudinal relaxation being an enthalpic process, the change in temperature is 
undetectable.(30,31) 
 
Figure 1.1 The effect of a 90o RF pulse on bulk magnetisation and recovery to the 
z-axis. 
 
By assuming equilibrium is approached exponentially, the recovery can be explained 
by the Bloch equation: 
d  
d 
 = 
     
 1
 (1.1) 
where   is the equilibrium magnetisation,   is the +z-magnetisation and T1 is the 
longitudinal relaxation time constant (though often referred to as the longitudinal 
relaxation time).(30,31) By solving the above equation, the longitudinal magnetisation 
at time t can be obtained: 
   =  (1 e
    1) (1.2) 
To achieve essentially full recovery of    magnetisation a period of 5T1 is 
required.(30,31) 
z
yx z
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z
yx
z
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After a 90o RF pulse the net magnetisation is in the x-y plane. If all spins experienced 
an identical magnetic field, precession at the same frequency would occur. 
However, each spin will experience a different magnetic field due to inhomogeneity 
of B0 and local magnetic fields that result from intramolecular and intermolecular 
interactions.(30,31) If the sample is thought to be divided into extremely small regions 
whereby the field was uniform within each region, magnetisation vectors would 
precess at the same frequency within each region. These regions are known as 
isochromats.(30,31) Spins subject to greater magnetic fields will precess more quickly 
and move ahead of the bulk magnetisation vector whilst those spins experiencing 
weaker magnetic fields will precess more slowly and fall behind the bulk 
magnetisation vector.(30,31) Given sufficient time, this fanning-out of the isochromats 
will lead to zero net magnetisation in the x-y plane (Figure 1.2). This type of 
relaxation is known as transverse, or spin-spin, relaxation, which follows an 
exponential decay represented by the time constant   
 : 
 
  
  
 
  
  
 
       
 (1.3) 
where local magnetic fields are characterised by T2, inhomogeneity of the static field 
is represented by         and the combined relaxation time characterised by   
 .(31)  
 
Figure 1.2 Individual spins fanning out causing zero net magnetisation in the x-y 
plane (transverse relaxation).(31) 
 
Transverse relaxation is an entropic process because energy is transferred between 
spins rather than lost to the surrounding lattice as per longitudinal relaxation.(30,31) 
Due to longitudinal relaxation being the return of the magnetisation to equilibrium 
and the +z-axis it follows that T2 ≤ T1.
(31) 
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Vectors that dephase quickly have short   
  times and because of large frequency 
differences between the vectors, broad lineshapes result as characterised by large 
half-height linewidths of the peaks for that molecule.(31) Long   
  times correspond 
to slow transverse relaxation and result in narrower lineshapes. High molecular 
weight (HMW) molecules typically display broader resonances than low molecular 
weight (LMW) molecules but these can be attenuated and resonances from LMW 
molecules are observed when using a spin-echo pulse sequence, such as the Carr-
Purcell-Meiboom-Gill (CPMG) sequence.(30,31) 
 
1.2.1.1 Spin-Echo Pulse Sequence 
 
The spin-echo pulse sequence was devised to measure an accurate T2 value of a 
sample by attempting to remove the effect of field inhomogeneity.(30,31) The initial 
90ox pulse pushes the magnetisation onto the y-axis where the inhomogeneity of 
the static field causes isochromats to fan-out during the time period τ. A second 
pulse rotates all the isochromats by 180o around the x-axis to the -y-axis allowing 
the differently precessing isochromats to catch up with the average position, hence 
the magnetisation vector is refocussed(30,31) (Figure 1.3). 
 
Figure 1.3 Magnetisation during the spin-echo pulse sequence and refocusing of 
the magnetic vectors dephased by field inhomogeneity.(31) 
 
The signal decays during the initial τ delay then increases to an echo peak after the 
180o pulse and second τ delay, therefore reappearing after 2τ. The second part of 
the echo is an exponential decay and is Fourier transformed to produce a spectrum 
z
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z
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which is free from field inhomogeneity effects.(30,31) However, local magnetic fields 
that result from intramolecular and intermolecular interactions cause diffusion of 
molecules which is not refocussed so the intensity of the echo is reduced by T2.
(30,31). 
The Carr-Purcell pulse sequence uses many repetitions of short τ delays and 180ox 
pulses resulting in the intensity of the echoes decaying according to T2 but because 
of the large number of echoes, the loss between each echo due to diffusion is small. 
However, if the 90ox pulse is incorrectly measured, any errors will become 
cumulative when the 180ox pulses are performed leading to less transverse 
magnetisation and resulting in a less intense signal.(30,31) The CPMG pulse sequence 
overcomes this problem by replacing the rotation of the magnetisation around the 
x-axis with that around the y-axis, thus making the error in the pulse width non-
cumulative and refocussing of the vectors is achieved after an even number of 180oy 
pulses(30,31) (Figure 1.4). 
 
Figure 1.4 The operation of the Carr-Purcell-Meiboom-Gill (CPMG) sequence in the 
presence of pulse imperfections.(31) 
 
NMR spectra can be edited according to molecular size due to differences in T2 
values(30). Large molecules have short T2 times so during the τ delay the isochromats 
will have fanned-out. Small molecules, which have long T2 times, will only be 
starting to fan-out so will be refocussed after the 180oy pulse and detected due to 
being in the x-y-plane(30,31). The intensities of signals from large molecules in 
biofluids, such as proteins and lipoproteins will thus be reduced (Figure 1.5). 
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Figure 1.5 500 MHz 1H-NMR spectrum of human blood plasma. Abbreviations: 3-
HB, 3-hydroxybutyrate; acac, acetoacetate; glu, glutamate; gp, glycoprotein; ile, 
isoleucine; LDL, low density lipoprotein; met, methionine; TSP, 3-
trimethylsilylpropionic acid; val, valine; VLDL, very low density lipoprotein. Citrate 
is present because it is the anti-coagulant used in the collection tubes. 
 
1.3 Metabolomics 
 
Living organisms will attempt to maintain homeostasis when confronted with 
disruptive influences such as disease and drug treatment. These stimuli can cause 
alterations to body conditions that disrupt the normal ratio of metabolites and 
hence alter the biofluid and tissue profile.(32) The normal ratio will be specific to 
each individual because of influences such as genetic composition, diet and lifestyle 
but loss of homeostasis is the initial step towards disease.(33)  
2010_01_20_plasma_ctrl_143D
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Metabonomics was first described in 1999 by Nicholson et al.(34) but the underlying 
principles and methodologies were developed in the previous decades whilst the 
concept of studying perturbations to body fluids is centuries old. Over 3,000 years 
ago disease indication was recognised as being linked to changes in biological 
fluids(33,35) but in the 1940s analytical techniques were used to profile these fluids to 
investigate normality. During the 1970s and early 1980s pattern recognition started 
to be used in conjunction with analytical techniques, mainly gas chromatography 
(GC) and GC coupled with mass spectrometry (gas chromatography-mass 
spectrometry; GC-MS).(33) Nuclear magnetic resonance (NMR) spectroscopy 
developed greatly during the latter decade and became used for profiling studies.(36) 
The basis of metabolomics had been established. 
 
The total collection of endogenous metabolites is known as the metabolome and is 
estimated there are at least 3,000 metabolites in the human metabolome.(37,38) 
Metabolomics and metabonomics are both terms for metabolome studies and in 
these approaches sampling provides a picture or snapshot of the metabolome at 
one point in time.(39) Each has a unique definition but the methods and approaches 
of metabonomics and metabolomics are now highly convergent(32,40) with the 
distinctions being mainly historical.(41) Metabolomics has been defined as the 
comprehensive analysis of all measurable metabolites in the metabolome under a 
given set of conditions, and metabonomics as the measurement of the fingerprint of 
biochemical perturbations caused by disease, drugs and toxins.(42) Metabolomics 
will be used throughout the report because this term is becoming more commonly 
used amongst research groups.  
 
Proteins, transcripts and genes can be measured in a similar way to metabolites by 
the corresponding ‘omics’ (Figure 1.6). The number of metabolites is less than the 
number of any of the three aforementioned body species but metabolite levels can 
be regarded as the final downstream product of biological systems,(43,44) thus 
providing an excellent insight into the result of influences on the system. 
Additionally, running costs associated with metabolome studies are generally lower  
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than with the other ‘omics’.(42) The most common biological samples used for 
metabolomics studies are urine and blood plasma and serum, with cell and tissue 
extracts, tissue, seminal fluid, amniotic fluid, cerebrospinal fluid, saliva, synovial 
fluid, digestive fluids, blister and cyst fluids, lung aspirates and dialysis fluids also 
having been used.(32,45,46) The more common biological samples are simple to collect 
and easily provide sufficient volume for analysis.  
 
 
 Figure 1.6 The relationship between the 'omics' technologies. DNA, 
deoxyribonucleic acid; RNA, ribonucleic acid. 
 
Despite providing a picture of the metabolome at a unique time, observation over a 
period can be achieved and monitored through dynamic modelling when samples 
from multiple time points are obtained. Every subject acts as their own control thus 
potentially negating the effect of every individual having a different ‘standard’ 
metabolite profile allowing variation around the individual ‘standard’ profile to be 
the focus of the investigation.(47) However, it is often not clinically feasible to obtain 
suitable samples at multiple time points; progression of slow forming disease is 
more difficult to monitor than for shorter term reactions, for example, in the days 
following organ transplantation when the patient is already in a clinical 
environment and it is likely there will be less variables in sample handling. 
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Metabolomics
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Today, the two main platforms used for data acquisition in metabolomics are NMR 
spectroscopy and mass spectrometry (MS). The latter is combined with a 
chromatography method, commonly liquid chromatography (LC) or GC, to enable 
separation of the metabolites prior to detection. Advantages and disadvantages are 
associated with each technique so combination of the two provides the most 
thorough analysis.(48) NMR spectroscopy was the more commonly employed 
method in early metabolomics studies(34,49) and has the advantages of high 
reproducibility,(50) requiring little preparation for most sample media(51) and being 
sample non-destructive. MS has emerged as an alternative method that is now 
frequently applied due to its high sensitivity(45,52) but metabolite identification is not 
as universal as for NMR spectroscopy(52,53) and different separation techniques are 
required for different substance classes.(53,54) 
 
Sensitivity is the largest weakness of NMR spectroscopy, which presents itself as a 
detection limit in the micromolar range for common biological samples rather than 
the nanomolar range as for MS.(37) A large water peak, which can obscure 
metabolites, is always observed for biofluids. Additionally, low molecular weight 
metabolites can be obscured by the broad envelope of high molecular weight 
resonances of proteins. Both problems can be substantially addressed by 
application of appropriate pulse sequences.(55,56)  
 
1.4 Data Analysis 
 
1.4.1 Chemometrics 
 
Chemometrics uses statistics and pattern recognition techniques to analyse 
chemical numerical data.(57) Metabolomics studies generate many more measured 
variables than there are observables (samples). Large and complex data tables are 
constructed that are not able to be summarised by traditional statistics.(58) The first 
stage of chemometrics involves data reduction through the process of spectral 
binning, whereby the spectrum is divided into smaller regions (bins) that can be 
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compared to the bins of other spectra in the data set. For each bin, the area under 
the spectral curve is calculated and analysed using multivariate analysis (MVA).(57) 
Additional data processing steps, namely normalisation and scaling, are required 
between data reduction and MVA to ensure fair comparisons are made.(42,59) An 
overview of the process is given in Figure 1.7. 
 
Figure 1.7 Overview of chemometrics. For this example, plasma is analysed using 
NMR spectroscopy followed by binning as the data reduction method. Principal 
components analysis (PCA) is the MVA employed producing a scores plot and a 
loadings plot, which can be used to identify trends across the set of patients. 
 
1.4.1.1 Data Reduction 
 
Data reduction is commonly achieved through binning (alternatively known as 
bucketing), whereby the spectrum is divided into smaller regions (bins) and the 
area under the signals contained in each bin is obtained. The binning step is 
required to take account of small changes in chemical shifts between samples so 
the same signals can be compared across spectra. 
 
Traditionally, spectra have been divided into equal sized bins of 0.04 parts per 
million (ppm).(59,60) This bin width has been used for urine because it is a good 
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Reduction: 
Binning
MVA: PCA
Loadings Plot
Sample 
Analysis: 
NMR
Scores Plot
9 8 7 6 5 4 3 2 1 0
Chemical Shift ppm
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
-0.20
-0.10
-0.00
0.10
0.20
0.30
-0.10 0.00 0.10 0.20 0.30 0.40 0.50
p
[2
]
p[1]
0.8
0.82
0.84
0.86
0.880.9
0.92
0.94
0.96
0.98
1
1.02
1.04
1.061.08
1.1 1.121.141.16
1.18
1.2
1.22
1.24
1.26
1.281.3
1.32
1.34
1.36
1.381.4. 21.44
1.46
1.48
.5
1.521.5461.581 61.621.6466
1. 871.721.7471.8.824
1.86
1.81.91.92 .91.96 8
2
2.02
2.04
2.1
2.12
2.14
2.16
2.12.27 2.292.31
2.33 2.35
2.37
2.39
2.41
2.43
2.45
2.47
2.492.5 .53
2.55
2 72 591
.63.65
2.67
. 9
2.717
2.752.77. 9
2.81
2.83
2 85
2
2.91
392 79
3.01
3.03
3.05.07
3.09
3.
3. 33. 5.17
3.56
3.58 3.6.623.64 3.66
3.93
3.95
3.97
3.99
4 014 3
4.0 4.07
4.09 4.114.13
4 5. 74 1924.234.25
.2
4.293. 3 .34. 7
5.39
5.415.43
5.45
5. 7
5.495.55.535 55.57.595.61
5.63
65.676
5.71
5.735.7
5.79
5.81.83.8
5
5. 991
.9395.979.016.036.06 07. 96 16.13
6.6 213. 5.. .33.3944.555 9.6577 15
6.87
6.89
6 91
936 9. 0
7. 3
57.
7 09
7 177.7.21
7.23
7
. 7
7
7.31
.33
3
7 3
9
7.47.43 4
4
577
7.6
.7 .71
. 3 .75
.77
7.8
857.9
7.97. 98
8
8
8 09
8 11
38 325
8.278. 388 35
78 34
SIMCA-P+ 12.0.1 - 2012-09-21 11:10:37 (UTC+0) 
-0.6
-0.4
-0.2
-0.0
0.2
0.4
0.6
-0.8 -0.6 -0.4 -0.2 -0.0 0.2 0.4 0.6 0.8
t[
2
]
t[1]
SIMCA-P+ 12.0.1 - 2012-09-21 11:39:47 (UTC+0) 
9 8 7 6 5 4 3 2 1 0
Chemical Shift ppm
15 
 
compromise between resolution and variation in peak positions.(59) All binning 
techniques result in a loss of information due to a reduction in the number of data 
points,(60) typically a 64k point NMR spectrum is reduced to about 250 variables 
(bins).(61) Chemical shift variations can occur for some components, such as citrate, 
due to ionic strength and pH variation across the samples.(59) Variations in these 
factors are less prevalent for other biofluids, such as plasma and serum, but the 
same bin width has been conventionally adopted in many studies involving these 
biofluids. Some of the first studies using MVA in metabolomics used different bin 
widths: 0.02 ppm(62) and 0.05 ppm.(63) 
 
Smaller bin widths have been used in more recent studies(64,65) because many 
computational limitations on data matrix sizes have been removed allowing 
improved interpretation of the results by relating peaks with individual metabolites 
but the size is limited by peak shifting. Variable bin widths have also been 
employed(66) whereby the bin width is allowed to vary by a percentage each way of 
a set bin width. This is aimed at accounting for small chemical shift differences by 
identifying local minima in the spectra and integrating a peak in a single bin(67) 
which extends the advantages, and reduces the disadvantages, of smaller bin 
widths. However, even with adoption of variable smaller bin widths, a bin can 
integrate two peaks that change oppositely with, for example, disease versus 
control, resulting in the bin amplitude not accurately reflecting the intensity of 
either peak.(68) 
 
An alternative method to binning to ensure comparable signals are analysed is to 
perform peak alignment on the original data thus eliminating the need for data 
reduction and allowing full resolution data to be used in further analysis. However, 
the magnitude of misalignments within a single sample may not be consistent so 
that a simple alignment correction across an entire spectrum cannot be performed 
and more sophisticated computer programmes are required.(68)  
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1.4.1.2 Normalisation 
 
For each spectrum the reduced data are then normalised to accommodate 
concentration changes that are unrelated to the factors being investigated. Urinary 
volume, and hence concentration, can vary greatly whereas greater regulation 
occurs for plasma and serum.(59) Compared to normal urine, drug effects and food 
deprivation can cause dilution by a factor of ten.(69) Two common normalisation 
procedures are constant sum and constant peak.(59) The former is the most widely 
employed and consists of normalising to the sum of the integrals of the whole 
spectrum. For every spectrum, each bin integral is divided by the total spectrum 
integral and the sum of all the new integrals is set to one.(70) For all biofluids and 
tissues, the influence of down-regulation of certain metabolites should be 
approximately balanced by the up-regulation of other metabolites.(69) However, this 
approximation can fail if certain metabolite levels change vastly, for example, the 
addition of a metabolite from a drug or ethanol from alcohol consumption, will 
cause the other peaks in the spectrum to appear to decrease because the total 
spectrum integral is greater.(59) Constant peak normalisation requires an internal 
reference compound or metabolite to be present at constant concentration. 
Proteins, including albumin, in plasma and serum for example, can bind non-
specifically to certain reference compounds, such as 3-trimethylsilylpropionic acid 
(TSP),(71) and cause variation in their free concentration. An alternative method is 
probabilistic quotient normalisation(69) whereby for each test spectrum every bin 
integral is divided by the integral of the same bin of a reference spectrum. The 
median of these quotients is calculated and the test spectrum bin integrals are 
divided by this value.(69) This negates potential problems with highly variable 
metabolites that would affect constant sum normalisation. 
 
1.4.1.3 Scaling 
 
Scaling regulates the relative importance of each variable. Metabolites that have a 
high concentration are not always the most informative, and without scaling, 
variation in lower concentration metabolites would be overlooked.(72) Scaling occurs 
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for the integral of one bin (variable) throughout the whole sample series and occurs 
for the variables of the whole spectrum.(59) 
 
All of the subsequent scaling methods firstly centre the data to allow differences in 
concentrations to occur around zero instead of around the concentration mean of 
the metabolite resulting in the only variation being that between the samples 
without any offset.(73) Mean-centred scaling is just the centring process; each value 
of the normalised variable has the mean of the whole sample set for that 
normalised variable subtracted from it. Without further scaling, high concentration 
metabolites have a large contribution.(74) Unit variance (UV) incorporates standard 
deviation into the scaling factor, whereby centred data is divided by the standard 
deviation of the whole sample set for that normalised variable.(72,73) All variables 
have equal potential to influence the model but as a result the noise level of spectra 
can contribute strongly.(74,75) The effect of pareto scaling is between that of mean 
centring and UV, whereby the influence of changes in the concentration of highly 
abundant metabolites is decreased more than that for changes in less abundant 
metabolites.(72) For pareto scaling, centred data is divided by the square root of the 
standard deviation of the whole sample set for that normalised variable.(73) Pareto 
scaling has been recommended for metabolomics data(58) but is still prone to 
enhancing the contribution of variables with high variance(76) and alternatives have 
been used.(77) 
 
1.4.1.4 Multivariate Analysis 
 
MVA considers several related variables simultaneously.(78) Multivariate statistical 
methods can be unsupervised, such as principal components analysis (PCA), or 
supervised, as for partial least squares-discriminant analysis (PLS-DA). Unsupervised 
models are used to reveal grouping within a data set without previous knowledge of 
the class of individual samples, whereas supervised models use class information to 
produce models, from which the class of further samples can be predicted.(79-81) All 
multivariate statistical analyses were performed using SIMCA-P+ software. 
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1.4.1.4.1 PCA 
 
PCA represents a multivariate data table (matrix X) as a low dimensional plane, 
providing an overview of the data that may reveal groups of observations, trends 
and outliers.(58) For n observations (samples), a k dimensional space is constructed 
where k is the number of variables (bins). Each sample is represented by one point. 
When k is greater than three, k dimensional space is difficult to visualise but 
mathematically this space is similar to two dimensional (2D) or three dimensional 
(3D) space.(82,83) The first principal component (PC) is fitted, which is the linear 
combination of the original variables, and is the line describing maximum variation 
between the points in multidimensional space, hence the line best accounts for the 
shape of the swarm of points. Following, the second PC, which accounts for the next 
largest amount of variation, is fitted, then the third PC and so on.(58) Each PC is 
orthogonal to all of the other PCs, thus ensuring there is no correlation between the 
PCs.(84) Most of the information in the original matrix is contained in the first few 
PCs, with two to five PCs usually providing a representative overview.(85,86) Any two 
PCs can form a plane, onto which each observation can be projected (Figure 1.8a). A 
scores value, which is the coordinate value along the PC line, can now be obtained 
and the resultant scores plot created.(86) 
 
Each PC is related to the original variables through the angles between the two, α1, 
α2 etc. where the number relates to the variable. The loadings vector of each PC, p, 
is related to all of the cos α values between that PC and the original variables (Figure 
1.8b).  
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a)  b)  
Figure 1.8: Overview of PCA. a) Formation of PCs and b) obtaining loadings 
vectors.  
 
If a PC lines up with a variable axis the angle will be small so the loading will be close 
to 1 indicating strong influence, whereas if the PC is nearly orthogonal to the 
variable axis the loading will be close to 0, hence showing little influence. A PC 
opposite to a variable axis provides a loading close to -1 and hence a strong negative 
influence(86). However, ∑p2 = 1 so the greater number of variables, the lower 
numerically the loadings will be.(78) Loading values can be plotted, in an analogous 
manner to the score values, to create a loadings plot. Directions in the scores plot 
correspond to directions in the loadings plot which allows the bins to be identified 
that cause separation between samples.(58) 
 
The original matrix, X, is summarised by T (scores) and P (loadings) matrices: 
              (1.4) 
where E is the residual matrix and contains the unexplained variation.(83) The better 
the model, the smaller the value of E.(86) 
 
Scores plots allow strong outliers to be visualised and can be detected by Hotelling’s 
T2, a multivariate generalisation of Student’s t-distribution, by defining a ‘normal’ 
area and providing a tolerance region for the data in a two-dimensional scores 
plot.(86) Distance to model (DModX) is the detection tool used to establish moderate 
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outliers. Geometrically, the greater the distance of projection of the sample onto 
the plane of PCs, the greater the DModX value and the less well represented the 
point is by the two PCs.(86) 
 
The number of PCs in a model is determined by the difference in degree of fit and 
predictive ability. The goodness of fit of a model is estimated by R2, the explained 
variation: 
R2 = 1 – (RSS/SSX) (1.5) 
where RSS (residual sum of squares) = ∑(observed – fitted)2 and SSX (sum of squares 
of X) represents the total variation in the X matrix after mean centring. When the 
number of components increases, R2 tends towards 1 but at this value everything is 
predicted, including noise, which is detrimental.(86) 
 
The predictive power of a model is summarised by Q2X, which uses cross validation, 
whereby the data is divided into groups and the model is generated devoid of one 
group. This model is used to predict the deleted group resulting in a partial 
predictive residual sum of squares (PRESS) value and this process is repeated many 
times to ensure the process occurs for each group.(81) SIMCA-P+ software (Umetrics, 
Umeå, Sweden) uses seven groups as default, though this can cause problems if 
samples are collected over a week because the samples could be dependent on the 
day, thus non-random groups would be removed. Removal of groups occurs firstly 
in rows (observations) followed by columns (variables).(86) The partial PRESS values 
are summed(81): 
PRESS = ∑(observed – predicted)2 (1.6) 
and 
Q2 = 1 – (PRESS/SSX) (1.7) 
If a new PC enhances the predictive power compared to the previous PRESS value 
then the new component is retained.(86) 
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Certain aspects of the usefulness of the model are associated with R2X and Q2X.(81) 
R2X is always greater than Q2X, high R2X and Q2X values are desirable, the difference 
between R2X and Q2X should not exceed 0.3 and R2X greater than 0.5 is considered 
good and typical for metabolomics.(86) 
 
1.4.1.4.2 PLS-DA 
 
Unlike PCA, partial least squares-discriminant analysis (PLS-DA) incorporates class 
identifiers to improve separation. In addition to an X-matrix of observations 
(samples) and variables (bins) that is used in PCA, a Y-matrix is created that consists 
of the same observations but the variables are classes,(86) e.g. case or control. 
Observations belonging to the class have a value of one and observations not 
belonging to the class have a value of zero. Geometrically, for both matrices a 
swarm of points is present in k-dimensional space where k is the number of 
variables. For the first component a line is added in each swarm that best describes 
the swarm, in a similar way to PCA, but additionally provides good correlation 
between the points along the line. This maximises the separation between 
observations belonging to the different classes.(86) Projecting the observations onto 
the first component gives scores values: t1 and u1 for X and Y swarms, respectively. 
The contribution of each variable in the X-matrix to the modelling of Y is reflected 
by the weights (w*1) with c1 the equivalent for the Y-variables. Further components 
can be added to improve the approximation of, and correlation between, X and Y. 
Similarly to PCA, the quality of PLS-DA models can be initially determined by R2 and 
Q2 values, however, the explained and predicted variation of the Y-data (R2Y and 
Q2Y, respectively) are considered; the values indicative of good models for PCA 
models also apply to PLS-DA models.(86) The number of components is assessed in a 
similar manner to PCA.(86)  
 
The aim of PLS-DA models is to predict class membership of samples from the X-
data. Models can overfit the data resulting in separation between classes arising by 
chance. Ideally, to validate the model new samples that were not used in the 
building of the model would have their class predicted. This is not always possible 
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for smaller sample sets. Alternative cross-validation methods are available.(79,87) Two 
methods have been employed in this study for prediction of samples depending on 
the sample numbers available. One-third of samples can be randomly excluded from 
generation of a new model and the classes of these samples predicted. This is 
repeated twice so that all samples have been predicted. For smaller groups ‘leave 
one out’ cross-validation builds a model devoid of one sample, the class of which is 
then predicted. This is repeated until every sample has been predicted thus the 
number of PLS-DA models generated for validation is the same as the number of 
samples. Permutation testing is an alternative validation method.(79,86) 
 
Permutation testing plots show how models in which the Y-variables, i.e. group 
classification, are randomised compare to the original PLS-DA model.(86) The y-axis 
represents the R2Y and Q2Y values of all models and the x-axis the correlation 
coefficients between permuted and original variables. For the original model the 
correlation coefficient is 1.0. Plots showing 5% or more of permuted models that 
outperform the original model, i.e. higher R2Y and Q2Y values, indicate a poorly 
modelled response.(88) Regression lines indicate model validity with the intercept 
values being interpretable as measures of ‘background’ R2Y and Q2Y values 
obtained by fit to random data. An R2Y intercept value below 0.3-0.4 and a Q2Y 
intercept value less than 0.05 indicate a valid model.(86)  
 
1.4.2 Univariate Statistics 
 
1.4.2.1 Hypothesis Testing and p-values 
 
A hypothesis is a statement about the population that is to be tested on a sample of 
the population. The null hypothesis, H0, is that there is no difference between, for 
example, two groups of the population and the alternative hypothesis, H1, is that 
there is a difference. Within the context of this work, the following is an example: 
H0: The mean integral for a peak in the NMR spectrum is the same for patients that 
do not have breast cancer as for those who do. 
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H1: The mean integral for a peak in the NMR spectrum is not the same for patients 
that do not have breast cancer as for those who do. 
 
Two tailed statistical analysis is required because H1 states that the integral is not 
the same meaning it can be either greater or less than the integral in H0. If there 
was reason to suspect the integral would be higher one-tailed analysis could be 
performed and the same would apply if there was evidence for a lower integral 
value.  
 
Acceptance or rejection of H0 is determined by a p-value that is related to the 
means of the two groups.(89) The p-value is the probability of obtaining a test value 
at least as extreme as the one that was observed, assuming that H0 was true.
(89) For 
example, if a p-value of 0.001 was obtained after comparing the means of two 
groups and H0 was true, the likelihood of the occurrence of this observation by 
chance is once every thousand times. There is strong evidence to suggest that there 
is a difference between the means of the two groups and H0 should be rejected. In 
this case the p-value is statistically significant.(89) 
 
The significance level determines whether a p-value is statistically significant. 
Conventionally, the 5% significance level is used so if a p-value is ≤0.05 it is 
concluded to be statistically significant and that there is a difference between the 
means of the two groups resulting in the rejection of H0.
(89) The significance level is 
important because it governs the number and type of errors. A type I error (false 
positive) occurs if H0 is rejected when it is true; the likelihood of this event is the 
same as the significance level whereas a type II error (false negative) results when 
H0 is accepted but it is false.
(89) 
 
1.4.2.2 Tests for Statistical Significance 
 
The appropriate test to be used for generation of a p-value depends on the 
distribution of the data in the two groups that are compared. The Shapiro-Wilk test 
ascertains whether the values of an integral are normally distributed within each 
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group.(90) For this test, H0 is that the data distribution is normal and H1 is that the 
data distribution is not normal.  
 
If both groups are independent and the data distribution is normal the Student’s t-
test can be used. This test assumes that the variances of the two groups are equal, 
which can be determined by the Levene’s test.(89) If the variances are not equal the 
Welch-Aspin test(91) is used, a modification of the Student’s t-test. If the data 
distribution is non-normal for one or both independent groups the Mann-Whitney U 
test can be applied. The median integral values are compared instead of the means 
to reduce the effect of any outliers that cause the data to be non-normally 
distributed.(89) 
 
If the two groups are not independent, for example if the groups are measurements 
of the same patients taken from two different sample types or at two different time 
points, the paired samples t-test is required for normally distributed data and the 
Wilcoxon Matched-Pair test for non-normally distributed data.(89) 
 
1.4.2.3 Tests for Multiple Comparisons 
 
For multiple testing, false positives can be a problem. For 200 tests (approximately 
the traditional number of bins used in metabolomics) it would be expected, 
implementing a significance level of 0.05, for 10 false positives to occur hence why 
univariate analysis alone cannot be employed. 
 
To overcome the multiple testing problem the assignment of an adjusted p-value to 
each test is performed. The Bonferroni method is a conservative technique where 
the p-values are multiplied by the number of tests and compared to the significance 
level chosen for the single test. While the number of false positives is reduced so is 
the number of true discoveries.(92) A more powerful alternative is the false 
discovery rate (FDR) correction. The FDR is the expected proportion of false positive 
findings among all rejected hypotheses, for example an FDR of 0.05 means that 
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among all findings called significant, 5% of these are truly not significant on 
average.(93) 
 
1.4.3 Alternative Pattern Recognition Methods 
 
Statistical total correlation spectroscopy (STOCSY) enhances peak identification and 
highlights metabolites linked via metabolic pathways by identifying correlations 
between peaks.(94) Correlation coefficients are calculated between the columns of 
two matrices, X1 (n x v1) and X2 (n x v2), where n is the number of samples and v1 
and v2 are the number of variables in each matrix. A correlation matrix C (v1 x v2) is 
produced with the strongest correlations indicating the peaks emanate from the 
same metabolite and weaker positive or negative correlations indicative of linked 
metabolites.(94) If X1 = X2 the 2D map will have the correlation of the peak with itself 
along the diagonal.(94)  
 
Statistical heterospectroscopy (SHY) is an extension of STOCSY whereby X2 could be 
generated from analysis of the same samples but using a different analytical 
platform,(95) a different sample type, e.g. X1 = plasma data and X2 = urine data, from 
the same subjects(96) or, again from the subjects, a sample at a different time point. 
 
1.4.4 Standardisation and Knowledge Sharing 
 
The metabolomics community has aimed to increase knowledge sharing, both in 
terms of methodology and results, and standardisation of reporting to allow 
successful data dissemination.(97) This has been attempted in part through the 
establishment of the Metabolomics Standards Initiative (MSI) and its subsequent 
publications regarding reporting requirements.(98-100) Some groups have freely 
allowed access to data, either raw or pre-processed, upon publication.(50) Although 
research groups will have individual optimum experimental procedures, protocol 
publications(51,101,102) have allowed wider distribution of successful procedures. 
Online databases such as Human Metabolome Database(103) (HMDB), Kyoto 
Encyclopedia of Genes and Genomes (KEGG) and Golm Metabolome Database 
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(GMD) provide access to detailed information about metabolites including 
compound identification by way of mass and NMR spectra libraries and metabolite 
pathways. 
 
1.5 Gas Chromatography 
 
A liquid sample is vaporised and injected into the head of chromatographic column. 
The mobile phase, an inert gas, flows through the column transporting the 
analytes.(104) Each analyte leaves the column at a different time depending on how 
strongly it is adsorbed by the stationary phase, which is a liquid fixed on the surface 
of an inert solid. The partition ratio for an analyte is equal to the ratio of its 
concentration in the stationary phase to its concentration in the mobile phase.(104) 
Therefore, a greater partition ratio results in a longer retention time. 
 
Flame ionisation detectors (FIDs) are extensively used in GC to produce 
chromatograms.(105) Upon exiting the column, the analytes pass through the nearby 
hydrogen/air flame and pyrolysis occurs (thermochemical decomposition of organic 
substances at elevated temperatures without the participation of oxygen). Electrons 
are formed that generates a current between the electrodes positioned by the 
flame, which is translated as a peak in the chromatogram.(105) 
 
1.6 Previous NMR and Metabolomics Studies of Breast Cancer 
 
Tissue has been examined by NMR spectroscopy for over 40 years.(106,107) Initial 
investigation of breast cancer tissue concentrated on T1 and T2 relaxation times for 
the water resonance and an increase in the values for tumour tissue compared to 
healthy tissue was attributed to an increase in the motional freedom of the water 
molecules of tumours.(106,108) Similar analyses followed for serum(109) including an 
extension into lipid spectra investigation.(110) Some of the first studies that 
investigated metabolite levels in serum, plasma and urine were performed by 
Nicholson et al.(111,112) A number of breast cancer metabolomic and metabolic 
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profiling studies have since been performed on biofluids, tissue and tissue extracts 
with most having used pattern recognition in the analyses, whereas some studies 
have targeted specific metabolites for investigation. Breast cancer research 
employing NMR spectroscopy pre-dates the time of a definition for 
metabolomics(34) but has been included because similar concepts and practices 
have been used. A summary of metabolomic and NMR studies of breast cancer are 
shown in Table 1.1. Reviews concerning metabolomics and cancer,(113-118) or 
specifically breast cancer,(119,120) have been published. 
 
Serum from breast cancer patients and healthy controls, with pre-, post- or 
unknown menopausal status, has been compared by the complementary techniques 
of NMR spectroscopy and MS.(121) PCA analysis of NMR data indicated lactate and 
lipids were by far the most influential species and increased levels were present in 
case samples. Conversely, taurine and glucose levels were decreased for this group. 
However, no scaling was performed so this may be the reason why the larger signals 
appear dominant. MS data was not separated by PCA or PLS-DA.  
 
Further studies have analysed serum in relation to breast cancer. For patients who 
had breast cancer, metabolic changes in serum due to recurrence (of cancer in any 
location) were analysed(122) and Oakman et al.(123) investigated differences between 
patients with early stage breast cancer and metastatic disease. Keun et al.(124) 
examined weight gain during chemotherapy because it had been suggested to lead 
to increased chance of cancer recurrence and possibly decreased overall survival. 
Lactate increased in patients who experienced weight gain (classed as >1.5 kilogram 
[kg]). For the same group valine, tyrosine and alanine mean levels increased but the 
difference was not statistically significant. A follow-on study by the group included 
investigation into response to treatment for breast cancer.(125) Concentrations of 12 
metabolites previously identified(124) were calculated but individually none showed 
statistically significant associations with treatment outcome. However, jointly high 
glucose, high lactate and low alanine were associated with progression of disease 
despite treatment.(125)  
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No metabolomics studies utilising plasma for breast cancer investigation could be 
identified but one of the earliest NMR spectroscopy studies of plasma samples was 
conducted by Fossel et al.(126) A statistically significantly narrower average line 
width of the methyl and methylene resonances of lipids in patients with breast 
cancer than in healthy subjects or those with benign tumours was concluded. Lipid 
alterations associated with breast cancer may change the distribution of the 
lipoprotein density profile and thereby influence the line shape of those signals. 
However, using similar methods, Holmberg disagreed with the findings stating it 
was not possible to distinguish between the three groups(127) though lipoprotein 
subclass profiling of plasma or serum has been used extensively in a commercial 
capacity to assess risk of cardiovascular disease (CVD).(128) The data handling, 
however, has been criticised with regards to its accuracy in resolving the lipoprotein 
signal into individual component signals.(129) 
 
Slupsky et al.(130) analysed urine from breast cancer patients and healthy controls 
and 26 metabolites were found to decrease in case samples. The lower metabolite 
levels have been attributed to the Warburg effect and consequential results. With 
less circulating glucose and amino acids, due to use by tumours, an overall decrease 
in energy metabolism elsewhere in the body has been postulated. This could reduce 
other pathways, such as the urea cycle, resulting in lower urea and creatine 
concentrations and possibly affect the gut microbial metabolism and population.(130) 
 
Menopausal status was shown to be a confounding factor in MS analysis of urine 
from patients with breast, ovarian or cervical cancer.(131) For patients with breast 
cancer compared to controls the concentrations of 5-hydroxymethyl-2-
deoxyuridine and 8-hydroxy-2-deoxyguanosine were significantly increased. 5α-
tetrahydrocorticosterone, as identified by PLS-DA loadings, was not significantly 
increased.(131) 
 
Pattern recognition was first incorporated into analysis of breast cancer tissue 
extracts by Gribbestad et al.(132) Tumour and healthy breast tissue was obtained 
from 16 patients and perchloric acid extraction performed, allowing polar 
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metabolites to be analysed. PCA showed a decrease of glucose and an increase of 
choline-containing compounds in tumour tissue.(132) Earlier studies using the same 
extraction procedure concluded a higher content of lactate, taurine, succinate, 
phosphocholine (PCho), uridine-5'-diphosphate-N-acetylglucosamine (UDP-GlcNAc) 
and uridine-5'-diphosphate-N-acetylgalactosamine (UDP-GaINAc) and lower levels 
of glucose, myo-inositol and phosphocreatine (PCr) were present in tumour tissue 
as compared to healthy tissue.(133,134) However, no statistical significance was 
attributed to the findings.  
 
Beckonert et al.(135) have analysed extracts from breast tissue. The extracts were 
prepared using a dual extraction method, which afforded both polar and lipophilic 
extracts. Myo-inositol and glucose were reduced in tumour tissue whereas taurine 
was increased. Alanine, PCho, phosphoethanolamine (PE) and UDP-hexoses (UDP-
GlcNAc and UDP-GaINAc) were raised in tumour tissue compared to adjacent 
healthy tissue. Following histopathological analysis of control tissue, samples that 
predominantly consisted of fatty tissue had a high content of myo-inositol whereas 
glucose was raised in samples with high amounts of connective tissue. The aromatic 
region of the spectra contained many more signals, such as UDP-hexoses, in tumour 
tissue compared with control; it was concluded water-soluble metabolites are more 
prevalent in tumour tissue,(135) in agreement with Sitter et al.(136) Lipid metabolites, 
including phosphatidylethanolamine (PDE), unsaturated and saturated fatty acids, 
cholesterol esters and sphingomyelin-like substances, showed concentration 
increases in grade 3 samples.(135) The statistical significance of the findings was not 
discussed. 
 
One of the first studies to use magic angle spinning (MAS) NMR spectroscopy to 
analyse intact breast tissue was performed by Cheng et al.(137) MVA was not used 
but levels of previously reported metabolites associated with breast cancer, stated 
within the paper, were investigated using a small number of samples. The relative 
intensity of phosphocholine to choline and lactate to choline increased for both 
intermediate grade 2-3 and grade 3 samples compared to grade 2 samples. The 
relative intensities involving lactate were statistically significant. 
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Further MAS NMR spectroscopy studies have been performed but using biopsy 
tissue samples.(138-140) Tumour and healthy tissue samples were separated using 
PCA but separation based on grade did not result.(138) Identification of metabolites 
was not the primary aim of the study instead class prediction of samples was the 
main interest. Using PLS-DA, Giskeodegard et al.(139) revealed separation between 
ER+/ER- samples and partial separation between PR+/PR- samples but not 
according to lymph node status. Loadings plots revealed ER- samples were 
associated with increased glycine, glycerophosphocholine (GPC), choline and 
alanine and decreased ascorbate, creatine, taurine and PCho whereas PR- samples 
have increased ascorbate, creatine, PCho, lactate, glycine, GPC, choline and alanine.  
 
For biopsy tissue samples, Li et al.(140) identified that taurine and choline-containing 
compounds were elevated in cancer tumours compared to non-cancerous samples 
(benign tumours and the adjacent normal tissue) as was the signal tentatively 
assigned to aspartate. The PR status (PR+ or PR-) of 10 from 13 (77%) cancer 
patients was correctly predicted by ‘leave one out’ cross-validation of an 
orthogonal partial least squares-discriminant analysis (OPLS-DA) model. Axillary 
lymph node status could not be predicted when all samples were used.(140)  
 
In a different study, PCA analysis of data acquired by MAS NMR spectroscopy from 
surgically removed tissue did not clearly differentiate between patients with good 
and poor prognosis of breast cancer.(136) PC 5, accounting for 6% of the variation, 
provided a tendency to separate samples based on prognosis with glycine raised in 
poor prognosis patients. Patients who subsequently died within five years of 
sample donation were separated in PC 2 (18% of the variation) from those who 
were not deceased, irrespective of cancer recurrence status. High levels of taurine, 
GPC and creatine combined with low levels of glycine and PCho characterised those 
patients alive five years after surgery.(136) However, the statistical significance of the 
change in these metabolite levels was not discussed. Ratios of metabolite levels 
were significantly different between patients with good and poor prognosis and 
also between those who either had recurring cancer or were deceased and 
“healthy” patients five years after sample donation. Taurine glycine, GPC/glycine 
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and total cholines/glycine ratios were higher for good prognosis patients and 
taurine glycine and GPC glycine ratios were raised in “healthy” patients. However, 
although mentioned, a correction for multiple tests was not employed for the 45 
ratio tests. Collagen in connective tissue contains much glycine and 
histopathological analysis revealed a higher percentage of connective tissue was 
present in samples from poor prognosis patients.(136) This was forwarded as the 
reason for higher glycine levels in poor prognosis patients and the subsequent 
lower ratios that contained glycine. 
 
The composition of tissue samples can vary with different percentages of cancer 
cells, connective tissue, fat and healthy tissue.(136) The level of metabolites could 
depend on the composition of the tissue.(136) Concentrations of glycine, GPC, PCho 
and total choline were positively correlated with the cancer cell fraction whereas 
taurine, GPC, choline and total choline-containing metabolites correlated negatively 
with fat tissue as did PCho with connective tissue. Myo-inositol positively correlated 
with healthy tissue. The authors concluded the majority of signals from low 
molecular weight metabolites arise from cancer cells whilst fat tissue contains 
minor amounts of these metabolites.(136) Further evidence of metabolite level 
variation with type of tissue was presented by Sitter et al.(141) The fraction of cancer 
cells within the tissue sample separated patients with grade 2 cancer using PCA: a 
higher percentage of cancer cells correlated with greater glycine and PCho levels. 
The cancer cell percentage varied from 0% to over 50%. The same study also 
indicated GPC/PCho and GPC/choline ratios were higher and the PCho/choline ratio 
lower in adjacent healthy tissue samples.(141)  
 
 
 
Table 1.1 Summary of metabolomics and NMR studies of breast cancer. 
Author [Year] Bio-
material 
Study Data 
acquisition 
method 
Region of 
variation 
identification 
method 
Changing metabolites 
Gu et al.(121) [2011] Serum BC (27) v. control (30) NMR PCA (+) lac, lip 
(-) tau, glc 
Asiago et al.(122) [2010] Serum Cancer recurrence (20) v. non-recurrence 
(36) 
NMR From own 
previous study 
(-) for, his, pro, cho 
Asiago et al.(122) [2010] Serum Cancer recurrence (20) v. non-recurrence 
(36) 
GCxGC/MS From own 
previous study 
(-) glu, NAG, 3-H-2-MBA 
Oakman et al.(123) 
[2011] 
Serum Metastatic BC (51) v. early BC (44) NMR OPLS (+) phe, glc, pro, lys, NAC 
(-) lip 
Keun et al.(124) [2009] Serum Weight gain (10) v. no weight gain (11) NMR PLS-DA (+) lac 
Stebbing et al.(125) 
[2012] 
Serum With treatment: Progression of BC v. no 
progression  
NMR From previous 
study(124) 
Combined (+) glc, lac and (-) ala  
Slupsky et al.(130) 
[2010] 
Urine BC (38) v. control (62) NMR Specialist 
software 
(-) cre, ace, suc, lac, pyr, for, ile, sur, 
leu, asn, ure, glc, eta, dim, 4-HPA, 
crt, ala, hip, ura, val, aco, unknowns 
at 4.34, 3.94, 3.35, 2.60, 2.36 ppm 
 
 
3
2
 
 
 
Table 1.1 Continued.  
Author [Year] Bio-
material 
Study Data 
acquisition 
method 
Region of 
variation 
identification 
method 
Changing metabolites 
Woo et al.(131) [2009] Urine BC (10) v. control (22) GC-MS PLS-DA (+) 5-HM-2-DOU, 8-H-2-DOG 
Gribbestad et al.(132) 
[1999] 
Tissue 
extracts 
Tumour (16) v. healthy (16) NMR PCA (+) cho compounds 
(-) glc 
Gribbestad et al.(133) 
[1993] 
Tissue 
extracts 
Tumour (11) v. healthy (7) NMR No PR (+) lac, suc, PCho  
(-) glc, ino  
Gribbestad et al.(134) 
[1994] 
Tissue 
extracts 
Tumour (unstated) v. healthy (unstated) NMR No PR (+) lac, suc, tau, PCho  
(-) glc, myo, PCr  
Beckonert et al.(135) 
[2003] 
Tissue 
extracts 
Tumour (49) v. healthy (39) NMR SOM   (-) myo, glc 
Beckonert et al.(135) 
[2003] 
Tissue 
extracts 
Grade severity (3 = 22, 2= 26, 0 = 41) NMR SOM (+) ala, UDP-H, PCho, PE 
Grade 3 (+) PDE, UFA, SFA, CE, sph 
Sitter et al.(136) [2010] Tissue Good prognosis (13) v. poor prognosis (16) NMR PCA See text 
Cheng et al.(137) [1998] Tissue Grade 3 or intermediate grade 2-3 v. grade 
2 
NMR From previous 
study 
(+) PCho/cho, lac/cho 
Bathen et al.(138) 
[2007] 
Biopsy 
tissue 
Tumour (91) v. healthy (48) NMR PCA Not identified 
 
3
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Table 1.1 Continued. 
Author [Year] Bio-
material 
Study Data 
acquisition 
method 
Region of 
variation 
identification 
method 
Changing metabolites 
Bathen et al.(138) 
[2007] 
Biopsy 
tissue 
Grade 3 (36) v. grade 2 (37) NMR PLS - no 
separation 
 
Bathen et al.(138) 
[2007] 
Biopsy 
tissue  
Positive hormone (ER+/PR+, ER+/PR- and 
ER-/PR+) (63) v. negative hormone        
(ER-/PR-) (13) 
NMR PLS (+) tau, GPC  
(-) lac, gly, scy, PCho 
Bathen et al.(138) 
[2007] 
Biopsy 
tissue 
Positive lymph node (36) v. negative 
lymph mode (43) 
NMR PLS (+) gly, PCho 
(-) tau 
Giskeodegard et al.(139) 
[2010] 
Biopsy 
tissue 
ER- (39) v. ER+ (118) NMR PLS-DA (+) gly, GPC, cho, ala  
(-) asc, cre, tau, PCho 
Giskeodegard et al.(139) 
[2010] 
Biopsy 
tissue 
PR- (60) v. PR+ (94) NMR PLS-DA (+) asc, lac, gly, GPC, PCho, cho, cre 
ala 
Giskeodegard et al.(139) 
[2010] 
Biopsy 
tissue 
Positive lymph node (64) v. negative 
lymph mode (88) 
NMR PLS-DA - no 
separation 
 
Li et al.(140) [2011] Biopsy 
tissue 
Cancer (13) v. non-cancer (18) NMR OPLS-DA (+) tau, cho, asp 
Sitter et al.(141) [2006] Tissue Tumour (85) v. healthy (18) NMR PCA Not identified 
 
3
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Table 1.1 Continued. 
For the study column, values in parenthesis are sample numbers. 3-H-2-MBA, 3-hydroxy-2-methyl-butanoic acid; 4-HPA, 4-hydroxyphenylacetate; 5-HM-2-
DOU, 5-hydroxymethyl-2-deoxyuridine; 8-H-2-DOG, 8-hydroxy-2-deoxyguanosine ace, acetate; aco, trans-aconitate; ala, alanine; asc, ascorbate; asn, 
asparagine; asp, aspartate; CE, cholesterol esters; cho, choline; cre, creatine; crt, creatinine; dim, dimethylamine; eta, ethanolamine; for, formate; glc, 
glucose; glu, glutamic acid; gly, glycine; GPC, glycerophosphocholine; hip, hippurate; his, histidine; ile, isoleucine; ino, inositol; lac, lactate; leu, leucine; lip, 
lipids; lys, lysine; myo, myo-inositol; NAC, N-acetyl-cysteine; NAG, N-acetyl-glycine; PCho, phosphocholine; PCr, phosphocreatine; PDE, 
phosphatidylethanolamine; PE, phosphoethanolamine; phe, phenylalanine; pro, proline; pyr, pyroglutamate; scy, scyllo-inositol; SOM, self organising map; 
SFA, saturated fatty acids; sph, sphingomyelin-like substances; suc, succinate; sur, sucrose; tau, taurine; UDP-H, uridine-5'-diphosphate-hexose; UFA, 
unsaturated fatty acids; ura, uracil; ure, urea; and val, valine. 
3
5
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Chapter 2. NMR Analysis of Plasma 
 
The following chapter will describe 1H-NMR spectroscopy analysis of plasma 
obtained from 69 women using CPMG pulse sequence. Of these, 40 had been 
collected from women who had been diagnosed as having a form of breast cancer, 
either non-invasive or an invasive tumour with associated grade 1, 2 or 3. For the 
purposes of classification in this study, cases of DCIS without invasive cancer were 
assigned as grade 0. Samples were available from 29 patients from a control group 
that had been referred to the clinic because of abnormal breast state, which was 
subsequently diagnosed as non-cancerous abnormalities such as cysts or fat 
necrosis. 
 
MVA of the spectra was performed as described in Section 1.4.1.4 in an attempt to 
identify possible biomarkers of breast cancer occurrence and progression. A number 
of confounding factors were considered either singly or in combination during the 
data interrogation. 
 
Samples were prepared as per Section 8.1.1.1 and data collected as detailed in 
Section 8.2.1. Section 8.3 applies for spectral processing with dark regions listed in 
Table 8.3. Constant sum normalisation was used. MVA was performed as detailed in 
Section 8.4. 
 
2.1 Results 
 
Each plasma sample was given a four digit identifier during collection. The first digit 
establishes breast cancer status: 1 for control and 2 for case. The subsequent digits 
indicate the order in which the samples were collected. Sample 2041 is an 
exception; it was saved prior to cancer status being confirmed and was initially 
given a control identifier but upon breast cancer diagnosis it was reclassified from 
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control to case. A summary of the demographic details for the participants in the 
study is provided in Table 2.1. 
 
Table 2.1 Selected demographics for the 40 case and 29 control samples. The 
range, average and median for cigarettes smoked refers to current and former 
smokers combined. 
 BMI        
(kg m-2) 
Age 
(Years) 
Cigarettes Smoked 
(Thousand) 
Smoking 
Status 
Case 
Range 18.9-50.2 51-97 4-365 Current 7 
Former 15 
Never 18 
Average 28.4 67 167 
Median 27.4 63 183 
Control 
Range 17.6-50.7 51-87 2-329 Current 3 
Former 13 
Never 13 
Average 30.2 63 129 
Median 29.2 62 110 
BMI = Body Mass Index. 
 
2.1.1 Analysis of Whole Spectrum 
 
2.1.1.1 Initial Analysis 
 
A PCA model was built for the data and produced five PCs; the scores plot of PC 2 
versus PC 1 is presented in Figure 2.1. The goodness of fit (R2X(cum), the fraction of 
the sum of squares of all the X-variables that are explained by the model) is 0.731. 
The predictive ability (Q2X(cum), the fraction of the total variation of the X-variables 
that can be predicted by the model) is 0.384. With a difference of more than 0.3 
between R2X and Q2X there is a greater likelihood that too much noise or outlying 
data points have been incorporated in the model.(86) Figure 2.1 supports this 
because three samples are indicative of being strong outliers being located a 
considerable distance outside of Hotelling’s T2. This defines the normal area 
corresponding to, in this case, 95% confidence, the extent of which is bound by the 
ellipse.(86) The complementary loadings plot is shown in Figure 2.2, which enabled 
identification of the plasma components responsible for the high scores. Bins in the 
range 1.163-1.200 ppm and 3.627-3.681 ppm are consistent with the presence of 
ethanol(103) in the samples and the bins centred at 0.892 and 1.288 ppm correspond 
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to lipid species.(103,142) In addition to the three suspected outliers a fourth sample, 
1003, was not positioned with the majority of samples, which exhibited tight 
clustering. The difference in signal intensities of lipids and ethanol between the four 
non-clustered samples and the remaining 65 is easily visible in the original spectra 
as shown by Figure 2.3. A large triplet signal (from the methyl group of ethanol) is 
displayed at around 1.18 ppm by the samples from patients 1003, 2003 and 2036. 
Plasma does not usually display signals in this region as illustrated by the red trace 
of sample 1017 in Figure 2.3. Sample 1003 has a much lower level of ethanol 
relative to the two other ethanol containing samples so is not as far removed from 
the cluster of samples in the scores plot (Figure 2.1). An extremely large lipid signal 
is present for the fourth outlier, sample 1002. Although the signal is present for all 
samples in the study the level is many times greater, as illustrated in Figure 2.3, and 
as such exerts a strong influence on the statistical analysis process. The medical 
records of the patients were consulted but no obvious reason for the presence of 
ethanol or excess lipids could be identified. Unrecorded consumption of alcohol was 
attributed for causing the ethanol signals. 
 
 
Key:  case and  control 
Figure 2.1 PCA scores plot of whole 1H-NMR plasma chemical shift data for all 40 
case and 29 control samples showing the first two model components. R2X = 0.307 
and 0.154, and Q2X = 0.240 and 0.115 for PC 1 and PC 2, respectively. 
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Figure 2.2 PCA loadings plot corresponding to the model displayed in Figure 2.1. 
 
Two options present themselves on how to address the ‘problematic’ regions. Either 
the regions can be removed from analysis by adding them to the ‘dark regions’, as 
described in Table 8.3, or the samples in question can be removed from further 
statistical analysis procedures. The latter option was chosen for two reasons. 
Regarding the ethanol signals, although the triplet centred at 1.18 ppm, resulting 
from the methyl protons, does not occur in a region where other signals are 
present, the signal from methylene protons, a quartet centred at 3.65 ppm, does 
and overlaps with glucose signals. By making the ethanol regions ‘dark regions’ 
unrelated signals would also be excluded. Secondly, due to the intensity of the lipid 
signals of sample 1002, wide spectral regions, in excess of 0.10 ppm, are occupied 
and incorporate underlying signals such as valine and lactate (Figure 2.3). Too broad 
a region would have to be excluded if sample 1002 was to be included in analysis. 
The four samples were therefore removed and PCA analysis was repeated. A four PC 
model was generated with an R2X(cum) value of 0.592 and 0.412 for Q2X(cum). 
Scores and loadings plots for PC 1 versus PC 2 are shown in Figure 2.4 and Figure 
2.5, respectively. 
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b)
 
Figure 2.3 Spectral region of four samples excluded from analysis plus a retained 
sample emphasising the size of a) ethanol methyl proton peaks (top) and b) lipid 
peaks (above). Trace colours: pink = 1002; blue = 1003; red = 1017 (retained); black 
= 2003; green = 2036. 
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Key:  case and  control 
Figure 2.4 PCA scores plot of plasma data for 38 case and 27 control samples 
excluding ethanol or atypical lipid level containing samples showing the first two 
model components. R2X = 0.278 and 0.160, and Q2X = 0.221 and 0.119 for PC 1 and 
PC 2, respectively. Samples 1004 and 1020 were from patients with a different 
ethnicity, i.e. not white British; their importance is discussed in further analysis. 
 
 
Figure 2.5 PCA loadings plot corresponding to the model displayed in Figure 2.4. 
 
Following removal of the four aforementioned samples the scores range is much 
smaller and there are no apparent outliers. However, there is still no discrimination 
between case and control samples. There is a very slight tendency for some case 
samples to occupy positive PC 1 and PC 2 scores space, which from the loadings 
plot (Figure 2.5) is indicative of higher lipid levels. This is supported by study 
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findings that for post-menopausal patients with breast cancer compared to those 
not afflicted there was a significant increase in total lipid levels in serum(143) and low 
density lipoprotein cholesterol and triglycerides in plasma.(144) The plasma findings 
were attributed to oxidative stress caused by an imbalance between reactive 
oxygen species and the antioxidant capacity of the cell, possibly due to the 
susceptibility of the lipoprotein to undergo oxidation. Overall, this can result in 
cellular damage leading to conversion to malignant cells.(144) Additionally, in the 
scores plot it can be noted that the majority of samples that have the highest 
negative scores value in PC 2 (>-0.35) are controls despite being fewer in number. 
Glucose is the species that occupies the corresponding space in the loadings plot 
therefore this indicates that the level of glucose is elevated in these samples. In 
tissue extracts the observation that glucose concentration is higher in unaffected 
tissue compared to malignant tissue has been reported with more active glycolysis 
in tumour tissue forwarded as the explanation.(135) 
 
At this stage close attention was paid to demographic details of the patients. It was 
noted that all but two of the women were British and white. As ethnicity is a known 
confounding factor in metabolomics,(92) highlighted by metabolomic analysis of 
urine that showed four separate clusters in PCA scores consisting of northern 
Chinese, southern Chinese, Japanese, and UK and American samples,(145) it was 
deemed best practice to remove the two samples from the study cohort for further 
analysis. The study was therefore reduced to 63 patients, consisting of 38 case and 
25 control samples, and PCA repeated. Note, however, that the metabolic profile of 
the two samples were not outliers (samples labelled in Figure 2.4) and the resultant 
scores and loadings plots with the two samples removed (data not shown) were 
almost identical to those where the two samples had been included. The 
summarised demographics for the 63 patients (table not shown) were very similar 
to that for the 69 patients (Table 2.1). Ranges for BMI, age and number of cigarettes 
smoked for case and control samples were unaffected. 
 
Four PCs were again generated, this time for the remaining 63 samples with 
R2X(cum) and Q2X(cum) values of 0.591 and 0.386, respectively (data not shown). 
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The above discussion, which related to when the two samples from patients whose 
ethnicity was not white British were included, is equally applicable to the new data 
with the two samples excluded. Given the slight tendency of grouping of some case 
and control samples in different scores space, PLS-DA was applied in an attempt to 
connect the information in the data matrix and properties of the samples, in this 
case breast cancer status. It was not possible to generate a model indicating that 
the data did not correlate with breast cancer status.  
 
2.1.1.2 Ductal Type and Cancer Grade Investigation 
 
Breast cancer is not a single disease, rather it is very heterogeneous because it 
represents multiple diseases,(146) therefore a reduction in diversity within case 
group classification could enhance separation between case and control groups via 
MVA. Case samples were separately categorised according to presence of single 
occurrence invasive ductal carcinoma and breast cancer grade. Two of the 38 case 
samples were diagnosed as having more than one instance of graded cancer 
resulting from multiple invasive carcinomas. Although these samples are included in 
case versus control analysis they have been excluded from investigation into 
differences between grades. Table 2.2 summarises selected parameters for samples 
with a single occurrence of graded tumour.  
 
Table 2.2 Selected demographics for the 36 samples with a single occurrence of 
breast cancer.  
Cancer 
Grade 
Zero                           
8 
One                          
6 
Two                                  
12 
Three                           
10 
Ductal 
Type 
No        
8 
Yes      
0 
No       
1 
Yes      
5 
No       
2 
Yes    
10 
No       
4 
Yes      
6 
Smoking 
Status 
N 
5 
F 
1 
C 
2 
N 
0 
F 
0 
C 
0 
N 
0 
F 
1 
C 
0 
N 
2 
F 
3 
C 
0 
N 
0 
F 
1 
C 
1 
N 
5 
F 
4 
C 
1 
N 
1 
F 
2 
C 
1 
N 
3 
F 
1 
C 
2 
Smoking status: N = never, F = former and C = current. 
   
Single occurrence invasive ductal carcinoma was identified for 21 samples; the other 
15 samples exhibited, for example, lobular or metaplastic carcinoma. Single 
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occurrence invasive ductal carcinoma samples acted as the case group, whilst the 
control group remained as previously. A similar range of positions in scores space 
was apparent for both groups hence no further separation was observed in the 
three component model (R2X = 0.553 and Q2X = 0.400) (Figure 2.6). 
 
 
Key:  case and  control 
Figure 2.6 PCA scores plot of plasma data for 21 single occurrence invasive ductal 
carcinoma case and 25 control samples showing the first two model components. 
R2X = 0.307 and 0.154, and Q2X = 0.240 and 0.115 for PC 1 and PC 2, respectively.  
 
In addition to case versus control investigation, potential markers of cancer grade 
can be explored. Figure 2.7 shows the scores plot whereby case samples are 
coloured according to breast cancer grade. The loadings plot (not shown) is very 
similar to Figure 2.5. The three component model had R2X(cum) and 
Q2X(cum) values of 0.548 and 0.333, respectively. Given that lower levels of glucose 
are associated with cancer cells(147) it is surprising that a selection of grade 2 
samples is clustered in the area corresponding to the glucose region in loadings 
space. Five other grade 2 samples are positioned very close to the centre of the 
scores plot indicating, comparatively, neither glucose nor lactate is elevated or 
reduced, whilst only one grade 2 sample has an elevated lactate level. Grade 3 
samples do not show increased glucose levels but only four are indicative of having 
elevated lactate levels with three having low levels of glucose and lactate. The 
sample that is most influenced by lipids (high PC 1 and 2 scores values) has an 
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associated grade of zero. Higher lipid levels are associated with greater BMI(148) so it 
is surmised that the patient’s BMI is high given that this is one of two patients for 
whom BMI data is not available. 
 
 
Key: grade =  0,  1,  2 and   3 
Figure 2.7 PCA scores plot showing the first two model components of plasma 
data for 36 single occurrence case samples coloured according to tumour grade. 
R2X = 0.260 and 0.192, and Q2X = 0.153 and 0.149 for PC 1 and PC 2, respectively.  
 
Given the heterogeneity and the non-discrete nature of the disease it is difficult to 
draw conclusions from the data especially when small samples numbers are 
involved. However, a compromise needs to be made between sample heterogeneity 
and number of samples, thus orchestrating scores to be determined for single 
occurrence ductal carcinoma case samples with cancer grade as the basis for 
identification of clustering. PC 2 versus PC 1 is shown in the scores plot Figure 2.8 
but the loadings plot of the five PC model (R2X(cum) = 0.729 and Q2X(cum) = 0.306) 
is not displayed. 
 
Many of the observations described for single occurrence case samples are not 
present for single occurrence ductal carcinoma case samples, in part due to the 
smaller number of samples. For both models, the information content of the data 
did not reflect cancer grade. The positioning of the data points displayed in the 
relevant PCA scores plots was not able to be explained by the grade of all single 
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occurrence case samples or just single occurrence invasive ductal carcinoma cases. 
Models were not able to be generated for either data set using PLS-DA. 
 
 
Key: grade =  1,  2 and   3 
Figure 2.8 PCA scores plot showing the first two model components of plasma 
data for 21 single occurrence ductal carcinoma case samples coloured according to 
tumour grade. R2X = 0.317 and 0.187, and Q2X = 0.170 and 0.124 for PC 1 and PC 2, 
respectively.  
 
2.1.1.3 Influence of Potential Confounding Factors 
 
Given that there is no clear discrimination between case and control samples or 
case grades, exploration of potential data correlation with factors that could be 
expected to influence sample content ensued, including BMI classification (Figure 
2.9; four component model, R2X(cum) = 0.581 and Q2X(cum) = 0.368) and smoking 
status (Figure 2.10; four component model, R2X(cum) = 0.591 and Q2X(cum) = 
0.386). BMI was classified according to values of <18.5, 18.5-24.9, 25-29.9 and 
≥30 kg m-2, suggestive of underweight, healthy weight, overweight and obese 
patients, respectively.(149) Smoking status was defined as ‘exposed’ (current or 
former smoker) or ‘never exposed’ (never-smoked). 
 
-0.6
-0.4
-0.2
-0.0
0.2
0.4
0.6
-0.8 -0.7 -0.6 -0.5 -0.4 -0.3 -0.2 -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
t[
2
]
t[1]
SIMCA-P+ 12.0.1 - 2012-04-24 17:14:49 (UTC+0) 
47 
 
 
Key: shape -  case and  control; colour - BMI (kg m-2) =  <18.5,  18.5-24.9,  25-
29.9 and  ≥30 
Figure 2.9 PCA scores plot showing the first two model components of plasma 
data for 37 case and 24 control samples coloured according to BMI (kg m-2) 
categories (<18.5 [case = 0 and controls = 1], 18.5-24.9 [13 and 6], 25-29.9 [16 and 
6+ and ≥3  *8 and 11], suggestive of underweight, healthy weight, overweight and 
obese patients, respectively). Two samples were excluded because BMI data was 
not available. R2X = 0.273 and 0.156, and Q2X = 0.211 and 0.099 for PC 1 and PC 2, 
respectively.  
 
 
Key: shape -  case and  control; colour - smoking status =  ‘never exposed’, 
‘exposed’ 
Figure 2.10 PCA scores plot showing the first two model components of plasma 
data for 38 case and 25 control samples coloured according to smoking status: 26 
‘never exposed’ [never smoked] (case = 17 and control = 9) and 37 ‘exposed’ 
[current or former smoker] (21 and 16). R2X = 0.272 and 0.163, and Q2X = 0.197 
and 0.122 for PC 1 and PC 2, respectively.  
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PCA did not show that data was reflective of the status of either factor and when 
PLS-DA was applied a model was unable to be built for BMI as the class identifier. A 
one component model (data not shown) was generated for smoking status but 
clustering of the two groups was not observed and additionally the R2X and R2Y 
values (the fraction of the sum of the squares of the X-variables and Y-variables 
explained by the model, respectively) were 0.165 and 0.237, respectively. The Q2Y 
value (the fraction of the total variation in the Y-variables that could be predicted by 
the model) was 0.093; all three values were too low for the model to be considered 
good. However, in PCA models there is a slight tendency for the samples that have 
the highest scores values in both PCs 1 and 2 to have an associated BMI of 25.5-29.9 
or ≥30 kg m-2, suggestive of overweight or obese patients, respectively, and 
originate from those whose smoking status is ‘exposed’. It is widely accepted that 
higher lipid levels are associated with greater BMI,(148) which the slight trend in 
Figure 2.9 supports in conjunction with the associated loadings plot (not shown but 
extremely similar to Figure 2.5). Figure 2.10 shows there could be a slight tendency 
for ‘exposed’ samples to have higher levels of lipids. In metabolomic analysis of 
serum by Wang-Sattler et al.(150) higher lipid levels were identified for current 
smokers compared to former or non-smokers whilst former smokers were found to 
be separated from non-smokers suggesting that the influence of cigarette smoke in 
human blood remains for years. Consequently, the ‘exposed’ category was divided 
into two categories: current and former smokers. The PCA scores plot Figure 2.11 
and loadings plot (not shown but extremely similar to Figure 2.5) clearly shows that 
samples from current smokers do not correspond with higher levels of lipids. 
However, given that patients who only recently ceased smoking could be classed as 
a former smoker, irrespective of the number of cigarettes smoked per day and 
length of exposure, the smoking habits of former smokers were investigated.  
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Key: shape -  case and  control; colour - smoking status =  never,  former and 
current.  
Figure 2.11 PCA scores plot showing the first two model components of plasma 
data for 38 case and 25 control samples coloured according to smoking status: 26 
never smoked (17 and 9), 27 former smokers (14 and 13) and 10 current smokers 
(7 and 3). Values in parentheses relate to number of case and control samples, 
respectively. Model descriptors as per Figure 2.10. 
 
Of the seven samples from former smokers that had positive PC 1 and 2 scores 
values, for the two with the highest PC 1 scores value (and most separated) 
cigarette consumption was not high relative for the study. The rank was 24th and 
33rd out of 37 for number of cigarettes smoked, plus the cessation periods were 10 
and 45 years, respectively. This further reduces the possibility that the slight trend 
is due to higher lipid levels in smokers. As an extension the number of cigarettes 
smoked was modelled for all ‘exposed’ samples but no trend in scores space was 
observed (data not shown; three component model, R2X(cum) = 0.539 and 
Q2X(cum) = 0.392). 
 
Neither the two (‘exposed’ or ‘never exposed’) nor three groups (never smoked, 
former smoker or current smoker) used for smoking status categorisation is 
optimum. There are three variables associated with smoking: number of cigarettes 
smoked per day, number of years smoked (together the number of cigarettes 
smoked can be calculated) and time since last cigarette, in terms of years. The 
former smokers pose the most problems for classification. It would be difficult to 
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differentiate between, for example, a patient who smoked heavily for a number of 
years but ceased shortly before sample donation from a current, light smoker of a 
few years. Additionally, it could be argued some former smokers could be classed 
as ‘never exposed’ in terms of the current effect of smoking given the low number 
of cigarettes smoked and long period of cessation, e.g. a patient who smoked 5 
cigarettes per day for 3 years and ceased 40 years ago. Any values for number of 
cigarettes smoked and cessation length used for classification would be arbitrary, 
hence the categories used.  
 
Although this study has not revealed any clustering of samples based on smoking 
status, cancer status was applied to samples from only patients whose smoking 
status was ‘never exposed’ (scores plot shown in Figure 2.12, loadings plot not 
shown; four component model, R2X(cum) = 0.662 and Q2X(cum) = 0.373) because it 
has been documented that smoking exposure could be a potential confounding 
factor.(150) Cancer status did not separate the 17 case and 9 control samples.  
 
 
Key:  case and  control 
Figure 2.12 PCA scores plot of plasma data for case and control samples from 
patients who have never smoked. R2X = 0.278 and 0.188, and Q2X = 0.147 and 
0.077 for PC 1 and PC 2, respectively.  
 
Further investigation related to BMI was performed. Each BMI classification, with 
the exception of <18.5 kg m-2 because there was only one sample in this class, was 
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subjected to application of cancer status for MVA. Separation in scores space was 
not observed according to cancer status for BMI ≥30 kg m-2 (Figure 2.13; five 
component model, R2X(cum) = 0.785 and Q2X(cum) = 0.456) or for the other two 
BMI classifications (data not shown). Unlike for BMI classifications of 18.5-24.9 and 
25-29.9 kg m-2 where PLS-DA models were unable to be fitted, a two component 
model (R2X(cum) = 0.454, R2Y(cum) = 0.669 and Q2Y(cum) = 0.238) was created for 
BMI ≥30 kg m-2 (Figure 2.14). The loadings plot (Figure 2.15) shows bins containing 
lactate and glucose are driving the separation between case and control samples.  
 
 
Key:  case and  control 
Figure 2.13 PCA scores plot showing the first two model components of plasma 
data for 8 case and 11 control samples from patients who had a BMI ≥3  kg m-2. 
R2X = 0.364 and 0.195, and Q2X = 0.261 and 0.138 for PC 1 and PC 2, respectively. 
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Key:  case and  control 
Figure 2.14 PLS-DA scores plot of plasma data for 8 case and 11 control samples 
from patients who had a BMI ≥3  kg m-2. 
 
 
Figure 2.15 PLS-DA loadings plot corresponding to the model displayed in Figure 
2.14. 
 
It is well known that glucose uptake and formation of lactate increases as normal 
cells transform to malignant cells(147) but this is not reflected in the plasma data set 
for these samples. The area occupied in the scores plot by most of the control 
samples is influenced by lactate and the equivalent metabolite for some of the case 
samples is glucose. All samples have an associated BMI of ≥30 kg m-2, and with 
some greatly above this value (the maximum BMI for case and control samples is 
50.2 and 50.7 kg m-2, respectively) the samples represented do not have typical 
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associated BMIs. Higher blood lactate levels have been observed with obesity and 
in patients who gained weight during chemotherapy.(124) None of the 63 patients 
received neoadjuvant therapy (chemotherapy prior to an operation) and because 
samples were taken before surgery, adjuvant therapy (chemotherapy after an 
operation) would not apply, therefore it cannot be postulated that obese patients 
were more likely to gain weight whilst receiving chemotherapy and hence have 
greater plasma levels of lactate. However, the validity of the model has to be 
considered. Table 2.3 shows the leave-one-out cross validation parameters.  
 
Table 2.3 ‘Leave-one-out’ cross-validation parameters of the PLS-DA model shown 
in Figure 2.14. 
Sample 
Excluded 
Number of 
Components 
R2X(cum) R2Y(cum) Q2Y(cum) 
Y-Predicted* 
1 2 
1006 2 0.467 0.693 0.257 0.307 0.693 
1008 2 0.462 0.723 0.199 0.281 0.719 
1013 2 0.432 0.680 0.176 1.097 -0.097 
1014 2 0.452 0.671 0.098 0.896 0.204 
1017 2 0.474 0.735 0.205 0.282 0.718 
1018 0 / / / / / 
1024 1 0.110 0.619 0.052 0.990 0.010 
1025 1 0.116 0.603 0.065 0.739 0.261 
1026 1 0.140 0.576 0.163 0.753 0.247 
1028 1 0.112 0.613 0.140 0.814 0.186 
1030 1 0.140 0.570 0.213 0.672 0.328 
2005 1 0.165 0.563 0.231 0.697 0.303 
2008 0 / / / / / 
2011 0 / / / / / 
2024 1 0.179 0.569 0.107 0.847 0.153 
2030 0 / / / / / 
2032 0 / / / / / 
2039 1 0.111 0.634 0.079 0.619 0.381 
2040 2 0.467 0.735 0.108 0.892 0.108 
*A sample was regarded as belonging to a grade by having a Y-predicted value >0.50. 
Incorrect classification is represented by red shading and correct by orange or green, 
corresponding to a Y-predicted value of 0.60-0.70 or >0.70, respectively. 
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Of the 11 control samples, seven (63%) were predicted correctly whilst the 
predictive ability of case samples was 0% due to having none of the eight samples 
correctly predicted. In total five of the 19 models were unable to be built, four 
controls and one case. Together, this indicates that the data could be overfitted by 
the model. Application of permutation testing allowed the model to be further 
scrutinised. 
 
Figure 2.16 shows many permuted models for the case class to have higher R2Y and 
Q2Y values than the original model. The intercept values of the regression lines for 
R2Y and Q2Y are 0.622 and -0.117, respectively. The R2Y value is much greater than 
0.4 so it is indicated that the model has overfitted the data thus furthering the 
conclusion from ‘leave-one-out’ cross validation. The permutation testing plot for 
the control class is not shown but with R2Y and Q2Y intercept values of 0.619 and      
-0.119, respectively, the same conclusion was made.  
 
 
Key:  R2Y and  Q2Y 
Figure 2.16 Permutation testing plots for the case class in the PLS-DA model 
shown in Figure 2.14. The R2Y and Q2Y intercept values of the regression lines are 
0.622 and -0.117, respectively. 
 
It is possible that there are distinct metabolic markers but these may be masked by 
potential confounding factors other than smoking status and BMI. Consequently, 
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other patient parameters were interrogated for potential data correlation (Table 
2.4). Parameters were classified in a number of ways dependent on the medical 
record information. For some parameters, such as hormone replacement therapy 
(HRT) usage, there was a positive or negative class whereas for others, for example 
PR value, a fixed number of values, and hence classes, were attributed. For many 
parameters where a range of values existed, three classes were devised to each 
accommodate one-third of the samples. Individual values were also modelled if 
appropriate. Some parameters were only applicable to case samples. 
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Table 2.4 Parameters, with type of classification, used to investigate potential 
correlation with observed data in multivariate analysis. 
Parameter (units) Classification 
Age [at time of sample donation] Individual values 
Height (m) Individual values 
Weight (kg) Individual values 
BMI (kg m-2) Individual values; 3 percentile groups 
Family history of breast cancer Positive or negative 
Menarche age Individual values 
Oral contraception usage Positive or negative 
Oral contraception usage for over one year Positive or negative 
Number of pregnancies Individual values 
Number of children Individual values 
Breastfed at least one child Positive or negative 
Breastfed more than one child Positive or negative 
Breastfed at least one child for two months 
or longer 
Positive or negative 
Breastfed more than one child for two 
months or longer 
Positive or negative 
Total number of months breastfed to 
children 
Individual values 
Menopause age Individual values 
HRT usage Positive or negative 
HRT usage within six weeks of breast cancer 
diagnosis 
Positive or negative 
Current smoker Positive or negative 
Never smoked Positive or negative 
Never smoked or stopped more than 10 
years ago 
Positive or negative 
Number of cigarettes smoked Individual values 
Cancer grade 1, 2 or 3 
DCIS [simplified grade] Low, intermediate, high and N/A 
ER alpha score 0/8 - 8/8 and N/A 
PR score 0/8 - 8/8 and N/A 
HER2 status Yes, no or N/A 
LCIS Yes, no or N/A 
Lympho-vascular invasion Yes, no or N/A 
Nottingham prognostic index Individual values 
Invasive cancer size (mm) Individual values 
Overall cancer size (mm) Individual values 
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Table 2.4 Continued. 
Prothrombin time Individual values 
White  blood cell count (x109 L-1) Individual values; 3 percentile groups 
Platelet count (x109 L-1) Individual values; 3 percentile groups 
Haemoglobin (g dL-1) Individual values; 3 percentile groups 
Red blood cell count (x1012 L-1) Individual values; 3 percentile groups 
Eosinophil count (x109 L-1) Individual values; 3 percentile groups 
Monocyte count (x109 L-1) Individual values; 3 percentile groups 
Lymphocyte count (x109 L-1) Individual values; 3 percentile groups 
Basophil count (x109 L-1) Individual values; 3 percentile groups 
Neutrophil count (x109 L-1) Individual values; 3 percentile groups 
International normalised ratio Individual values; 3 percentile groups 
Activated partial thromboplastin time (s) Individual values; 3 percentile groups 
Glucose (mmol L-1) Individual values; 3 percentile groups 
Alanine transaminase (units L-1) Individual values; 3 percentile groups 
Bilirubin (µmol L-1) Individual values; 3 percentile groups 
Phosphate (mmol L-1) Individual values; 3 percentile groups 
Alkaline phosphatase (units L-1) Individual values; 3 percentile groups 
Albumin (g L-1) Individual values; 3 percentile groups 
Albumin-adjusted calcium (mmol L-1) Individual values; 3 percentile groups 
Sodium (mmol L-1) Individual values; 3 percentile groups 
Potassium (mmol L-1) Individual values; 3 percentile groups 
Creatinine (µmol L-1) Individual values; 3 percentile groups 
Urea (mmol L-1) Individual values; 3 percentile groups 
BMI, body mass index; DCIS, ductal carcinoma in situ; ER, oestrogen receptor; HER2, human 
epidermal growth factor 2; HRT, hormone replacement therapy; LCIS, lobular carcinoma in 
situ; and PR, progesterone receptor. 
 
The observed data did not correlate with any of the 55 parameters (plots not 
shown), which would indicate that via the data acquisition and analysis methods 
used none of the parameters can be identified as individual confounding factors. 
Given this and the number of parameters, it was not feasible to combine two or 
more parameters to investigate the cumulative effect of potentially confounding 
factors or exploration using parameter matched samples, with the exception of BMI, 
age and smoking status because these are commonly identified as confounding 
factors.(151) 
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Ten case and ten control samples were matched singly according to BMI or age. For 
both groups the ten samples closest to the median of the 63 samples, 27.3 kg m-2 
for BMI and 63 years for age, were chosen. Furthermore, selecting only five case 
and five control matched samples from patients who had never smoked ensured the 
range for BMI and age was kept as small as possible whilst incorporating another 
matched factor. Although using a larger sample number would be better practice 
for MVA, the range for the two parameters of BMI and age would increase greatly, 
otherwise former smokers would have to be included in an attempt to limit the 
range expansion in both groups. Table 2.5 summarises the demographics for the 
parameters age, BMI and smoking status.  
 
Table 2.5 BMI and/or age range for parameter matched samples.  
Cancer 
Status 
Matched Parameter(s) Range 
[Never Smoked Cases/Controls] 
BMI [4/4] Age [3/3] BMI and Age [5/5] 
BMI Age 
Case 25.8 - 28.7 60 - 64 24.7 - 29.1 56 - 68 
Control 24.4 - 31.4 60 - 66 22.0 - 30.0 53 - 75 
Units: BMI = kg m-2. 
 
The PCA scores plots for the BMI matched (Figure 2.17; three component model, 
R2X(cum) = 0.571 and Q2X(cum) = 0.153) and age matched samples (Figure 2.18; two 
component model, R2X(cum) = 0.465 and Q2X(cum) = 0.235) did not exhibit two 
clusters of samples in scores space based on breast cancer status. Further evidence 
is therefore provided that metabolites that are indicative of breast cancer status 
cannot be identified from this data set when the variation of a single potential 
confounding factor is much reduced. 
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Key:  case and  control 
Figure 2.17 PCA scores plot showing the first two components of plasma data for 
best BMI matched 10 case and 10 control samples. R2X = 0.257 and 0.205, and Q2X 
= 0.035 and 0.099 for PC 1 and PC 2, respectively. 
 
 
Key:  case and  control 
Figure 2.18 PCA scores plot of plasma data for best age matched 10 case and 10 
control samples.  
 
Figure 2.19 indicates a separation between case and control samples in scores 
space for the best age, BMI and smoking status matched five samples for case and 
control groups (two component model, R2X(cum) = 0.543 and Q2X(cum) = 0.089). 
The bins that have the most effect on the observed separation in the loadings plot 
(Figure 2.20) contain lactate, lipids and glucose. Positioning of these bins in loadings 
space is similar to that in the corresponding space when the full range of samples 
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has been included (Figure 2.5) with the exception of bins containing lactate (1.314 
and 1.342 ppm), which are influential in PC 2 for the full sample range but in PC 1 
for the matched samples.  
 
 
Key:  case and  control 
Figure 2.19 PCA scores plot of plasma data for best BMI, age and ‘never smoked’ 
status matched 5 case and 5 control samples. 
 
 
Figure 2.20 PCA loadings plot corresponding to the model displayed in Figure 2.19. 
 
The scores plot (Figure 2.21) of the one component PLS-DA model (R2X = 0.287, R2Y 
= 0.733 and Q2Y = 0.394) separated all samples according to class except for 2007, 
which was closer to control rather than case samples in scores space. The loadings 
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plot (not shown) identified the same bins contributing to the separation in scores 
space as those influencing PC 1 in the PCA loadings plot.  
 
 
Key:  case and  control 
Figure 2.21 PLS-DA scores plot of plasma data for best BMI, age and smoking 
status matched 5 case and 5 control samples. Classed according to sample type. 
 
Validation of the model was performed by ‘leave-one-out’ cross-validation (Table 
2.6). Four out of five (80%) case and control samples were correctly predicted. 
Singly, this value is sufficiently high to suggest that the model has not overfitted the 
data although three of the eight samples had a Y-predicted value between 0.50 and 
0.60 so the classification of these should be treated with caution. Additionally, the 
R2Y value of the first component was high for all models and for many, more than 
one component resulted but the R2Y value approached one so predictions were 
made using a single component. Permutation testing was required to evaluate 
whether the model had overfitted the data (case class plot shown in Figure 2.22, 
control class plot not shown). The R2Y intercept value of the regression line was 
0.622 for the case class and 0.620 for the control class whilst the Q2Y intercept value 
was -0.085 for both classes. Some permuted values had greater R2Y and Q2Y values 
than the original model. 
 
Taking all of this into consideration, it cannot be substantiated that case samples 
compared to control samples that are matched according to BMI, age and ‘never 
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smoked’ status have increased levels of lipids and lactate but reduced glucose as 
indicated by both the PCA and PLS-DA models. Although ‘leave-one-out’ cross-
validation supported the findings of the PLS-DA model, permutation testing did not. 
This is possibly due to the small number of samples included, which resulted in a 
large R2Y value for the first component and subsequent high fit of the data. A 
greater number of samples would be required to confirm whether levels of lipids, 
lactate and glucose were different in case and control samples. 
 
Table 2.6 ‘Leave-one-out’ cross-validation parameters for the PLS-DA model 
shown in Figure 2.21. 
Sample 
Excluded 
Number of 
Components 
R2X R2Y  Q2Y  
Y-Predicted* 
1 2 
1009 1 0.272 0.742 0.481 1.015 -0.015 
1010 1 0.302 0.763 0.570 0.537 0.463 
1017 1 0.314 0.726 0.540 0.575 0.425 
1022 1 0.289 0.710 0.472 0.903 0.097 
1027 1 0.321 0.800 0.606 0.313 0.687 
2007 1 0.301 0.848 0.540 0.741 0.259 
2023 1 0.302 0.757 0.438 0.440 0.560 
2033 1 0.302 0.694 0.454 0.133 0.867 
2037 1 0.282 0.735 0.519 0.193 0.807 
2041 1 0.288 0.711 0.510 -0.015 1.015 
*A sample was regarded as belonging to a grade by having a Y-predicted value >0.50. 
Incorrect classification is represented by red shading and correct by pink, orange or green, 
corresponding to a Y-predicted value of <0.60, 0.60-0.70 or >0.70, respectively. 
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Key:  R2Y and  Q2Y 
Figure 2.22 Permutation testing plots for the case class in the PLS-DA model 
shown in Figure 2.21. The R2Y and Q2Y intercept values of the regression lines are 
0.622 and -0.085, respectively. 
 
Sample 2007 exhibited high-grade DCIS rather than invasive ductal carcinoma 
meaning the case type is different to three other case samples, which could 
indicate why it is not positioned with the other case samples. However, 2041 is also 
a DCIS sample and is of intermediate grade with a smaller overall size, thus is not 
supportive of the above argument. The medical record for sample 1027 does not 
indicate any characteristics that could suggest a greater tendency to develop 
cancer, for example, there is no family history of breast cancer, and although none 
of the control samples had normal breasts, 1027 is not unique being one of five in 
total to exhibit breast cysts.  
 
Using a greater number of samples would increase the reliability of any model 
findings but, for this study, would result in the samples being unable to be matched 
according to BMI, age and smoking status; the ranges of the two parameters and 
smoking status would be similar to that when all samples were used. With just five 
samples in each group the age range has already increased greatly and the BMI 
range has also expanded.  
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2.1.2 Analysis of Spectrum Excluding the Glucose Region 
 
For whole spectra, the data distribution along PC 1 was shown to be strongly 
influenced by bins in the region containing glucose (3.180-3.940 ppm) for case and 
control samples (Figure 2.5) and as previously noted, a decreased level of glucose 
has been associated with breast cancer(135,147) though the level can be directly and 
rapidly affected by diet.(66,152,153) It was not possible to regulate dietary consumption 
before sample donation so as a result the region containing glucose signals was 
removed to reduce any potential effect of diet on analysis.  
 
The same systematic procedures were followed as per whole spectrum analysis: 
PCA and PLS-DA were performed for case and control samples combined and 
classed according to various parameters. A summary of the models is shown in 
Table 2.7. 
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Table 2.7 Parameters used for classification and model descriptors excluding the 
glucose region (3.180-3.940 ppm). PLS-DA models were not able to be built if 
model descriptors are not listed. 
Samples Included Parameter 
(class)  
Plot (PCA unless 
stated) 
PCs R2X 
(cum) 
R2Y 
(cum) 
Q2X/
Q2Y 
(cum) Scores  Loadings  
All State (case and 
control) 
Figure 
2.23 
Figure 
2.24 
3 0.517 / 0.371 
All BMI (<18.5, 
18.5-24.9, 25-
29.9 and ≥30) 
Figure 
2.25 
/ 3 0.507 / 0.329 
All Smoking status 
(‘never exposed’ 
and ‘exposed’) 
Figure 
2.26 
Figure 
2.24 
3 0.517 / 0.371 
All Smoking status 
(‘never exposed’ 
and ‘exposed’) 
PLS-DA 
Figure 
2.27 
PLS-DA 
Figure 
2.28 
2 0.316 0.360 0.112 
Single occurrence 
invasive ductal 
carcinoma and 
control 
State (case and 
control) 
Figure 
2.30 
/ 2 0.446 / 0.298 
Never-smoked State (case and 
control) 
Figure 
2.31 
/ 3 0.586 / 0.362 
Single occurrence 
case 
Grade (0, 1, 2, 3 
and 4) 
Figure 
2.32 
/ 2 0.458 / 0.245 
Single occurrence 
invasive ductal 
carcinoma tumour 
Grade (1, 2 and 
3) 
/ / 0 / / / 
Units: BMI = kg m-2. 
 
There is not clear separation between case and control samples in scores space 
(Figure 2.23) but a very slight tendency for some case samples to have higher lipid 
levels (bins centred at 0.892 and 1.288 ppm; Figure 2.24) is apparent as is the case 
when the region that includes glucose is retained (Figure 2.4). The bin centred at 
2.032 ppm has a high PC 1 loadings value. The main signal contained within this bin 
is attributed to glycoproteins.(142) Lactate also has a high PC 1 loadings value so it is 
difficult to ascertain the contribution of each metabolite towards the positioning of 
samples in the scores plot but there does not seem to be correlation between 
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glycoproteins and case samples despite glycoprotein association with breast cancer 
along with various other cancers.(154-156) 
 
 
Key:  case and  control 
Figure 2.23 PCA scores plot showing the first two components of plasma data 
excluding the glucose region (3.18-3.94 ppm) for 38 case and 25 control samples. 
R2X = 0.237 and 0.196, and Q2X = 0.140 and 0.203 for PC 1 and PC 2, respectively. 
 
 
Figure 2.24 PCA loadings plot corresponding to the model displayed in Figure 2.23. 
 
In Figure 2.25, of the 12 samples with the highest PC 1 scores value (>0.4), six have 
an associated BMI ≥30 kg m-2 and five of these are controls. The main corresponding 
bins in the loadings plot (not shown, extremely similar to Figure 2.24) contain 
lactate and glycoproteins. When PCA was employed, increased lactate was not 
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associated with controls from this BMI group when the glucose region was included 
(Figure 2.9) but was when PLS-DA was applied to only the case and control samples 
that had an associated BMI ≥30 kg m-2 (Figure 2.14). Unfortunately, due to the small 
number of samples and the trend not always being present, it is not possible to 
make substantiated conclusions regarding the lactate level for those with a BMI of 
≥30 kg m-2 in relation to cancer status. There appears to be no association between 
glycoproteins and BMI. 
 
 
Key: shape -  case and  control; colour - BMI (kg m-2) =  <18.5,  18.5-24.9,  25-
29.9 and  ≥30 
Figure 2.25 PCA scores plot showing the first two components of plasma data 
excluding the glucose region (3.18-3.94 ppm) based on BMI. Group sample 
numbers from Figure 2.9 apply. R2X = 0.243 and 0.178, and Q2X = 0.141 and 0.170 
for PC 1 and PC 2, respectively. 
 
Regarding smoking status, the samples with the highest lipid levels are from 
patients who conform to the ‘exposed’ (current or former smoker) category (scores 
and loadings plots shown in Figure 2.26 and Figure 2.24, respectively), which is the 
same observation as when the glucose region was included. Additionally, of the 13 
samples with the highest PC 1 scores value (>0.4), ten originated from ‘exposed’ 
patients.  
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Key: shape -  case and  control; colour - smoking status =  ‘never exposed’, 
‘exposed’ 
Figure 2.26 PCA scores plot showing the first two components of plasma data 
excluding the glucose region (3.18-3.94 ppm) based on smoking status. Group 
sample numbers from Figure 2.10 apply. R2X = 0.237 and 0.196, and Q2X = 0.140 
and 0.203 for PC 1 and PC 2, respectively. 
 
PLS-DA did not completely separate ‘exposed’ and ‘never exposed’ groups in scores 
space though a strong tendency towards separation could be observed (Figure 
2.27). Much of the separation is along PC 1 with a contribution from PC 2. Lipids and 
lactate strongly influence PC 1 and levels are indicated to be lower in ‘exposed’ 
patients (Figure 2.28). However, the quality of the model is low (Table 2.7) so 
validation is even more imperative. The validity of the model was assessed through 
exclusion of a third of the samples and their class memberships predicted using 
models built from the remaining samples. For one instance, a model was not able to 
be built using two-thirds of the samples thus the maximum total number of samples 
for which class could be predicted correctly was 67%. One of the other models only 
had a Q2Y value of 0.087 so predictions made based on this model would have to be 
treated with caution. Permutation testing (‘exposed’ class plot shown in Figure 2.29, 
‘never exposed’ samples plot not shown) indicated the model had not overfitted the 
data because the R2Y intercept value of the regression line was 0.323 for the 
‘exposed’ class and 0.320 for the ‘never exposed’ class whilst the Q2Y intercept 
values were -0.174 and -0.177, respectively. However, the model was poor due to 
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the high number of permuted models that had R2Y and Q2Y values in excess of the 
values for the original model. Combined, this information leads to the conclusion, 
despite tentative indication from PLS-DA, that lower levels of lipids and lactate are 
not present in plasma from patients whose smoking status was ‘exposed’. 
 
 
Key: shape -  case and  control; colour - smoking status =  ‘never exposed’, 
‘exposed’ 
Figure 2.27 PLS-DA scores plot of plasma data excluding the glucose region (3.18-
3.94 ppm) based on smoking status. Group sample numbers from Figure 2.10 
apply. 
 
 
Figure 2.28 PLS-DA loadings plot corresponding to the model displayed in Figure 
2.27. 
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Key:  R2Y and  Q2Y 
Figure 2.29 Permutation testing plots for the ‘exposed’ class in the PLS-DA model 
shown in Figure 2.27. The R2Y and Q2Y intercept values of the regression lines are 
0.323 and -0.174, respectively. 
 
No clear separation was observed between: single occurrence ductal cases and 
controls (Figure 2.30); cases and controls amongst the ‘never exposed’ smoking 
group (Figure 2.31); and single occurrence case samples based on tumour grade 
(Figure 2.32). It is interesting to note for tumour grade that although some grade 3 
samples do exhibit higher lactate levels the three samples that have the greatest 
negative PC 1 value are all grade 3, which from the loadings plot (not shown but 
very similar to Figure 2.24) would indicate low levels of lactate. Although a similar 
observation is apparent with the glucose region retained (Figure 2.7) it is more 
visible with the glucose region removed. This is indicative that for plasma the lactate 
level, known to increase in malignant cells,(147) is not reflective of tumour grade. 
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Key:  case and  control 
Figure 2.30 PCA scores plot of plasma data excluding the glucose region (3.18-
3.94 ppm) for 21 single occurrence ductal case and 25 control samples. 
 
 
Key:  case and  control 
Figure 2.31 PCA scores plot showing the first two components of plasma data 
excluding the glucose region (3.18-3.94 ppm) for 17 case and 9 control  samples 
from patients who have never smoked. R2X = 0.271 and 0.202, and Q2X = 0.133 
and 0.151 for PC 1 and PC 2, respectively. 
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Key: grade =  0,  1,  2 and   3 
Figure 2.32 PCA scores plot of plasma data excluding the glucose region (3.18-
3.94 ppm) for 36 single occurrence case samples based on tumour grade. 
 
PLS-DA models were not created for any parameter with the exception of smoking 
status (Figure 2.27). Together, for all samples, this indicates that removal of glucose 
does not improve the possibility that the data could be related to cancer status, 
cancer grade, BMI classification or smoking status in this study. Given none of the 
PCA or PLS-DA models characterised the specific groups clearly it was deemed 
prudent to investigate best matched samples, thus eliminating some sources of 
variation. 
 
Samples were again matched according to BMI, age or BMI, age and ‘never smoked’ 
status. The PCA scores plots for ten case and ten control BMI matched samples 
(Figure 2.33; two component model, R2X(cum) = 0.442 and Q2X(cum) = 0.065) or age 
matched samples (Figure 2.34; one component model, R2X = 0.248 and Q2X = 0.076) 
did not show separation between cases and controls in scores space. For both sets 
of samples, a PLS-DA model was not able to be built.  
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Key:  case and  control 
Figure 2.33 PCA scores plot of plasma data excluding the glucose region (3.18-
3.94 ppm) for best BMI matched 10 cases and 10 controls. 
 
 
Key:  case and  control 
Figure 2.34 PCA scores plot of plasma data excluding the glucose region (3.18-
3.94 ppm) for best age matched 10 cases and 10 controls. 
 
A PCA model was unable to be created for the five case and five control samples 
that were matched according to BMI, age and ‘never smoked’ status but a one 
component PLS-DA model (R2X = 0.247, R2Y = 0.816 and Q2Y = 0.422) was built. 
Scores and loadings plots are shown in Figure 2.35 and Figure 2.36, respectively. 
Lipids and lactate are indicated to be higher in case samples. 
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Key:  case and  control 
Figure 2.35 PLS-DA scores plot of plasma data excluding the glucose region (3.18-
3.94 ppm) for best BMI, age and ‘never smoked’ status matched 5 case and 5 
control samples. Classed according to cancer status. 
 
 
Figure 2.36 PLS-DA loadings plot corresponding to the model displayed in Figure 
2.35. 
 
Validation of the model was performed by ‘leave-one-out’ cross-validation (Table 
2.8). Four out of five (80%) control samples and three out of five (60%) case samples 
were correctly predicted but two of the eight samples had a Y-predicted value 
between 0.50 and 0.60 so the classification of these should be treated with caution. 
Only three samples had a correct Y-predicted value of over 0.70. For many of the 
models created that had one sample excluded, more than one component resulted 
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but the R2Y value approached one so predictions were made using a single 
component. Permutation testing (case samples plot shown in Figure 2.37, control 
samples plot not shown) indicated the model had overfitted the data because the 
R2Y intercept value of the regression line was 0.601 for the case class and 0.606 for 
the control class whilst the Q2Y intercept values were -0.074 and -0.096, 
respectively. It cannot be concluded that case samples compared to control samples 
that are matched according to BMI, age and ‘never smoked’ status have increased 
levels of lipids and lactate. The removal of glucose from the analysis did not 
enhance separation between case and control groups or validity of PLS-DA models. 
 
Table 2.8 ‘Leave-one-out’ cross-validation parameters for the PLS-DA model 
shown in Figure 2.35. 
Sample 
Excluded 
Number of 
Components 
R2X R2Y  Q2Y  
Y-Predicted* 
1 2 
1009 1 0.254 0.815 0.565 0.670 0.330 
1010 1 0.265 0.847 0.659 0.530 0.470 
1017 1 0.257 0.817 0.579 0.691 0.309 
1022 1 0.230 0.830 0.552 1.218 -0.218 
1027 1 0.294 0.862 0.675 0.287 0.713 
2007 1 0.270 0.827 0.410 0.500 0.500# 
2023 1 0.259 0.861 0.514 0.510 0.490 
2033 1 0.265 0.781 0.502 0.095 0.905 
2037 1 0.256 0.830 0.625 0.740 0.260 
2041 1 0.248 0.807 0.590 -0.040 1.040 
*A sample was regarded as belonging to a grade by having a Y-predicted value >0.50. 
Incorrect classification is represented by red shading and correct by pink, orange or green, 
corresponding to a Y-predicted value of <0.60, 0.60-0.70 or >0.70, respectively. 
#Y-predicted value >0.50 when more than three decimal places retained. 
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Key:  R2Y and  Q2Y 
Figure 2.37 Permutation testing plots for the case class in the PLS-DA model 
shown in Figure 2.35. The R2Y and Q2Y intercept values of the regression lines are 
0.601 and -0.074, respectively. 
 
2.2 Conclusions 
 
All parameters in the patients’ medical records were treated as potential 
confounding factors but for whole spectra, when the effects of each were analysed 
singly, none were identified as such for this study. However, when the five case and 
five control samples that were best matched according to BMI, age and ‘never 
smoked’ status, PCA provided tentative separation between case and control 
samples based on increased levels of lactate and decreased glucose for case 
samples. This is in agreement with the Warburg effect: in malignant cells glucose 
uptake increases as does lactate formation.(147) ‘Leave-one-out’ cross validation 
supported the validity of the same finding from the PLS-DA model but permutation 
testing indicated the model had overfitted the data, possibly due to the small 
sample number. A larger cohort with well defined BMI and age ranges for the same 
smoking status, i.e. ‘never smoked’, would be needed to verify the observation.  
 
The same models indicate a slight tendency for case samples to be associated with 
higher lipid levels, which is in accordance with oxidative stress caused by an 
imbalance between reactive oxygen species and the antioxidant capacity of the cell, 
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possibly due to the susceptibility of the lipoprotein to undergo oxidation. Overall, 
this can result in cellular damage leading to conversion to malignant cells.(144) 
However, greater prominence of case samples having a higher lipid level would be 
required to evidence this trend. 
 
Clear grouping of case and control samples was not observed using PCA nor was 
there correlation between breast cancer status and data acquired when PLS-DA was 
utilised, indicating for this study there is no substantive evidence to suggest an 
association between breast cancer and a change in metabolism that can be 
determined by metabolomic analysis of NMR spectroscopy acquired data from 
plasma. This also applies to tumour grade, whether to all cases or just invasive 
ductal carcinoma cases. The same conclusions were made following analysis of data 
from whole spectra and spectra with the glucose region removed. 
 
Despite glucose levels being rapidly affected by diet it is advised to retain the region 
in initial analysis of plasma. Dietary affects can be subsequently analysed. There is 
no evidence to suggest removing glucose enhances separation between groups in 
question and although the level of the metabolite has not been found in this study 
to determine breast cancer status or grade, the Warburg effect(147) highlights its 
importance in cancer studies. 
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Chapter 3. NMR Analysis of Urine 
 
In an analogous manner to that described in Chapter 2, urine from the same patient 
cohort has been analysed by 1H-NMR spectroscopy with the exception that 1D (one 
dimensional) Nuclear Overhauser Effect Spectroscopy (NOESY) pulse sequence was 
used. Chemical shift data was used in analysis. 
 
Samples were prepared as per Section 8.1.1.2 and data collected as detailed in 
Section 8.2.2. Section 8.3 applies for spectral processing with dark regions listed in 
Table 8.3. Constant sum normalised data was used initially. MVA was performed as 
detailed in Section 8.4.  
 
3.1 Results 
 
Ethanol was found to be present in urine samples from the three patients previously 
identified through analysis of their plasma sample as likely to have consumed 
alcohol prior to sample donation. These samples were excluded from all analyses; 
no other samples contained ethanol signals. Additionally, patients’ samples whose 
ethnicity was not ‘white British’ were excluded because they were not sufficiently 
represented (Section 2.1.1.1). The urine sample from patient 1002, whose plasma 
sample contained abnormal lipid levels, was included but the spectrum from sample 
1008 was incorrectly saved thus leaving the same number of case and control 
samples: 38 and 25, respectively. 
 
3.1.1 Initial Analysis of Spectrum and Comparison of Normalisation Methods 
 
A PCA model was built for constant sum normalised data and produced two PCs; the 
scores plot is presented in Figure 3.1 and the corresponding loadings plot in Figure 
3.2. R2X(cum) is 0.460, with PC 1 explaining 0.374 of the variation, whilst Q2X(cum) 
is 0.390. 
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Key:  case and  control 
Figure 3.1 PCA scores plot of whole 1H-NMR constant sum normalised urine 
chemical shift data for case and control samples. 
 
 
Figure 3.2 PCA loadings plot corresponding to the model displayed in Figure 3.1. 
 
There were 13 samples, three controls and ten cases, which had positive PC 1 scores 
values that were isolated from the remainder of the samples in scores space. The 
loadings plot showed a number of bins with positive PC 1 loadings values greater 
than or equal to 0.10: 2.158, 2.186, 3.604, 3.616, 3.630, 3.892, 3.913, 7.131, 7.154, 
7.307, 7.324, 7.344, 7.371, 7.446 and 7.467 ppm. The origin of these signals could 
not initially be identified through metabolite lists or databases(66,103,142,157-163) so the 
aforementioned 13 patients’ last food and drink consumption details prior to 
sample donation, as well as drug and supplement history, were analysed for 
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recurrent substances. Additionally, records of other diseases and ailments were 
studied for frequent instances amongst patients; hypertension was the most 
diagnosed disease with eight patients being affected but seven of the other 50 
patients were also afflicted. No food or drink item was common that might cause 
such distinct signals. Irrespective of dosage or strength, 70 different drugs or 
supplements were recorded for the 13 patients but no substances, including 
common ‘over-the-counter’ medication such as acetaminophen (paracetamol) and 
aspirin, were taken by more than three patients. Apart from a doublet at 7.32 ppm, 
signals in the spectrum did not correspond with acetaminophen signals,(103) 
however other sources suggested signals around 2.16 ppm were resultant from 
acetaminophen.(164,165) Signals from acetaminophen glucuronide, acetaminophen 
sulphate and N-acetylcysteine conjugate of acetaminophen were correlated with 
acetaminophen signals(165) and matched all of the unknown signals in the previously 
stated bin regions. It was concluded that acetaminophen and associated breakdown 
products were responsible for the unassigned signals in the spectra and patients 
had consumed acetaminophen on an ad hoc basis that was not reported. It was not 
possible to generate a PLS-DA model. 
 
Whilst investigation proceeded to determine the origin of influential signals in PC 1, 
the impact of these signals on the normalisation procedure was considered. 
Although constant sum normalisation attempts to account for dilution differences 
between samples it assumes that changes in concentrations of single metabolites 
have a small influence on the total concentration change therefore a linear 
concentration series of samples would result in a linear series of integrals. This is in 
addition to the assumption that the influence of down-regulation of certain 
metabolites should be approximately balanced by the up regulation of other 
metabolites.(69) However, this approximation can fail if there is a large change in the 
concentration of a metabolite(s), in this instance those associated with 
acetaminophen. This is because other signals in the spectrum will appear to 
decrease due to lower normalised intensities as a result of the total spectrum 
integral being greater.(59) Dieterle et al.(69) proposed probabilistic quotient 
normalisation (PQN) as a solution. This method assumes that concentration 
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changes of a single metabolite only influences parts of the spectrum hence the 
intensity of the majority of signals, rather than all, is a function of dilution. A most 
probable quotient between the signals of each spectrum in the series and of a 
reference spectrum is calculated as the normalisation factor, effectively this is a 
number that is required to make the most number of data point or bin intensities 
the same as the reference spectrum. A full description of the method to obtain 
probabilistic quotient (PQ) normalised data is provided in Section 8.3.1.2 but in 
brief, perform constant sum normalisation to ensure the absolute magnitude is 
constant, calculate a reference spectrum, calculate the quotients of all variables of 
the test spectrum with those of the reference spectrum, calculate the median of 
these quotients, excluding any noise regions (Table 8.7 lists regions included in the 
calculation of the median quotient), and divide all variables of the test spectrum by 
this median.(69)  
 
The samples with acetaminophen signals had the lowest median quotients; the 
eight samples with the highest positive PC 1 scores values had the lowest values, 
the range being 0.627-0.767. Median quotients less than 1 would be expected 
because given there are more signals present the relative intensity for each signal 
would be less using constant sum normalisation. Therefore, dividing all variables of 
the test spectrum by the associated median quotient would increase the intensity 
of signals, the majority to a similar level to those of the calculated median 
spectrum. As expected, the scores plot (Figure 3.3; loadings plot not shown) of the 
model created using PQ normalised data (two PCs, R2X(cum) = 0.455 and 
Q2X(cum) = 0.362) compared to constant sum normalised data exhibited higher PC 
1 scores values for those samples containing acetaminophen. However, the relative 
positions of the samples remained very similar and separation between case and 
control samples was not apparent. It was not possible to generate a PLS-DA model. 
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Key:  case and  control 
Figure 3.3 PCA scores plot of PQ normalised urine data for case and control 
samples. 
 
3.1.2 Analysis of Spectrum Excluding Acetaminophen Regions Using Probabilistic 
Quotient Normalisation 
 
The aforementioned bin regions of acetaminophen and associated breakdown 
products were excluded and the data re-normalised. The median quotients now 
ranged from 0.624 to 1.199. Separation was not present between case and control 
samples in PCA scores space (Figure 3.4; two PC model, R2X(cum) = 0.303 and 
Q2X(cum) = 0.186). Creatinine (bin regions 3.034-3.064 and 4.043-4.073 ppm) 
dominated PC 1 in the loadings plot whilst PC 2 was most heavily influenced by 
hippurate (bin regions 3.954-3.984, 7.530-7.590, 7.611-7.662 and 7.815-7.866 ppm) 
(Figure 3.5). 
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Key:  case and  control 
Figure 3.4 PCA scores plot of PQ normalised urine data excluding acetaminophen 
regions for case and control samples. 
 
 
Figure 3.5 PCA loadings plot corresponding to the model displayed in Figure 3.4.  
 
Given there was no clear separation between case and control samples subsequent 
investigation focused on breast cancer specific parameters (Table 3.1).  
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Table 3.1 Parameters used for classification in PCA and model descriptors 
excluding acetaminophen regions. 
Parameter (Classification) Sample Numbers (Total) PCs R2X 
(cum) 
Q2X 
(cum) 
Grade (0, 1, 2, 3, 1 and 2 
or 2, 2, and 2) 
7, 5, 12, 11, 1, 1 (37) 2 0.356 0.176 
Grade (0, 1, 2 or 3) 7, 5, 12, 11 (35) 2 0.360 0.179 
Grade (1, 2 or 3) 5, 12, 11 (28) 2 0.361 0.122 
Ductal and grade (1, 2 or 
3) 
4, 10, 7 (21) 1 0.257 0.129 
ER score (0/8 - 8/8) 11=0/8, 2=3/8, 1=6/8, 21=8/8 (35) 2 0.362 0.184 
PR score (0/8 - 8/8) 13=0/8, 1=2/8, 1=3/8, 1=4/8, 
1=5/8, 1=6/8, 4=7/8, 9=8/8 (31) 
2 0.375 0.181 
HER2 status (-ve or +ve) 27, 6 (33) 1 0.230 0.135 
Combined ER/PR/HER2 
class (1 - 8) 
13=2, 2=4, 2=7, 6=8 (23) 1 0.220 0.058 
 
With the exception of the model that included 37 samples, all models contained 
samples that were from patients with a single tumour occurrence; one patient 
exhibited two, and another three, separate occurrences.  
 
In the clinical environment both ER and PR status can be represented by a score out 
of eight and reflects confidence of assignment: 8/8 is undoubtedly positive status 
whereas 0/8 is undoubtedly negative status and 1/8 is not possible(18,19). 
Conventional practice of assigning ER and PR scores of 3/8 to 5/8 as positive 
status(19) has not been adopted (Table 3.2). This was to provide greater disparity 
between the two statuses whilst only eliminating two and three samples based on 
ER and PR scores, respectively. Only positive and negative status samples were 
included in the assignment of combined ER/PR/HER2 values (Table 3.3).  
 
Table 3.2 ER and PR status used in this study based on respective scores. 
ER or PR Score 0/8 2/8 3/8 4/8 5/8 6/8 7/8 8/8 
Status Assigned (-) (-) None None None (+) (+) (+) 
(-) = negative, (+) = positive 
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Table 3.3 Arbitrary classes assigned to ER/PR/HER2 statuses. 
Class 1 2 3 4 5 6 7 8 
Status of 
Descriptors 
ER+ 
PR+ 
HER2+ 
ER- 
PR+ 
HER2+ 
ER+ 
PR- 
HER2+ 
ER+ 
PR- 
HER2- 
ER- 
PR+ 
HER2- 
ER+ 
PR+ 
HER2- 
ER- 
PR- 
HER2+ 
ER- 
PR- 
HER2- 
Subtype 
Indication 
Luminal 
B 
Luminal 
B 
Luminal 
B 
Luminal 
A 
Luminal 
A 
Luminal 
A 
Basal 
like 
Basal 
like 
 
Clear separation in the PCA scores plots was not visible based on any of the eight 
parameters (data not shown). Only the scores plot classed according to grade of 
single occurrence tumours is shown (Figure 3.6). PCA was not performed solely for 
the samples that were assigned as ER+ or ER- because information could be inferred 
from the model created based on ER scores; the same applied to PR status. From 
the scores plot for combined ER/PR/HER2 values, evaluation based on tumour 
subtypes was conducted by combining classes 7 and 8 to form the basal like group: 
no separation was present based on luminal A, luminal B and basal like tumours. 
 
 
Key: grade =  0,  1,  2 and   3 
Figure 3.6 PCA scores plot of PQ normalised urine data excluding acetaminophen 
regions for single occurrence tumour grade. Coloured according to grade. 
 
PLS-DA was performed based on all of the eight parameters as well as for ER+/- and 
PR+/- statuses but a model was only created based on ER/PR/HER2 class. The one 
PC model was poor (R2X = 0.202, R2Y = 0.202 and Q2Y = 0.050) and no separation 
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was observed between classes (scores plot shown in Figure 3.7, loadings plot not 
shown). Of note though, in both PCA and PLS-DA scores plots, samples assigned as 
class 4 (ER+, PR- and HER2-; luminal A) had the greatest negative PC 1 scores values. 
Samples belonging to class 2 (luminal B) were also hormone receptor positive 
therefore it could be hypothesised that samples in classes 2 and 4 would be 
positioned in similar scores space but this is not observed. Additionally, there were 
only two samples in class 4.  
 
 
Key: ER/PR/HER2 class =  2,  4,  7 and   8 
Figure 3.7 PLS-DA scores plot of PQ normalised urine data excluding 
acetaminophen regions for ER/PR/HER2 class. Descriptors related to classes 
shown in Table 3.3. 
 
3.1.3 Analysis of Spectrum Excluding Acetaminophen, Creatinine and Hippurate 
Regions 
 
Further analysis ensued whereby creatinine (3.034-3.064 and 4.043-4.073 ppm) and 
hippurate signals (3.954-3.984, 7.530-7.590, 7.611-7.662 and 7.815-7.867 ppm) 
were also removed and the remaining data re-normalised. The median quotient 
range was 0.775-1.249.  
 
For the eight aforementioned parameters, PCA models could not be generated. 
Only single occurrence case samples graded as 0, 1, 2 or 3 were modelled by PLS-DA 
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(one PC; R2X = 0.155, R2Y = 0.142 and Q2Y = 0.017) and separation of grades was not 
observed. PLS-DA models were not able to be generated based on ER+/- or PR+/- 
status. 
  
3.1.4 Analysis of Spectrum Excluding Acetaminophen Samples 
 
Due to the intensity of the acetaminophen signals, it was possible that underlying 
peaks were obscured that could influence separation between sample classes. To 
determine whether this scenario was applicable, samples that contained 
acetaminophen signals were excluded. Creatinine and hippurate regions were not 
excluded. The remaining 50 samples were re-normalised resulting in median 
quotients within the range 0.613-1.210. A summary of the PCA models is shown in 
Table 3.4. 
 
Table 3.4 Parameters used for classification in PCA and model descriptors 
excluding acetaminophen samples. 
Parameter (class) Samples in class (total) PCs R2X Q2X 
State (case or control) 23, 27 (50) 1 0.147 0.034 
Grade (0, 1, 2, 3 or 1 and 
2) 
7, 3, 7, 9, 1 (27) 1 0.196 0.041 
Grade (0, 1, 2 or 3) 7, 3, 7, 9 (26) 1 0.200 0.057 
Grade (1, 2 or 3) 3, 7, 9 (19) 1 0.224 0.051 
Ductal and grade (1, 2 or 
3) 
3, 6, 5 (14) 1 0.253 0.041 
ER status (0/8 - 8/8) 10=0/8, 1=3/8, 1=6/8, 14=8/8 (26) 1 0.199 0.051 
PR status (0/8 - 8/8) 9=0/8, 1=2/8, 1=3/8, 1=4/8, 1=5/8, 
1=6/8, 3=7/8, 5=8/8 (22) 
1 0.206 0.053 
PR status (-ve or +ve) 10, 9 (19) 0 / / 
HER2 status (-ve or +ve) 18, 5 (23) 1 0.205 0.042 
Combined ER, PR and 
HER2 status (1 - 8) 
8=2, 2=7, 5=8 (15) 0 / / 
 
All models generated were poor and no separation was observed irrespective of the 
parameter tested. PLS-DA was performed for all parameters but models did not 
result. 
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3.1.5 Analysis of Spectrum with Potential Confounding Factors Minimised 
 
BMI, age and smoking are well known confounding factors(151) and analysis of a 
small plasma data set, where variation amongst the three factors had been 
minimised, resulted in partial separation between case and control samples (Section 
2.1.1.3). As per Chapter 2, ten case and ten control samples were matched singly 
according to BMI or age whilst five samples of each type were matched according to 
BMI, age and ‘never smoked’ status. With the inclusion of sample 1002 and 
exclusion of sample 1008, figures related to BMI and age changed (Table 3.5). The 
demographics of the five best matched control samples according to BMI, age and 
never smoked status were unchanged because sample 1008 was not one of samples 
included and sample 1002 was sourced from an ex-smoker.  
 
Table 3.5 Demographics of samples included in plasma and urine data sets. 
Samples Biofluid Sample Exclusive 
to Biofluid 
Age BMI (kg m-2) 
Average Median Average Median 
All Plasma 1008 66.0 63.0 29.0 27.3 
Urine 1002 65.8 63.0 28.9 27.3 
Best age 
matched 
Plasma 1008 63.4 63.5 / / 
Urine 1001 63.6 63.5 / / 
Best BMI 
matched 
Plasma 1026 / / 27.2 26.8 
Urine 1002 / / 27.0 26.8 
 
PCA and PLS-DA were applied to the data sets. Values associated with the models 
are shown in Table 3.6. 
 
Separation between case and control samples was not visible when variation in age 
or BMI, age and ‘never smoked’ status was minimised. For BMI matched samples 
there is a slight tendency for case samples to have lower t[1] values (Figure 3.8) 
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Table 3.6 Model descriptors for analysis using samples that were best matched 
according to a parameter(s). 
Parameter(s) Matched  PCA PLS-DA 
PCs R2X Q2X PCs R2X R2Y Q2Y 
BMI  1 0.234 0.059 1 0.221 0.436 0.126 
Age  1 0.246 0.103 0 / / / 
BMI, age and ‘never smoked’ 1 0.314 0.044 0 / / / 
Units: BMI = kg m-2. 
 
 
Key:  case and  control 
Figure 3.8 PCA scores plot of PQ normalised urine data for case and control 
samples matched according to BMI. 
 
Creatinine, which is positively associated with BMI,(166) strongly dominated positive 
PC 1 loadings space (figure not shown) despite these samples being BMI matched 
with a range of 24.4-30.0 kg m-2. This data set indicates creatinine could have a 
greater influence than that associated with BMI alone, however, the association 
between BMI and creatinine for all samples warrants further investigation. 
 
Models were created based on two classifications of patients’ BMI; data was 
available for 61 samples. The first classification was determined as follows: samples 
with the lowest third of BMI values were designated as class 1, class 2 for the middle 
third and the highest third was assigned class 3 status. The scores plot of the two PC 
model (R2X(cum) = 0.297 and Q2X(cum)  = 0.156) is shown in Figure 3.9; the loadings 
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plot (not shown) is extremely similar to Figure 3.5. The other form of classification 
was directly dependent on BMI values being indicative of weight status: classes 1, 2, 
3 and 4 corresponded to <18.5, 18.5-24.9, 25-29.9 and ≥30.0 kg m-2, suggestive of 
underweight, healthy weight, overweight and obese patients, respectively (data not 
shown).(149) The BMI ranges when the data was split into three classes were similar 
to those for weight status: 1 = <24.9, 2 = 25.0-28.9 and 3 = ≥29.0 kg m-2.  
 
For both, no correlation was observed between BMI and creatinine levels. The 
seven samples with the greatest positive PC 1 scores values in Figure 3.9 did not 
belong to the class that contained the greatest BMI values. The same applied to ten 
samples when BMI was modelled as being an indicator of weight status.  
 
 
Key: shape -  case and  control; colour - BMI class =  lowest,  middle and  
highest 
Figure 3.9 PCA scores plot of PQ normalised urine data coloured according to 
three classes of BMI (kg m-2) value (one-third of samples in each class).  
 
Creatinine positively correlates with muscle mass(167,168) to a greater extent than 
with BMI(166) and because the latter is not a measure of muscle mass this could 
explain why correlation is not shown between creatinine and BMI. 
 
Analysis was previously performed excluding samples that contained 
acetaminophen signals (Section 3.1.2) and sample 2023, which was included in the 
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best age matched samples, had these signals present. Given there was no 
separation between the ten case and ten control samples analysis using a 
replacement for this sample was not performed. Additionally, the age range would 
increase if 2023 (63 years) was substituted by the sample from the patient with the 
next closest age to the median (Table 3.7). A similar argument applies to the best 
BMI matched samples. Samples 2017, 2023 and 2026 would need to be replaced 
and there was not clear separation between the 10 control and seven other case 
samples. 2023 was also one of the five best BMI, age and ‘never smoked’ samples 
and, again, a model was not created using a replacement. 
 
Table 3.7 Current and potential range of parameters with acetaminophen 
containing samples included (current range) or excluded (potential range). 
Parameter(s) 
Matched 
Samples to be 
Replaced 
Current Range Potential Range 
Age 2023 60-64 60-67 
BMI 2017, 2023, 2026 25.8-28.7  25.5-28.9  
BMI, age and 
‘never smoked’ 
2023 24.7-29.1 and 56-68 23.9-29.1 and 56-78   
or 
24.7-32.4 and 56-68 
Units: BMI = kg m-2. For best matched BMI, age and ‘never smoked’ samples, all samples 
were from patients who had never smoked and the first range value refers to BMI and the 
second age; the potential range would depend on whether greater emphasis was placed on 
BMI or age. 
 
3.2 Conclusions 
 
Non-prescribed medication can exert a strong influence on metabolomics 
investigations as shown by the presence of signals originating from acetaminophen 
or acetaminophen breakdown products. 
 
Exclusion of acetaminophen regions resulted in creatinine and hippurate 
dominating loadings space but discrimination based on case and control samples 
and numerous descriptors of tumours was not possible. Additional exclusion of 
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these two metabolites generally made building of models unfeasible and removal of 
samples that contained acetaminophen signals did not provide further information 
regarding separation of the remaining samples. Analysis of select samples matched 
according to age, BMI or BMI, age and ‘never smoked’ status did not differentiate 
between case and control samples. 
 
Analysis of urine data did not provide discrimination between samples based on 
various descriptors for this sample set. 
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Chapter 4. SHY Analysis of Plasma and Urine Data 
 
SHY is an extension of STOCSY and allows latent variables to be identified between 
data acquired using different platforms, such as NMR spectroscopy and MS, or 
between different biofluids and/or tissues.(96) Covariance between signal intensities 
in the same or related molecules is analysed.(95) If different technologies were used 
and a known signal from NMR spectroscopy data was shown to be correlated to an 
unknown ion from MS, identification of that ion could be possible. The reverse 
could also apply if the origin of the signal in NMR spectra was uncertain due to low 
intensity or it being poorly resolved.(169) Different metabolites that are not common 
to both of the data acquisition methods but are linked via metabolic pathways 
could also be highlighted. By using different sample types the same principles 
would apply. Additionally, if tissue was used as one of the sample types or one of 
the biofluids was more difficult to obtain than the other and covariances were 
identified, the need to collect the more invasive biofluid or tissue would be 
reduced.(96,170) This would have positive implications for patients.  
 
4.1 Data Acquisition Methodology 
 
Plasma (Chapter 2) and urine (Chapter 3) NMR spectroscopy data from the same 
patient set were analysed by SHY however full resolution data was used.(96) For 
both biofluids PQN was applied (Section 8.3.1.2) and Table 8.7 lists regions included 
in the calculation of the median quotient. Case and control samples were analysed 
separately to allow any potential differences in correlations to be visualised. 
Correlation coefficients were calculated between data point intensities of the two 
biofluids as detailed in Section 8.6. The script used in MatLab, version 7.12.0.635 
(R2011a) (The MathWorks, Inc., Natick, Massachusetts, USA) to generate 
correlation coefficients was written in-house by C. McRae and modified by T. 
Bansagi. Pearson’s(95,96,170,171) and Spearman’s correlation coefficients(96) have been 
used in previous studies. The magnitude of correlation coefficients is indicated by 
the colourmap of plots: darkest red shows the strongest positive correlation and 
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darkest blue the strongest negative correlation. Numerically +1 indicates perfect 
correlation and -1 perfect anti-correlation. Correlation coefficients with p-value 
>0.001 were considered to be spurious(95,96,171) and set to zero, appearing as white 
in plots. The stringent p-value limit was implemented to reduce spurious 
correlations and is equivalent to a Bonferroni correction for 50 independent 
tests.(96) Other studies have not considered a correction factor implementing p 
<0.05 as the cut-off value.(170) The same study argued that only correlations 
between the same signals from the same metabolites in different biofluids could be 
investigated but this eliminates many benefits of performing SHY. Even using a 
confidence level of 99.9% spurious correlations will result through random chance 
due to thousands of points present.(171) However, by using full resolution data the 
two-dimensional space occupied in the plot by each potential correlation is smaller 
and it is unlikely that multiple spurious points would result at regions of signal 
intensity in both biofluids. Additionally, it would be possible to observe potential 
correlation that involved a metabolite whose signal overlapped with that of a non-
correlated metabolite, which could be obscured using binned data. Larger areas of 
correlation would be investigated to confirm whether the correlation was non-
spurious by distinguishing points that are clustered or arranged in patterns that 
coincide with the spectra.(95) 
 
Data points were used in analysis with conversion to chemical shift values 
implemented for clarity in this chapter including labelling of SHY plots. Processing of 
full resolution data is intensive in terms of computing power: a personal computer 
(Evesham Technology, Evesham, Worcestershire, UK; processor speed = 3.0 GHz, 
random access memory (RAM) = 2032 MB, processor type = Intel(R) Pentium(R) 4 
central processing unit (CPU)) could only process data that resulted in 
approximately a 6,000 x 6,000 matrix and the highest specification personal 
computer (Dell Inc., Round Rock, Texas, USA; processor speed = 2.93 GHz, RAM = 
16 GB, processor type = Intel(R) Core(TM) i7 CPU) accessible for which these 
analyses could be performed was unable to produce a square 37,815 matrix that 
included p-values. Removal of the 4.500-6.200 ppm region that had been set to zero 
because it contained water and additionally urea for urine, reduced each spectrum 
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to 30,852 data points but generation of a SHY plot was still not possible. Removing 
regions that had a value of zero for all samples resulted in 9,060 and 27,450 data 
points for plasma and urine, respectively, and allowed plot generation. PQN was 
implemented for both data sets.(96) 
 
Due to the large number of data points in plots, subsequently points have been 
approximated to the nearest 25; this number of points equates to approximately 
0.006 ppm. Within the text a capital letter and in some instances additionally a 
number, in parentheses refers to an area highlighted in Figures. 
 
4.2 Results 
 
4.2.1 Pearson’s Analysis 
 
Figure 4.1 shows the SHY plot for case samples obtained using full digitised data 
excluding regions that had an integral value of zero for all samples with Figure 4.2 
the equivalent for control samples. Differences in covariance can be identified 
between case and control samples. For example, there is strong correlation for 
cases in areas A and B whereas for controls this is not apparent. The reverse applies 
to areas C and D. To assess the validity of correlation, determination of the cause(s) 
is required. 
  
 
 
 
Figure 4.1 Output from Pearson’s SHY analysis of urine and plasma data from case samples. The colour bar indicates the Pearson correlation 
coefficients. Boxed areas, with labels, highlight areas referred to in the text.  
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Figure 4.2 Output from Pearson’s SHY analysis of urine and plasma data from control samples. The colour bar indicates the Pearson 
correlation coefficients. Boxed areas, with labels, highlight areas referred to in the text.  
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Areas of potential true correlations for case samples were investigated. Figure 4.3 is 
an expansion of Figure 4.1 that includes areas A and B. The Figure shows strongest 
correlation of plasma occurs at 0.956 ppm (P1). The correlated urine ppm values, 
with ranges in parenthesis, are 8.128 ppm (8.123-8.133 ppm; U1), 8.311 ppm 
(8.299-8.323 ppm; U2), 8.448 ppm (8.445-8.450 ppm; U3), 8.500 ppm (8.494-
8.506 ppm; U4) and 8.567 ppm (8.555-8.579 ppm; U5). In plasma, strong 
correlation centred at 2.058 ppm (P3) is visible with the aforementioned urine 
areas (U1-U5) though the correlation area at 8.448 ppm (U3) is very small. The 
plasma correlation region centred at 2.058 ppm (P3) extends from 2.046 ppm to 
2.070 ppm whereas for 0.956 ppm the continuous region is between 0.932 ppm 
and 0.981 ppm (P1) and for the non-continuous region the range is 
0.932-1.042 ppm (P1+P2). The majority of an upfield signal of a valine doublet and 
likely a leucine triplet, possibly with an underlying isoleucine triplet, are contained 
between 0.932 ppm and 0.981 ppm (P1).(103) Extending the range to 1.042 ppm 
(P1+P2) incorporates the whole of the valine doublet and the upfield half of 
another valine doublet as well as an isoleucine doublet. The correlation region 
2.046 ppm to 2.070 ppm (P3) consists of indistinct signals.  
 
 
Figure 4.3 Expansion of output from Pearson’s SHY analysis of urine and plasma 
data from case samples showing the urine 8.079-8.665 ppm and plasma 
0.871-2.100 ppm area. The colour bar indicates the Pearson correlation 
coefficients. Boxed areas, with labels, highlight areas of correlation referred to in 
the text.  
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Sample 2039 contains a broad singlet in each of the aforementioned urine ranges 
whereas other samples only display noise. The exception is 8.555-8.579 ppm, which 
contains the upfield half of a very broad signal visible in most samples; this range 
has the least strong correlations. To determine whether the correlations are due to 
sample 2039 alone the urine and plasma signal intensities of all samples were 
plotted for the data point that has approximately the strongest correlation in each 
region. The plot related to 0.956 ppm and 8.311 ppm in plasma and urine spectra, 
respectively, is shown in Figure 4.4. One sample, 2039, is vastly different to all 
others and would heavily influence the correlation coefficients and p-values. The 
same applies to the equivalent plot (data not shown) using the same plasma value 
but 8.567 ppm for urine. Replacing 0.956 ppm with 2.058 ppm for plasma also 
resulted in a similar plot (data not shown) to that shown in Figure 4.4. The unique 
signals to sample 2039 were not able to be identified. 
 
 
Figure 4.4 Scatter plot for case samples showing intensities of data points with 
maximum correlation within urine 8.299-8.323 ppm and plasma 0.932-0.981 ppm 
ranges. 
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4.277 ppm (U2 centre) and 3.641 ppm (P3 centre) for urine and plasma, 
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signals:(103,142) a complete doublet of doublets centred at 3.65 ppm is contained in 
P3 and two downfield peaks of another are located in P1, the other two peaks 
overlap with a glycine signal (Figure 4.6). Additionally, a threonine doublet(103,142) is 
present that spans 3.58-3.61 ppm but this is approximately the area in Figure 4.5 
that correlations are not present (P2). Glycerol is a component of triglycerides and 
phospholipids.(103) 
 
 
Figure 4.5 Expansion of output from Pearson’s SHY analysis of urine and plasma 
data from control samples showing the urine 4.198-6.411 ppm and plasma 
3.519-4.113 ppm area. The colour bar indicates the Pearson correlation 
coefficients. Boxed areas, with labels, highlight areas of correlation referred to in 
the text. 
 
 
Urine (data point number x10 )
P
la
sm
a 
(d
at
a 
p
o
in
t 
n
u
m
b
er
 x
1
0
 )
 
 
1.101.121.141.161.181.201.221.241.261.28
0.10
0.12
0.14
0.16
0.18
0.20
0.22
0.24
0.26
0.28
0.30
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
P
la
sm
a 
(d
at
a 
p
o
in
t 
x1
0
4
) 
Urine (data point x104) 
P6 
P5 
P3 
P2 
P1 
U2 U9 U8 U7 U6 U5 U4 U3 U1 
P4 
     4.25                  4.34                  4.42                   6.24                  6.34 
Urine (ppm) 
4.08 
3.92 
3.82 
3.73 
3.63 
3.53 
P
la
sm
a 
(p
p
m
) 
a) 
101 
 
 
Figure 4.6 Expansion of plasma spectra that incorporates 3.555-3.677 ppm for 
which positive correlation is present with urine. 
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range;(103,172) the remaining signals would be obscured by large glucose signals. 
Additionally, Nicholson et al.(142) reported glycerol presence at 3.87 ppm. 
 
In Figure 4.7 the trend of signal intensities for the data point with the strongest 
correlation between urine and plasma (U2 centre, P3 centre) can be approximated 
as linear with a percentage increase in one mirrored by the other; an outlying 
sample is not causing correlation. Identification of the urinary metabolite 
responsible for correlation could not be established. 
 
 
Figure 4.7 Scatter plot for control samples showing intensities of data points with 
maximum correlation within urine 4.222-4.497 ppm and plasma 3.555-3.677 ppm 
ranges. 
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metabolism and endogenous methanethiol metabolism.(174) Medical records for the 
patient indicated no drug or supplement history but given acetaminophen was 
detected in a number of urine samples (Chapter 3) despite no record of 
consumption it is conceivable that the patient neglected to inform of DMSO2 usage 
especially because it is a non-prescribed supplement. Most of the urine chemical 
shift values do not correspond with maximum intensities of signals and no clear 
intra-sample pattern is observed between signal intensities of the aforementioned 
urine regions. It is indicated that correlations resulted due to the effect of one 
sample. 
 
 
Figure 4.8 Expansion of output from Pearson’s SHY analysis of urine and plasma 
data from control samples showing the urine 6.899-8.689 ppm and plasma 
2.426-3.250 ppm area. The colour bar indicates the Pearson correlation 
coefficients. Boxed areas, with labels, highlight areas of correlation referred to in 
the text. 
 
4.2.2 Spearman’s Analysis 
 
Pearson’s correlation is sensitive to exogenous perturbations and potential 
outliers,(96) for example the unique signals of sample 2039 could be termed outliers 
as could the greatly increased DMSO2 signal for sample 1017. Spearman’s 
correlation is considered more robust and both approaches should be used in a 
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coefficients were calculated and plots shown in Figure 4.9 and Figure 4.10 for case 
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Figure 4.9 indicates, through paucity of correlation in areas A and B, the 
correlations exhibited in Figure 4.1 in these areas were as the result of unique 
signals in sample 2039. 
 
The largest area exhibiting strong (positive) correlation is in area E, centred at 
1.275 ppm and 1.285 ppm for urine and plasma, respectively. The latter 
corresponds to presence of lipids(142) and is further verified through a smaller area 
of correlation (F) displayed in the same urine region but at 0.901 ppm for plasma, 
also characteristic of lipids.(103,142) A number of sources(103,158-160,163,175) were used in 
an attempt to identify the urine signal that was present in all samples but the 
singlet was not been able to be assigned. However, Engelke et al.(176) determined 3-
hydroxyisovaleric acid as the species responsible for a singlet at 1.28 ppm. 
 
The concentration of 3-hydroxyisovaleric acid is an indicator of reduced activity of 
the biotin-dependent enzyme 3-methylcrotonyl-CoA carboxylase.(177) The enzyme 
converts 3-methylcrotonyl-CoA, which is derived from leucine, to 3-
methylglutaconyl-CoA but with reduced enzyme activity the pathway to 3-
hydroxyisovaleryl-CoA is favoured. CoA and 3-hydroxyisovaleric acid are the 
degradation products of 3-hydroxyisovaleryl-CoA.(103) In summary, SHY indicates 
positive correlation between 3-hydroxyisovaleric acid, and hence negative 
correlation between biotin, and lipids; negative correlation between biotin levels 
and plasma lipids has been reported.(178,179) The most abundant biotin signal, a 
triplet at 2.21 ppm,(103) was not detected in either biofluid. A study reported 
3-hydroxyisovaleric acid was greater in urine for smokers than control subjects and 
suggested smoking increased biotin catabolism.(180) 
 
Smoking parameters were evaluated relative to the normalised value for the data 
point at 1.275 ppm in urine, corresponding to the tentatively assigned 
3-hydroxyisovaleric acid signal. Different smoking statuses (‘current smoker’, ‘ex-
smoker’ and ‘never smoked’ assigned as per Chapter 2 and Chapter 3) were not 
grouped relative to data point integral. When ranked on integral value the ‘ex-
smoker’ group occupied the highest and lowest (36th) positions whilst ‘current 
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smoker’ group ranged between 3rd and 34th and ‘never smoked’ 5th to 35th. The 
number of cigarettes smoked also did not correlate with integral value. Of the 20 
patients who did not form the ‘never smoked’ class, consumption was highest for a 
current smoker whose integral was ranked 34th. Ranks 1 to 4 corresponded to 18th, 
16th, 6th and 19th greatest amount of cigarettes smoked. No evidence is presented 
to suggest a correlation between the signal area at 1.275 ppm and smoking.  
 
Figure 4.10 shows similar correlation coefficients to Figure 4.2 for area D (urine 
4.222-4.497 ppm and plasma 3.555-3.677 ppm). Due to the robust test and high 
confidence level used it is indicative that the correlation in the aforementioned 
area, for which responsible signals were assigned to glycerol in plasma, is not 
spurious. Within the aforementioned urine region negative correlation is shown 
with the plasma region 0.810-1.267 ppm (G and H) and the strongest (negative) 
correlation is located between 0.810 ppm and 0.883 ppm (G). The latter region 
corresponds to part of a lipid signal: the upfield side to approximately 0.005 ppm 
from the maximum intensity. The upfield side of another lipid signal corresponds to 
1.267 ppm; the maximum intensity is located at approximately 1.285 ppm.  
 
The urine metabolite shows opposite associations with glycerol and part of lipid 
signals. Glycerides are lipid esters of the glycerol molecule and fatty acids, with 
triglycerides having three fatty acids. Triglycerides are a major component of very 
low density lipoproteins (VLDL),(181) which of the lipoprotein types contributes most 
strongly to the downfield part of the aforementioned lipid signals whereas high 
density lipoproteins (HDL) influences the upfield region of lipid signals.(128) This 
would indicate negative association between glycerol and HDL in control patients 
but conversely negative association has been observed between triglycerides and 
HDL-cholesterol in patients with breast cancer compared to controls;(182) CVD is 
indicated by this triglyceride/HDL-cholesterol profile.(183) Although breast cancer is a 
risk factor for developing CVD(182) non-breast cancer medical conditions are not 
known for patients in this study so it is conceivable that control patients could have 
been afflicted by CVD. 
  
 
 
 
Figure 4.9 Output from Spearman’s SHY analysis of urine and plasma data from case samples. The colour bar indicates the Spearman 
correlation coefficients. Boxed areas, with labels, highlight areas referred to in the text. 
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Figure 4.10 Output from Pearson’s SHY analysis of urine and plasma data from control samples. The colour bar indicates the Spearman 
correlation coefficients. Boxed areas, with labels, highlight areas referred to in the text. 
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4.3 Conclusions 
 
Incorporating a stringent p-value into both Pearson’s and Spearman’s tests for 
covariance reduced the chance of spurious correlations between urine and plasma 
data but because of the many thousands of data points some erroneous 
correlations have occurred. Deciphering true and false correlations was problematic 
though larger areas and greater intensity correlations indicated potentially 
biologically relevant correlations.  
 
Both tests indicated glycerol in plasma from case samples was positively correlated 
to a urine species that could not be identified. Further, Spearman’s analysis showed 
the urine area was correlated with the upfield section of lipid signals for which a 
speculative hypothesis has been reasoned involving triglyceride presence in 
lipoprotein species of different density. 
 
Spearman’s correlations identified a urine signal, tentatively identified as 
3-hydroxyisovaleric acid, to be connected with plasma lipid signals in an inverse 
relationship. Relationships between 3-hydroxyisovaleric acid, biotin and lipids are 
established that corroborate the SHY findings.  
 
SHY has provided data that could relate metabolites in urine and plasma for which 
it may have been difficult to discern connections. However the non-spurious nature 
of the correlations would need to be established before more definitive conclusions 
could be made. Spearman’s analysis is an initial step towards this, here showing 
some correlations were due to unique or greatly elevated signal intensities and 
highlights the need for detailed medical records including consumption of non-
prescription drugs and supplements. 
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Chapter 5. Gas Chromatography Analysis of Plasma 
 
The concentrations of amino acids (AAs) in plasma, as determined by GC, will be 
described in the following chapter. Aliquots of plasma obtained from the same 
cohort as described in Chapter 2 were available, comprising of 33 case and 24 
control samples. 
 
MVA and univariate analysis of the GC data was performed in an attempt to identify 
possible AA biomarkers of breast cancer occurrence and progression. MVA and 
univariate analysis were performed as described in Section 8.4 and Section 8.5, 
respectively, with the exceptions that data were not normalised and UV scaling was 
performed rather than Pareto.  
 
5.1 Determination of Amino Acid Concentrations  
 
The commercially available system EZ:Faast (Phenomenex, Macclesfield, UK) has 
been developed for quantitative analysis of amino acids in a number of biological 
matrices, including plasma and urine. Briefly, the procedure involves a solid phase 
extraction step followed by derivatisation and a liquid/liquid extraction with the 
sample preparation procedure followed that was listed in the information booklet 
that accompanied the system. Further details of the methodology are in Section 8.7. 
Following earlier ‘in-house’ studies (E. Turner, unpublished work) it was decided to 
use this system to test whether AA biomarkers could be established for the sample 
set available. 
 
Each sample was injected three times and any chromatogram that was deemed not 
to have sufficient signal to noise ratio, whereby the signal area was unduly affected 
by noise, was discarded. For two control samples and one case sample two 
chromatograms were considered too poor to use so without a replicate the data 
from the acceptable chromatogram was excluded from analysis. Resultantly, data 
from 32 case and 22 control samples were used in analysis. For five control samples 
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and six case samples data from one chromatogram was considered too poor to use 
so the average values for the concentrations of AAs were calculated using two runs 
of the samples. 
 
Every sample contained an internal standard (IS) that allowed determination of AA 
concentrations relative to it. However, the detector response factor is dependent on 
the AA so a calibration curve for each of the 26 AAs was required (structures and 
retention times shown in Appendix 2, Table A2.1). Calibration curves were created 
using data obtained from calibration standard sets that consisted of three runs, 
each of a different concentration (50, 100 and 200 nmol ml-1), containing all of the 
AAs. Multiple injections of the same standard set were performed. A gradient from 
the calibration curve was obtained for every run of each standard set. Upon 
optimisation of the gas chromatograph parameters three runs each from two 
standard sets were disregarded to account for variability in detector response 
resulting from a change of settings. A single run of a standard set was performed 
prior to the initial run of the first test sample. After every 10 test samples a standard 
set was run. Up to three runs per standard set were performed within a 24 hour 
time period (the maximum storage time at room temperature recommended by the 
kit manufacturers). In total, calibration curves were generated for 20 runs from 
seven calibration sets. A representative chromatogram from a standard is shown in 
Figure 5.1. 
 
The calibration curve gradient was analysed across the 20 runs of calibration 
standard sets. The maximum value of the gradient divided by the minimum value 
(max/min) and residual standard deviation (RSD) determined the consistency of 
calibration curve gradient values. For six of the 26 AAs calibration curve gradients 
were not obtainable for all runs of standard sets. This was due to the concentration 
being below the lower limit of detection (LLOD) of the gas chromatograph for all 
three concentrations within a run of a standard set. When the max/min value was 
less than or equal to 1.5 the RSD range was 6.9-12.8% so the calibration curve 
gradient value was deemed acceptable; for metabolomics studies where GC-MS has 
been employed, use of an RSD of less than 20%(184) or 30%(185) as the determinant 
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for data retention has been applied. Seven of the max/min values were 1.6 or above 
(RSDs 13.0-31.8%) thus leaving concentrations of 13 AAs to be investigated in the 
biological samples (Table 5.1). 
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Table 5.1 Retention times and further investigation status of AAs. 
AA Retention Time 
(minutes) 
Further 
Investigation Full Name Abbreviation 
Alanine ALA 1.59 Yes 
Sarcosine SAR 1.65 Yes 
Glycine GLY 1.69 Yes 
α-Aminobutyric acid ABA 1.79 Yes 
Valine VAL 1.88 Yes 
β-Aminoisobutyric acid β-AIB 1.96 Yes 
Norvaline (internal standard) IS 2.00 N/A 
Leucine LEU 2.08 Yes 
Allo-Isoleucine α-ILE 2.11 Yes 
Isoleucine ILE 2.14 Yes 
Threonine THR 2.34 No 
Serine SER 2.38 No 
Proline PRO 2.45 Yes 
Asparagine ASN 2.54 No 
Aspartic acid ASP 3.05 Yes 
Methionine MET 3.09 Yes 
Hydroxyproline HYP 3.22 No 
Glutamic acid GLU 3.39 No 
Phenylalanine PHE 3.43 Yes 
α-Aminoadipic acid AAA 3.68 No 
Glutamine GLN 4.01 No 
Ornithine ORN 4.37 No 
Lysine LYS 4.62 No 
Histidine HIS 4.80 No 
Tyrosine TYR 5.07 No 
Tryptophan TRP 5.36 No 
Cystine C-C 6.01 No 
 
In addition to the detector response factor differing inter-AA, variation could occur 
intra-AA with time due to column degradation. Running a set of standards regularly 
between samples reduced the impact of potential response factor deviations. For 
every AA that was investigated further the calibration curve gradient from every run 
of standards was plotted against run order. Despite all but one of the new gradients 
being negative, the r2 values were low with values ranging between -0.03 for VAL 
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and -0.49 for both LEU and GLY (Appendix 2, Figure A2.1). For ASN, which had a 
positive gradient, the r2 value was 0.04. For an intra-AA difference in response factor 
to be concluded much higher (modulus) r2 values than those observed would be 
required. 
 
Collectively, AA response factor variation was assessed through interpretation of IS 
area divided by total amino acid area (IS/AA) values. For each concentration the 
values were plotted against run order of calibration standard sets. Plots indicated 
weak positive association between IS/AA and run order (data not shown). Given the 
weak negative association shown between individual AA calibration curve gradient 
values and run order, the finding was not unexpected. Given that the maximum r2 
value of the three plots was 0.32 and the fourth set of standards consistently 
provided some of the highest IS/AA values there was no clear evidence of differing 
response factor for AAs collectively.  
 
Additionally, for each concentration of every calibration standard set, IS/AA values 
of runs were plotted against run order. For some calibration standard sets there was 
strong negative association between IS/AA and run order. The first, second and 
third runs of Standard VII and Standard VIII at 100 nmol ml-1 and Standard XI at 50 
nmol ml-1 showed almost perfect correlation with r2 values all in excess of -0.99 
(data not shown). All but one of the plots revealed a negative correlation (data not 
shown) but with just three points the gradient and r2 value can be heavily influenced 
by a single point. Degradation of standards with time could also be assessed by 
evaluation of the plots. If degradation occurred, strongest negative association 
would be expected to be shown by plots for standards that had the longest time 
period between the first and last run. This time was 23 hours 55 minutes for both 
Standard X and Standard XI but stronger negative association was not observed than 
for standards with a shorter elapsed time such as Standard VII, which had an 
equivalent time of 6 hours 30 minutes (Appendix 2, Figure A2.2). There is no 
evidence to suggest degradation of standards and because the elapsed time 
between runs of test samples was no more than the maximum time between runs 
of standards it can be postulated no degradation of test samples occurred.  
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5.2 Results 
 
Having performed the appropriate calibration procedures the concentrations of the 
13 AAs were investigated in the plasma samples. No more than four samples 
exhibited detectable levels of SAR, β-AIB, α-ILE and ASP so these AAs were excluded 
from analysis. ABA and MET were detectable in the majority of samples so were 
retained in analyses; for some samples not all runs provided a signal for either AA or 
MET that was above the LLOD so the average was calculated using only the runs 
where the signal was quantifiable. A typical chromatogram of a sample is shown in 
Figure 5.2.  
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5.2.1 Amino Acid Concentration as a Function of Case and Control Samples 
 
5.2.1.1 Application of Multivariate Analysis 
 
Usually MVA is used when there are more variables than observations. In the case 
of the GC analysis procedure used here this is not the situation. However, MVA has 
been employed to allow potential interconnectivities between AAs to be visualised. 
For NMR spectroscopy data pareto scaling is normally preferred to UV scaling to 
avoid the over-inflation of spectral noise regions (Section 1.4.1.3) but for GC data 
the difference in magnitude between the smallest and largest values of AA 
concentrations is substantially less so UV scaling is suitable.  
 
Prior to averaging concentrations the reproducibility of GC data was assessed by 
PCA of individual runs. NMR spectroscopy produces data that is highly 
reproducible,(50) hence replicates are not required, but GC is less robust.(186) ABA 
and MET were excluded because presence was not detectable in all runs of samples. 
The scores plot (Figure 5.3) of the one component model (R2X = 0.439 and Q2X = 
0.252) shows that multiple runs are needed because the positions of the runs from a 
sample in scores space are not the same. However, they are sufficiently similar to 
allow analysis of sample data that has been averaged from runs. 
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Key: shape -  case and  control 
Figure 5.3 PCA plot of individual runs of case and control samples. Adjacent runs 
with the same colouring originate from the same sample. Label numbering refers 
to the order of runs. 
 
AA concentrations from runs were averaged, including those for ABA and MET, and 
PCA was performed. A one component model was created with an R2X value of 
0.386 and a Q2X value of 0.234 (data not shown). There was no separation between 
case and control samples. The data could not be modelled using PLS-DA. 
 
The average concentration values for ABA and MET were not as accurate as for 
other AAs. Calculating the average signal area, and hence concentration, through 
division of the sum of detectable signal areas by the number of runs for which the 
signal was detectable produced a concentration value higher than the true value: if 
a signal was present but below the LLOD the area was not recorded and hence could 
not be included in concentration calculations. Averaging over all runs irrespective of 
whether the signal area was below the LLOD produced a lower value than the true 
one because any area less than that could be detected was set to zero. For ABA the 
average concentration of case (22.0 nmol ml-1) and control samples (20.7  nmol ml-1) 
combined was 21.5 nmol ml-1 (excluding samples for which the average was zero; 
range 9.3-38.2 nmol ml-1) and the lowest concentration of any run was                    
8.2 nmol ml-1, which is an indicator of the LLOD. Given this value is almost 40% of 
the overall average, values just below the LLOD could strongly influence the sample 
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average. For MET, the equivalent case, control and combined concentrations were 
19.6, 19.9 and 19.7 nmol ml-1, respectively, whilst the range was 9.4-33.2 nmol ml-1 
and the lowest concentration of a run was 9.2 nmol ml-1. Including zero sample 
averages the combined average was reduced to 17.9 and 11.2 nmol ml-1 for ABA and 
MET, respectively. 
 
Repeating PCA with ABA and MET excluded had little effect on the appearance of 
scores and loadings plots (data not shown; one PC model, R2X = 0.463 and 
Q2X = 0.259). 
 
5.2.1.2 Application of Univariate Analysis 
 
The mean concentrations of AAs in case and control samples were evaluated to 
establish whether significant differences were present between sample types. All 
data were tested for normality with a null hypothesis that data distribution was 
normal (Section 1.4.2.1). A Shapiro-Wilk p-value ≥0.05 led to the conclusion that the 
data was normally distributed, hence the Student’s t-test was used but if non-
normal distribution of data was proven, as evidenced by p-value <0.05, the Mann 
Whitney U test was performed to determine whether potential differences were 
statistically significant. The null hypothesis was no difference between mean 
concentration values for the two sample types.  
 
Box plots (Figure 5.4) summarised the data and allowed possible outliers to be 
identified. All chromatograms were reinvestigated if an AA concentration was 
observed beyond the whiskers of the plot. On 14 occasions (including plots for ABA 
and MET that excluded samples with zero average) for the nine AAs, case or control 
sample concentrations were more extreme than 1.5 times the respective 
interquartile range beyond the upper or lower quartile. Every sample was retained 
because all runs provided consistent signal areas therefore no reason could be 
identified to permit exclusion. 
 
 
   
   
Figure 5.4 Box plots of nine AA concentrations for case and control samples. Except where specified the plots represent data from 54 
samples. Red filled box = control samples, black filled box = case samples. * = samples more extreme than 1.5 times the interquartile range 
beyond the upper quartile, coloured as per filled box with sample label. Numbers on the y-axis relate to AA concentration (nmol ml-1 x101).  
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The mean concentrations of case and control samples were calculated for each AA 
and a conclusion forwarded as to whether there was a significant difference 
between values (Table 5.2). For all tests performed a p-value >0.05 resulted so the 
null hypothesis was retained in each case: there was no difference between mean 
concentration values for case and control samples. Correction for multiple testing 
did not need to be performed. For ABA and MET, excluding samples that had an 
average concentration of zero did not change the conclusion that there were no 
differences between the concentration values of the two sample types. 
 
Table 5.2 Summary of data regarding mean concentration differences of AAs 
between case and control samples. 
AA Number 
of 
Samples 
Mean 
Concentration 
(nmol ml-1) 
Data 
Distribution 
Uncorrected 
p-value 
Mean 
Concentration 
Conclusion 
Control Case 
ALA 54 308.7 297.5 Non-normal 0.660 No difference 
GLY 54 275.3 257.8 Non-normal 0.408 No difference 
ABA 54 17.0 18.6 Normal 0.819 No difference 
ABA 
(excluding 
zero sample 
averages) 
45 20.7 22.0 Normal 0.499 No difference 
VAL 54 342.8 320.6 Non-normal 0.958 No difference 
LEU 54 109.0 117.4 Non-normal 0.379 No difference 
ILE 54 59.4 62.8 Non-normal 0.561 No difference 
PRO 54 230.4 243.2 Non-normal 0.916 No difference 
MET 54 13.5 9.5 Non-normal 0.322 No difference 
MET 
(excluding 
zero sample 
averages) 
30 19.9 19.6 Normal 0.927 No difference 
PHE 54 58.9 57.0 Non-normal 0.846 No difference 
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5.2.2 Amino Acid Concentration as a Function of Breast Cancer Grade 
 
Two individuals included in this study were reported to have been diagnosed with 
more than one invasive tumour. Consequently, samples from these patients were 
excluded from analysis. The remaining 30 case samples were graded 0, 1, 2 or 3 with 
7, 5, 9 and 9 samples, respectively.  
 
5.2.2.1 Application of Multivariate Analysis 
 
PCA was performed on the 30 samples resulting in a one component model 
(R2X = 0.392 and Q2X = 0.219; scores plot shown in Figure 5.5 but loadings plot not 
shown). No clear separation was observed between the four groups and a PLS-DA 
model was not able to be created. Excluding ABA and MET from PCA resulted in a 
one component model (R2X = 0.478 and Q2X = 0.282; data not shown) but, again, no 
clear separation was observed between the groups in the scores plot. A PLS-DA 
model was not able to be generated. 
 
 
Key: grade =  0,  1,  2 and   3 
Figure 5.5 PCA scores plot for single tumour case samples coloured according to 
tumour grade. 
 
It was proposed that assessing two groups might reveal separation of samples that 
was not apparent when the four groups were considered together. The model 
parameters, including and excluding ABA and MET, are summarised in Table 5.3 and  
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Table 5.4, respectively. 
 
Table 5.3 Parameters for models that included ABA and MET. 
Grades 
Compared  
PCA PLS-DA 
PCs R2X(cum) Q2X(cum) PCs R2X(cum) R2Y(cum) Q2Y(cum) 
0 v. 1 2 0.812 0.453 4 0.915 0.917 0.658 
0 v. 2 1 0.385 0.107 0 / / / 
0 v. 3 2 0.707 0.269 0 / / / 
1 v. 2 1 0.345 0.040 2 0.542 0.682 0.454 
1 v. 3 0 / / 1 0.268 0.54 0.203 
2 v. 3 0 / / 0 / / / 
 
Table 5.4 Parameters for models that excluded ABA and MET. 
Grades 
Compared  
PCA PLS-DA 
PCs R2X(cum) Q2X(cum) PCs R2X(cum) R2Y(cum) Q2Y(cum) 
0 v. 1 2 0.841 0.425 1 0.647 0.352 0.212 
0 v. 2 1 0.480 0.191 0 / / / 
0 v. 3 2 0.787 0.388 0 / / / 
1 v. 2 1 0.425 0.095 3 0.759 0.759 0.523 
1 v. 3 2 0.784 0.495 1 0.375 0.437 0.202 
2 v. 3 0 / / 0 / / / 
 
PCA did not show separation between any of the pairs of groups when incorporating 
all nine AAs (data not shown). Tentative separation could be viewed between the 
groups in the three PLS-DA models (data not shown). For each model all AA 
concentrations except ABA were indicated as being lower in grade 1 samples. Given 
the previously stated problems with ABA (and MET) concentration measurements 
and small number of samples in the groups, it is not possible to make reliable 
conclusions at present and further samples would be required to increase 
confidence in this observation. 
 
Excluding ABA and MET data resulted in tentative separation between most grade 0 
and 1 samples when PCA was employed (Figure 5.6); this model gave the best 
separation between any combinations of two groups. R2X(cum) and Q2X(cum) 
values (Table 5.4) were high though with only seven variables it would be expected 
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that the model represented the data to a high level. The loadings plot (data not 
shown) indicated all of the AA concentrations were elevated in samples located in 
positive PC 1 scores space compared to those in negative space. Similar 
observations, though not as pronounced, were made when grade 1 samples were 
compared to grade 2 or 3 samples. No improvement in separation was visible upon 
application of PLS-DA for grade 0 and 1 samples (data not shown); the scores plot 
generated using grade 1 and 3 samples displayed similar positioning of samples in 
scores space (data not shown), as did the scores plot for grade 1 and 2 samples 
(Figure 5.7). 
 
Validation of PLS-DA results is always required; the ‘leave one out’ method was 
employed for the three models that were generated using data from seven AAs. 
Associated information for the grade 1 and 2 model is shown in Table 5.5. 
 
 
Key: grade =  0 and  1 
Figure 5.6 PCA scores plot for grade 0 and grade 1 samples excluding ABA and MET 
data. 
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Key: grade =  1 and  2 
Figure 5.7 PLS-DA scores plot for grade 1 and grade 2 samples excluding ABA and 
MET data. R2X = 0.375 and 0.266, R2Y = 0.541 and 0.108 and Q2Y = 0.393 and 0.118 
for PC 1 and PC 2, respectively. 
 
Table 5.5 ‘Leave one out’ cross-validation parameters for the PLS-DA model shown 
in Figure 5.7.  
Sample 
Excluded 
Number of 
Components 
R2X 
(cum) 
R2Y 
(cum) 
Q2Y 
(cum) 
Grade Y-Predicted* 
1 2 
2002 3 0.774 0.781 0.521 2 0.396 0.604 
2009 4 0.877 0.848 0.463 1 1.087 -0.087 
2010 1 0.377 0.527 0.294 1 0.530 0.470 
2011 3 0.760 0.804 0.465 2 0.550 0.450 
2013 1 0.329 0.521 0.308 1 0.769 0.231 
2017 1 0.370 0.539 0.349 1 0.556 0.444 
2018 2 0.703 0.665 0.451 2 -1.307 2.307 
2019 1 0.432 0.539 0.449 2 0.392 0.608 
2022 1 0.349 0.575 0.486 2 -0.407 1.407 
2026 5 0.957 0.883 0.697 2 0.334 0.666 
2030 1 0.379 0.542 0.468 2 0.307 0.693 
2034 1 0.314 0.509 0.415 1 0.925 0.075 
2037 1 0.393 0.565 0.493 2 0.355 0.645 
2039 1 0.326 0.581 0.419 2 -0.330 1.330 
*A sample was regarded as belonging to a grade by having a Y-predicted value >0.50. 
Incorrect classification is represented by red shading and correct by pink, orange or green 
corresponding to a Y-predicted value of <0.60, 0.60-0.70 or >0.70, respectively. 
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All but one of the 14 samples was correctly predicted, giving a 93% predictive 
ability. The PLS-DA loadings plot (data not shown) indicated all AAs were elevated in 
grade 2 samples. The accuracy of class prediction is reduced for samples as the 
Y-predicted value tends towards 0.50; predictions made based on values less than 
0.60, of which there are two, as indicated by pink shading in Table 5.5, should be 
treated with caution whilst those made using values greater than 0.70 (shaded 
green) could be regarded as the most reliable. The extent of the Y-predicted value 
beyond 0.5 is not regularly considered.(140)  
 
Of the 12 grade 0 and 1 samples 50% were correctly predicted, the percentage 
expected by random chance, with two having a Y-predicted value of over 0.70. For 
grade 1 and 3 samples, nine from 14 (64%) samples were correctly predicted. Only 
two predictions were made based on 0.60-0.70 Y-predicted values and the rest from 
values greater than 0.70, though one value was generated using a one component 
PLS-DA model that had a negative Q2Y value. Despite high Y-predicted values for 
correctly predicted grade 1 and 3 samples, the combination of a predictive ability 
that is too close to 50% and high Y-predicted values (up to 1.010) for incorrectly 
predicted samples does not allow the conclusion to be made that grade 1 samples 
have lower concentrations of seven AAs.  
 
Although there is closeness in scores space between some of the grade 1 and 2 
samples, the high predictive ability percentage could indicate that grade 1 samples 
have lower concentrations of ALA, GLY, VAL, LEU, ISO, PRO and PHE. Validation 
using a prediction set is a more rigorous method than ‘leave one out’ 
cross-validation because for the latter method the predicted samples would have 
been used to build the original model. Given the small number of samples in each 
grade a prediction set was not available. However, permutation testing did validate 
the model and supported ‘leave one out’ cross-validation findings. The associated 
plot for the grade 2 class (Figure 5.8) shows all but 15 of the 999 permuted models 
to have lower R2Y values than the original model whilst the equivalent for Q2Y is two 
permuted plots. The intercept values of the regression lines for R2Y and Q2Y are 
0.367 and -0.369, respectively. The permutation testing plot for the grade 1 class 
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(plot not shown) displayed R2Y and Q2Y intercept values of 0.357 and -0.375, 
respectively, with six and one permuted models having higher R2Y and Q2Y values, 
respectively. Although the original model should have higher R2Y and Q2Y values 
than the permuted models as one of the criteria for validation, using 999 
permutations, the maximum that SIMCA-P+ software can perform, it is not 
unexpected that a small proportion will be higher than the original model in some 
cases. The R2Y intercept values are close to 0.4, the maximum value to allow the 
original model to be validated. The better the model, the lower the intercept values 
and the fewer permuted models that will have R2Y and Q2Y values above those of 
the original model. This could explain why classes were correctly predicted using 
‘leave-one-out’ cross-validation for seven of the 13 samples with Y-predicted values 
between 0.50 and 0.70.  
 
 
Key:  R2Y and  Q2Y 
Figure 5.8 Permutation testing plots for the grade 2 class in the PLS-DA model 
shown in Figure 5.7. The R2Y and Q2Y intercept values of the regression lines are 
0.367 and -0.369, respectively. 
 
5.2.2.2 Application of Univariate Analysis 
 
Mean concentrations of nine AAs were compared for every combination of two 
groups to determine whether there were significant differences between tumour 
grades. Table 5.6 shows the mean concentrations of AAs for the different grades 
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and Figure 5.9 the box plots. All chromatograms from a sample were reinvestigated 
if any AA concentration was more extreme than 1.5 times the interquartile range 
beyond the upper or lower quartile of the group; this was performed for 19 
instances. Every sample was retained because all runs provided consistent signal 
areas therefore no reason could be identified to permit exclusion. 
 
Table 5.6 Mean concentration of AAs with different breast cancer grades. 
AA 
Number of 
Samples 
Sample Grade Mean Concentration (nmol ml-1) 
0 1 2 3 
ALA 30 321.8 233.6 321.6 288.4 
GLY 30 247.1 205.2 266.7 255.8 
ABA 25 25.0 23.0 22.7 19.2 
VAL 30 348.2 282.8 359.9 286.6 
LEU 30 136.3 101.9 117.7 109.8 
ILE 30 77.3 51.7 59.8 60.9 
PRO 30 2.419 165.7 301.1 232.3 
MET 15 20.5 19.4 23.7 17.2 
PHE 30 61.5 48.9 59.7 56.1 
 
For the seven AAs present in all samples, as listed previously, all were normally 
distributed for all grades with the exception of GLY for grade 1, PRO for grade 2 and 
both VAL and ILE for grade 3. Significant differences in concentrations of these 
seven AAs between grades are summarised in Table 5.7. Corrections for multiple 
comparisons were performed using FDR. Due to different numbers of samples in 
groups that contained ABA and MET, these two AAs were analysed separately and 
their p-values were not included in the aforementioned multiple test correction 
calculations. 
  
 
 
 
Figure 5.9 Box plots of concentrations of AAs for case samples of different grade. * = samples more extreme than 1.5 times the interquartile 
range beyond the upper or lower quartile. Numbers on the y-axis are AA concentration (nmol ml-1 x101). 
1
3
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Figure 5.9 Continued. 
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Table 5.7 Summary of differences in the concentrations of AAs excluding ABA and 
MET between grades. ↑ or ↓ indicates whether the AA mean concentration is 
higher or lower (though not necessarily significantly) in the first listed grade 
compared to the second; only concentrations of AAs listed under the ‘mean 
concentration conclusion’ heading are significantly different. 
Grades 
Compared 
AA 
Identified 
Data 
Distribution 
p-value Mean 
Concentration 
Conclusion 
Uncorrected Corrected 
0 v. 1 
↑ALA  Normal 0.033 0.154 No difference 
↑PRO  Normal 0.044 0.154 No difference 
0 v. 2 None / / / No difference 
0 v. 3 None / / / No difference 
1 v. 2 
↓ALA Normal 0.047 0.122 No difference 
↓PRO  Non-normal 0.007 0.049 ↓PRO 
↓PHE  Normal 0.018 0.063 No difference 
1 v. 3 None / / / No difference 
2 v. 3 None / / / No difference 
 
MVA had indicated concentrations of all AAs except ABA were lower in grade 1 
samples compared to other grades. This was substantiated by Table 5.6 but nearly 
all of the differences were not statistically significant (Table 5.7). A few AAs were 
identified as potentially significantly different between grades (uncorrected p-value 
<0.05) but after correction for multiple comparisons only PRO was significantly 
different between grades 1 and 2. Data verification proceeded to investigate the 
reliability of the result due to the influence of sample 2018. Although the sample’s 
chromatograms had been concluded to be suitable for analysis the mean PRO 
concentration was much higher than for any other sample. The concentration of the 
three runs ranged from 722.1 to 804.7 nmol ml-1 with a mean of 777.0 nmol ml-1. 
The mean concentration range was 144.7-204.5 nmol ml-1 for grade 1 and 152.7-
362.4 nmol ml-1 for grade 2 excluding sample 2018. With a mean of more than 
double that of the sample with the next greatest concentration, sample 2018 had a 
large influence on the group mean especially given the small number of samples in 
the group (nine). Analysis was repeated that excluded sample 2018. The difference 
in mean concentrations between the groups was no longer significant (Table 5.8). 
Clear justification for removing the sample cannot be provided but due to the 
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sample’s vastly greater concentration and the borderline difference at the 95% 
significance level when the sample is included, further samples would be required to 
verify a potential difference in the mean concentration of PRO between grades 1 
and 2. 
 
Table 5.8 Summary of differences in the concentration of PRO between grades 1 
and 2. ↓ indicates (non-significantly) lower mean concentration in grade 1 
compared to grade 2. 
Grades 
Compared 
AA 
Identified 
Data 
Distribution 
p-value Mean 
Concentration 
Conclusion 
Uncorrected Corrected 
1 v. 2 
(excluding 
2018) 
↓PRO  Normal 0.027 0.095 No difference 
 
Table 5.9 shows the sample distribution of ABA and MET. It was deemed there were 
sufficient numbers of ABA samples in each of the groups for mean concentrations to 
be compared for all combinations of two groups. For MET, only one sample 
belonged to the grade 1 group so comparison of concentrations excluded this group 
thus reducing the number of combinations of groups to three. For all tests no 
p-value was less than 0.05 so it was concluded there was no difference in the 
concentration of ABA or MET between different grades of tumour. 
 
Table 5.9 Sample distribution of ABA and MET with breast cancer grade. 
           Grade 
AA 
0 1 2 3 
ABA 6 5 7 7 
MET 6 1 4 4 
 
5.3 Conclusions 
 
Due to max/min and RSD values obtained from calibration standards being 
unacceptably high for some AAs only 13 from 26 were able to be quantified in 
samples. For the 9 AAs present in the majority or all of the samples none of the 
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mean concentrations were revealed to be significantly different between case and 
control samples. MVA did not show clear separation between the different types of 
samples. In an analogous manner to Chapter 2 where NMR spectroscopy was used, 
there is no evidence to suggest an association between breast cancer and a change 
in AA concentrations that were determined by analysis of data acquired by GC. 
Furthermore, the conclusion can generally be extended to different grades of breast 
cancer though there is some evidence to suggest that grade 1 samples have lower 
concentrations of ALA, GLY, VAL, LEU, ISO, PRO and PHE. The numbers in each class 
were small and further samples would be necessary for rigorous validation of 
models. Univariate analysis generally did not confirm MVA observations regarding 
grade 1 samples to the extent that they were statistically significant thus indicating 
the differences observed were not due to individual AA concentration variance, with 
the possible exception of PRO. Further experimentation in the form of increased 
sample numbers would be needed to determine whether there is a significant 
difference in the mean concentration of PRO between grades 1 and 2 as identified 
when no potential outlying samples were excluded from analysis. 
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Chapter 6. NMR Analysis of Tissue Extracts 
 
Analysis of aqueous and lipophilic tissue extract data acquired by 1H-NMR 
spectroscopy will be detailed in the following chapter. Breast cancer tissue (Tumour) 
samples and adjacent non-cancerous tissue (Normal) samples were available from 
15 post-menopausal women with differing severity of disease: 5 each with single 
occurrence grade 1, 2 or 3 tumours. The receptor status of the tumours was highly 
uniform with 12 samples having ER+, PR+ and HER- status, 11 of which are known to 
be DCIS positive (Table 6.1). The patient cohort is different to that of previous 
chapters. 
 
Table 6.1 Receptor and DCIS statuses of Tumour samples. 
Tumour Receptor Status (Subtype) 
DCIS Status 
Present Unknown 
ER+, PR+, HER- (Luminal A) 11 1 
ER+, PR-, HER- (Luminal A) 0 1 
ER+, PR+, HER unknown (Luminal A or B) 0 1 
ER-, PR-, HER- (Basal) 0 1 
 
Samples were prepared as per Section 8.1.1.3 and data collected as detailed in 
Section 8.2.3. Section 8.3 applies for spectral processing with dark regions listed in 
Table 8.5 and Table 8.6 for aqueous and lipophilic extracts, respectively. Constant 
sum normalised data was used initially. MVA and univariate analysis were 
performed as detailed in Section 8.4 and Section 8.5, respectively, in an attempt to 
identify possible biomarkers of breast cancer occurrence and progression in both 
extract types.  
 
6.1 Results 
 
Each tissue sample was given an identifier during collection, the format dependent 
on the source site and generalised for this work as a three or four digit number to 
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establish the ‘non-identifiable’ patient provider combined with N or T to describe 
Normal or Tumour tissue sample types, respectively.  
 
Samples from nine patients, thus 18 samples in total, were sourced from the Breast 
Cancer Campaign Tissue Bank (BCCTB). For this chapter a paired sample is described 
as a single sample, either N or T, for which the other tissue sample type is available 
from the same patient. Of the 18 paired samples, 12 were collected at Site A and six 
at Site B. The remaining 12 paired samples were sourced directly from Site A. 
 
The frozen weight and appearance of samples was recorded. In addition the 
appearance of the non-homogenised part of the sample was noted along with both 
wet and air-dried non-homogenised weights. After addition of extraction liquids the 
colour was recorded as for cellular debris following centrifugation. Due to the small 
size of some samples, volumes of extraction liquids had to be scaled up from the 
values calculated using the ratios detailed in Section 8.1.1.3.1 to achieve the 
minimum required for homogeniser use (200 µl). 
 
One tissue sample (T6876; ER+, PR+, HER-, DCIS present) was destroyed during 
homogenisation and one lipophilic extract sample (T6758; ER+, PR+, HER-, DCIS 
present) contaminated during processing. An aqueous sample (N116; paired 
Tumour sample ER+, PR+, HER-, DCIS present) spectrum was not suitable for 
analysis. Numbers of samples available for data analysis are summarised in Table 
6.2.  
 
Table 6.2 Summary of sample numbers available for data analysis. Paired relates 
to number of samples, either Normal or Tumour type, with opposite sample type 
from the same patient. Values in parentheses refer to breast cancer grades 1, 2 
and 3, respectively. 
                      Sample 
Extract Type 
Normal Tumour Paired 
Aqueous 14 (4, 5, 5) 14 (5, 4, 5) 26 (8, 8, 10) 
Lipophilic 15 (5, 5, 5) 13 (5, 4, 4) 26 (10, 8, 8) 
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6.1.1 Aqueous Extracts Analysis  
 
A high level of citrate was present in the aqueous extract spectrum of two samples. 
This unnatural level is undesirable for metabolomics studies and is known to source 
from sodium citrate that is present in certain collection tubes(185) so for the two 
samples it is possible that the collection tubes were the source of  citrate. The 
region 2.517-2.750 ppm that contained citrate signals was removed from all 
samples in further analysis. The region 3.341-3.371 ppm was excluded because it 
contained methanol from the extraction process. A typical spectrum that did not 
contain citrate is shown in Figure 6.1. A variety of sources were used to identify 
metabolite signals.(103,118,135,136,138,141,142,187-191)  
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Chemical Shift (ppm)10 8 6 4 2
 
 
 
 
 
 
 
Figure 6.1 1H-NMR spectrum of tissue aqueous extracts from a Tumour sample. a) 
main: whole spectrum; inset: aromatic region. b) aliphatic region. The x-axis is 
chemical shift in ppm.  
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6.1.1.1 Evaluation of Breast Cancer Occurrence 
 
6.1.1.1.1 Analysis Implementing Sum Normalisation 
 
PCA was performed initially for 28 samples. A model could not be generated so 
components were forced to investigate the samples. The first two components 
showed T132 to be greatly separated in scores space (Figure 6.2). The sample was 
noted as unusual during data acquisition because spectrometer tuning was not able 
to be performed to the usual standard and presence of signals (large, broad singlets 
at 3.619 and 3.882 ppm) that were non-standard compared to other samples 
(excluding citrate signals). The loadings plot (Figure 6.3) confirmed the signals 
unique to the sample were causing scores space isolation for the sample. 
 
 
Key:  Tumour and  Normal 
Figure 6.2 Forced PCA scores plot coloured according to tissue type for all 28 
aqueous extract samples. 
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Figure 6.3 PCA loadings plot corresponding to the model displayed in Figure 6.2. 
The blue ellipse highlights bins containing unknown signals unique to T132 areas. 
 
Unlike citrate, the unidentified signals could not be attributed to a source, either 
natural or ‘contaminant’. Given this, the influence of the signals in PCA and 
importantly irregularities during data acquisition, sample T132 was removed from 
all further analysis. The signals were not present in the Normal sample from the 
same patient. 
 
PCA was repeated and a three PC model was generated with R2X(cum) and 
Q2X(cum) values of 0.594 and 0.337, respectively. The scores plot is shown in Figure 
6.4 and loadings plot in Figure 6.5. 
 
The majority of Normal and Tumour samples were separated diagonally along PC 1 
and PC 2 (Figure 6.4). The loadings plot indicated bins centred at 1.329, 3.228 and 
4.112 ppm strongly contributed to positive p[1] and negative p[2] loadings space in 
Figure 6.5, which discriminated Tumour from Normal samples and indicated 
increased levels in Tumour samples. The first and last bin contained lactate signals 
whilst for the other both GPC and PCho were present. 
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Key:  Tumour and  Normal 
Figure 6.4 PCA scores plot coloured according to tissue type for aqueous extract 
samples excluding T132 showing the first two model components. R2X = 0.311 and 
0.184, and Q2X = 0.171 and 0.151 for PC 1 and PC 2, respectively. 
 
 
Figure 6.5 PCA loadings plot corresponding to the model displayed in Figure 6.4. 
 
Other bins were present in the same loadings quadrant, though less influential, as 
well as in the opposite quadrant, the latter indicating lower signal levels in Tumour 
samples. A cut-off loadings value was used to determine whether the bin would be 
investigated further in determining significant differences between mean levels of 
metabolites in this study for the two sample types. One of the lesser intensity peaks 
of the lactate quartet (bin centred at 4.136 ppm) had a loadings value between 0.08 
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and 0.09 in the first component; due to the diagonal nature of separation the 
modulus loadings values of the first and second components were combined and a 
cut-off value of 0.08 employed for bins located in the two quadrants previously 
referred to. This allowed signals of lesser intensity to be considered without 
incorporating too many bins otherwise the purpose of using MVA would not be able 
to be upheld. Some discretion was used regarding bins that had a high loadings 
value in one component but were just outside of either quadrant in question, such 
as the bin centred at 1.305 ppm (Figure 6.5) For instances where a metabolite signal 
was present in an adjacent bin(s) to those identified in the loadings plot the 
normalised integrals were summed across all of the bins.  
 
In total, 24 integral regions were evaluated (Figure 6.6) though other bins were also 
identified. The bin centred at 3.469 ppm had the largest p[1] scores value in the top 
left (negative p[1] and positive p[2]) quadrant; the signal present was attributed to 
glucose. Numerous other glucose containing bins that fulfilled the criteria for 
further investigation were located in the same quadrant including those centred at 
3.491, 3.507, 3.522, 3.669, 3.697, 3.716, 3.729, 3.829, 3.855, 3.880, 3.909, 4.638, 
4.663 and 5.239 ppm. Due to α- and β-glucose signals centred at 5.233 and 
4.648 ppm, respectively, being readily resolved and no signals from other 
metabolites contained in the same bins, the integrals of the bins for these 
resonances were analysed to determine whether there was a difference between 
mean integrals of glucose for Tumour and Normal samples. α- and β-glucose are the 
same molecule but were evaluated separately to enable a relative overview of the 
ratios between the two sample types. 
 
Due to a Normal and Tumour sample emanating from the same patient the samples 
could not be treated as independent and metabolite level differences between the 
sample types from a patient, i.e. paired samples, had to be considered. As a result, 
the unpaired samples were excluded, thus leaving 24 samples for univariate 
analysis. Box plots in Figure 6.6 summarised the paired sample data.  
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All data were tested for normality with a null hypothesis that data distribution was 
normal. A Shapiro-Wilk p-value <0.05 led to the conclusion that the data was not 
normally distributed, hence the Wilcoxon signed rank test was used but if normal 
distribution of data was proven, as evidenced by p-value ≥0.05, a paired Student’s t-
test was performed to determine whether there was a difference between the 
mean levels of metabolites in Normal and Tumour samples. The null hypothesis was 
no difference between mean integral values for the two sample types. FDR was 
used to correct for multiple comparisons. Table 6.3 displays the bins identified as 
having potentially different mean integrals and conclusions regarding whether the 
difference was statistically significant.  
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a)  b)  
c)  d)  
e)  f)  
g)  h)  
 
Figure 6.6 Box plots of integrals for Normal (N, red filled box) and Tumour (T, black 
filled box) paired samples. * = samples more extreme than 1.5 times the 
interquartile range beyond the upper or lower quartile, coloured as per filled box 
with sample label. Refer to Table 6.3 for assignments of spectral regions.  
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i)  j)  
k)  l)  
m)  n)  
o)  p)  
 
Figure 6.6 Continued. 
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q)  r)  
s)  t)  
u)  v)  
w)  x)  
 
Figure 6.6 Continued.  
 
 
Table 6.3 Summary of data regarding mean integral differences between tissue types from bins identified in Figure 6.5. 
Identified Bin 
[centre] (ppm) 
Bin Range 
Tested (ppm) 
Major Metabolite Shapiro-Wilk 
p-value (1st = 
N, 2nd = T)  
Data 
Distribution  
p-value Mean Integral 
Conclusion 
Uncorrected Corrected 
0.879-0.890 [0.885] 
0.879-0.934 CH3 of fatty acid chain 0.400, 0.000 Non-normal 0.084 0.119 No difference 
0.890-0.920 [0.905] 
1.136-1.165 [1.151] 1.126-1.165 Unidentified 0.056, 0.647 Normal 0.044 0.075 No difference 
1.188-1.217 [1.203] 1.188-1.217 3-hydroxybutyrate 0.058, 0.082 Normal 0.077 0.116 No difference 
1.276-1.286 [1.281] 
1.276-1.315 CH2 of fatty acid chain 0.001, 0.000 Non-normal 0.034 0.063 No difference 1.286-1.297 [1.292] 
1.297-1.315 [1.306] 
1.315-1.344 [1.329] 1.315-1.344 Lactate 0.826, 0.213 Normal 0.003 0.018 ↑T 
1.483-1.507 [1.495] 1.439-1.507 Alanine 0.504, 0.382 Normal 0.026 0.052 No difference 
2.153-2.182 [2.168] 2.153-2.182 Glutamate 0.849, 0.202 Normal 0.013 0.035 ↑T 
2.246-2.275 [2.261] 2.246-2.275 Lipid 0.061, 0.426 Normal 0.007 0.024 ↑N 
2.346-2.371 [2.359] 2.346-2.371 Glutamate 0.874, 0.452 Normal 0.002 0.016 ↑T 
2.447-2.472 [2.459] 2.447-2.472 Glutamine 0.041, 0.023 Non-normal 0.012 0.035 ↑T 
2.948-2.978 [2.963] 2.948-2.978 Unidentified 0.042, 0.443 Non-normal 0.060 0.096 No difference 
3.021-3.050 [3.035] 3.021-3.050 Creatine 0.000, 0.030 Non-normal 0.182 0.190 No difference 
3.216-3.241 [3.229] 3.216-3.241 GPC and PC 0.010, 0.887 Non-normal 0.158 0.181 No difference 
3.254-3.284 [3.269] 3.254-3.284 Taurine 0.000, 0.400 Non-normal 0.099 0.132 No difference 
3.405-3.435 [3.420] 3.405-3.435 Taurine 0.370, 0.469 Normal 0.782 0.782 No difference 
3.922-3.947 [3.935] 3.922-3.947 Creatine 0.004, 0.020 Non-normal 0.182 0.190 No difference 
1
4
7
 
 
 
Table 6.3 Continued. 
Identified Bin 
[centre] (ppm) 
Bin Range 
Tested (ppm) 
Major Metabolite Shapiro-Wilk 
p-value (1st = 
N, 2nd = T)  
Data 
Distribution  
p-value 
 
Mean Integral 
Conclusion 
Uncorrected Corrected 
3.958-3.968 [3.963] 3.958-3.997 Unidentified 0.127, 0.883 Normal 0.002 0.016 ↑T 
3.968-3.997 [3.983] 
4.085-4.098 [4.092] 
4.085-4.144 Lactate 0.759, 0.419 Normal 0.000 0.000 ↑T 4.098-4.128 [4.113] 
4.128-4.144 [4.136] 
4.154-4.183 [4.169] 4.154-4.183 Glycerophospholipid 0.000, 0.127 Non-normal 0.136 0.172 No difference 
4.364-4.394 [4.379] 4.364-4.394 Glycerophospholipid 0.302, 0.180 Normal 0.149 0.179 No difference 
4.499-4.529 [4.514] 4.499-4.529 Unidentified 0.040, 0.090 Non-normal 0.019 0.044 ↑T 
4.628-4.648 [4.638] 4.628-4.678 β-glucose 0.182, 0.554 Normal 0.007 0.024 ↑N 
5.224-5.253 [5.239] 5.224-5.253 α-glucose 0.452, 0.001 Non-normal 0.005 0.024 ↑N 
5.315-5.344 [5.330] 5.294-5.374 CH=CH of fatty acid chain 0.070, 0.135 Normal 0.020 0.044 ↑N 
 
1
4
8
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Discussion will ensue on conclusions of mean integral analysis for those integrals 
where a significant difference was identified. Many of the species are connected 
and their relationships are summarised in Figure 6.7.  
 
 
Figure 6.7 Simplified summary of relationships that include many metabolites 
whose levels were significantly different between Tumour and Normal samples. 
Green lines indicate the border of mitochondria and cytosol; pink and red boxed 
species are present in the cytosol. NADP+ = nicotinamide adenine dinucleotide 
phosphate; NADPH = reduced form of NADP+; PDH = pyruvate dehydrogenase; TCA 
= tricarboxylic acid and coA = coenzyme A. 
 
Lactate levels were concluded to be significantly higher in Tumour samples 
compared to Normal samples. This is in agreement with the Warburg effect 
whereby glucose uptake and lactate formation are both increased.(25,147) Glucose 
levels were higher in Normal tissue, again supporting the Warburg effect. 
Additionally, the same p-values indicated a similar ratio of α- and β-glucose for 
Normal and Tissue samples. Production of lactate and alanine has been attributed 
as accounting for over 90% of total glucose metabolism in cancer cells.(28) 
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Increased alanine has been associated with cancerous tissue(135,192) though for this 
study after adjustment for multiple testing the p-value was just above the threshold 
for which the null hypothesis could be rejected. When cells undergo glycolysis 
greater levels of pyruvate result, a precursor of both alanine and lactate, but under 
these conditions activity of pyruvate dehydrogenase (PDH) is impaired.(135) PDH 
converts pyruvate to acetyl-CoA, which is part of the TCA cycle, so with reduced 
levels of conversion more lactate is produced(193) and more pyruvate could be 
converted into alanine through a transaminase reaction with glutamate that also 
produces 2-oxoglutarate.(118,135) Due to reduced PDH activity acetyl-CoA also derives 
from glutaminolysis (oxidation of glutamine).(194) 
 
Glutamine is readily consumed by cancerous cells in addition to glucose.(28,195) A 
high proportion of glutamate is initially synthesised from glutamine(135) with lactate 
and alanine subsequently produced.(28,196) Glutamine can be converted into 
2-oxoglutarate through a transaminase reaction as described previously, along with 
production of alanine, or by glutamate dehydrogenase (GDH). Upon 
implementation of the latter, malate is formed from 2-oxoglutarate after a number 
of intermediate metabolites and can subsequently undergo reaction with NADP+ to 
form NADPH, the reduced version of NADP+, and pyruvate, and hence lactate.(194) 
Production of lactate and alanine has accounted for 60% of total glutamine 
utilisation in cancer cells.(28) From this evidence it would be expected levels of the 
first two metabolites to be elevated in Tumour tissue and the opposite for 
glutamine and glutamate. Levels of lactate and alanine have been discussed; 
glutamine and glutamate, however, were also elevated in Tissue samples. An 
increase in glutamine and glutamate has previously been associated with breast 
cancer(135) and severity of meningioma,(197) a common form of brain tumour; an 
elevated glutamate level has been associated with tumour recurrence(198) and 
tumour versus normal cell lines.(199) Kung et al.(200) note that whilst the importance 
of glutamine has been shown in many cancer types, for breast cancers its 
prominence is not well defined. The authors provide evidence that breast tumour 
subtypes vary in their glutamine dependence observing luminal-type breast cancer 
cells were much more glutamine independent than basal-type breast cancer cells 
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with regards to survival. In this study 14 out of 15 Tumour samples were luminal 
type (13 luminal A and one unknown luminal A or B) with just one basal-type thus 
greatly reducing metabolic effects due to subtype variation. 
 
Glutathione can be synthesised from glutamate,(201) and vice-versa,(199) and a similar 
trend between levels of the two metabolites have been observed with regards to 
tumour severity in MAS of brain tissue: increased amounts with higher cancer 
grade.(197) Glutathione may act both as a protective and pathogenic factor in that it 
is an antioxidant in cells but increased levels in tumour cells, including breast,(202) 
can interfere with the cytotoxic action of a number of anticancer drugs.(203) 
Although Monleon et al.(197) identified glutathione in tissue they have stated it is 
relatively difficult to find in tissue extracts and signals cannot be attributed to the 
metabolite in this study.  
 
Citrate is formed in the TCA cycle from the reaction of acetyl-CoA and oxaloacetate 
(OAA). Much citrate reforms OAA and acetyl-CoA in the cytosol.(194) Fatty acids are 
synthesised from acetyl-CoA and malonyl-CoA in the presence of NADPH.(204) Due to 
the high level of lactate produced from glutamate sufficient NADPH is generated to 
enable fatty acid synthesis.(28) OAA can lead to the formation of pyruvate via 
malate, which generates further NADPH and allows the cycle to continue.(194) Due 
to much citrate leaving the mitochondria the TCA cycle would be depleted but 
glutamate can contribute to formation of metabolites within the cycle further to 
previously described. Instead of conversion to pyruvate from glutamate derived 
malate, OAA can be produced thus providing an essential metabolite for the 
synthesis of fatty acids. 
 
Lipid levels at 2.261 ppm and 5.330 ppm were adjudged to be higher in Normal 
samples. Healthy tissue samples have a higher level of adipocytes than Tumour 
tissue samples, which are mainly composed of epithelial tissue.(135) It could be 
expected to observe increased levels of some lipids in samples that contain a higher 
amount of fat. Changes in metabolite levels have been observed between healthy 
samples that had different amounts of fatty tissue and fibrotic tissue.(135) Histology 
152 
 
records were not available for the samples but notes made related to appearance 
during the homogenisation process were assessed relative to lipid level in the 
aforementioned regions. The majority of samples were pink or light orange with 
some primarily dark (black/brown/grey) and others mainly white. No correlation 
was observed between lipid amounts and any of the groups.  
 
Alanine, CH2 of fatty acid chain and an unassigned resonance in the 
1.126-1.165 ppm bin displayed significantly different levels before multiple test 
correction but not afterwards. With an increased number of tests there is an 
increased chance of false outcomes; if fewer tests were performed the multiple test 
correction applied would be less severe.(92)  
 
PLS-DA was also applied, the scores and loadings plots are shown in Figure 6.8 and 
Figure 6.9, respectively. 
 
 
Key:  Tumour and  Normal 
Figure 6.8 PLS-DA scores for aqueous extract samples excluding T132. Classed 
according to tumour type. 
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Figure 6.9 PLS-DA loadings plot corresponding to the model displayed in Figure 
6.8. 
 
The one component model (R2X = 0.275, R2Y = 0.613 and Q2Y = 0.487) separated the 
majority of Tumour and Normal samples from each other. The bins that contained 
lactate, centred at 1.329 and 4.112 ppm, were the two most influential in the 
loadings plot (Figure 6.9) with the bin centred at 3.228 ppm also contributing to the 
separation, all three of which were indicated to be raised in Tumour samples. 
PLS-DA can overfit data so validation is required.(79) ‘Leave-one-out’ cross-validation 
was performed using 27 samples with unpaired samples predicted singly and paired 
samples predicted together. Table 6.4 summarises the results. 
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Table 6.4 ‘Leave-one-out’ cross-validation parameters of the PLS-DA model shown 
in Figure 6.8. 
Sample 
Excluded 
Number of 
Components 
R2X 
(cum) 
R2Y 
(cum) 
Q2Y 
(cum) 
Y-Predicted* 
N T 
N007 1 
0.261 0.647 0.456 
0.415 0.585 
T007 1 0.104 0.896 
N014 1 
0.256 0.594 0.383 
1.000 0.000 
T014 1 -0.017 1.017 
N023 1 
0.254 0.648 0.470 
0.693 0.307 
T023 1 0.384 0.616 
N040 1 
0.244 0.624 0.420 
0.768 0.232 
T040 1 -0.164 1.164 
N093 1 
0.266 0.620 0.457 
0.681 0.319 
T093 1 0.298 0.702 
N122 1 
0.271 0.668 0.523 
0.137 0.863 
T122 1 0.288 0.712 
N6758 2 
0.417 0.779 0.530 
0.307 0.693 
T6758 2 -0.161 1.161 
N7178 1 
0.238 0.635 0.460 
0.996 0.004 
T7178 1 0.174 0.826 
N7242 1 
0.274 0.672 0.568 
0.791 0.209 
T7242 1 0.983 0.017 
N7388 1 
0.246 0.648 0.502 
1.146 -0.146 
T7388 1 0.453 0.547 
N7428 1 
0.251 0.613 0.426 
0.689 0.311 
T7428 1 -0.028 1.028 
N015 1 
0.273 0.663 0.533 
0.556 0.444 
T015 1 0.511 0.489 
T116 1 0.251 0.630 0.460 0.298 0.702 
N132 1 0.260 0.603 0.379 1.060 -0.060 
N6876 1 0.449 0.744 0.405 0.935 0.065 
*A sample was regarded as belonging to a grade by having a Y-predicted value >0.50. 
Incorrect classification is represented by red shading and correct by pink, orange or green, 
corresponding to a Y-predicted value of <0.60, 0.60-0.70 or >0.70, respectively. 
 
Of the 14 Normal samples, 11 (79%) were predicted correctly whilst the predictive 
ability of Tumour samples was 85% due to having 11 of 13 samples correctly 
predicted. Both percentages were high, which indicated the classes were modelled 
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well and the data was not overfitted. Of those samples correctly predicted, 64% of 
Normal samples had a Y-predicted value greater than 0.70 and for Tumour samples 
82% achieved this figure. The accuracy of class prediction is reduced for samples as 
the Y-predicted value tends towards 0.50 so classifications based on values less than 
0.60, coloured pink in Table 6.4, should be treated with caution: both N015 and 
T7388 samples had low modulus t[1] values. Given the positioning of N122 and 
T7242, both located in scores space that was predominantly occupied by the 
opposite sample type, incorrect class prediction of the two samples was not 
unexpected. 
 
Permutation testing was also performed for further validation of the model. Figure 
6.10 shows all but two of the 999 permuted models for the Tumour class to have 
lower R2Y and Q2Y values than the original model. The intercept values of the 
regression lines for R2Y and Q2Y are 0.239 and -0.148, respectively. The 
permutation testing plot for the Normal class (plot not shown) displayed R2Y and 
Q2Y intercept values of 0.240 and -0.146, respectively, with no permuted models 
having higher values. Both R2Y values are less than 0.4 and both Q2Y values are 
below 0.05 so it is indicated that the model is validated thus furthering the 
conclusion from ‘leave-one-out’ cross validation. 
 
Validation of the PLS-DA model supported the observation that Tumour samples can 
be distinguished from Normal tissue using MVA. 
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Key:  R2Y and  Q2Y 
Figure 6.10 Permutation testing plots for the Tumour class in the PLS-DA model 
shown in Figure 6.8. The R2Y and Q2Y intercept values of the regression lines are 
0.239 and -0.148, respectively. 
 
6.1.1.1.2 Analysis Implementing Probabilistic Quotient Normalisation and Removal 
of Sample N122 
 
Using sum normalisation N122 was observed on eight occasions as more extreme 
than 1.5 times the interquartile range beyond the upper quartile of Normal samples 
in Figure 6.6. Sample preparation and data acquisition records were investigated 
but no anomalous factors were apparent. Visual inspection of spectra showed N122 
to contain very little glucose, which was surprising since glucose levels were 
generally higher in Normal compared to Tumour samples (Table 6.3). The next 
lowest Normal sample glucose level, as measured by β-glucose signal integral, was 
nearly five times that of N122. Glucose is prevalent in spectra so for samples with a 
low level, normalisation is affected resulting in increased integrals for all other 
signals. Ascertaining whether differences for this sample were due to genuine 
variation of metabolite levels or the effect of normalisation was difficult. Using the 
bin containing GPC and PCho as an example, N122’s normalised integral value was 
more than 20% larger than the next greatest irrespective of sample type and almost 
twice the value of the second largest Normal sample integral. N122’s integral was 
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more than nine-fold larger than that of the paired Tumour sample. Given the 
potential problem using sum normalisation, PQN was used. 
 
PQN has been advocated as superior to constant sum normalisation(69) but the 
method has been shown to be not always the optimum choice when many 
normalisation methods were compared,(158) hence why it was not used from the 
beginning of analysis. Section 8.3.1.2 describes the PQN methodology and Table 8.7 
lists regions included in the calculation of the median quotient. The scores and 
loadings plots were very similar using both normalisation methods as shown by PC 1 
in Figure 6.11 and Figure 6.12, respectively. A three component model was 
produced in each case with R2X(cum) values of 0.594 and 0.602 for sum 
normalisation and PQN, respectively, and related Q2X(cum) values of 0.337 and 
0.307.  
 
Although the scores and loadings plots generated using the two different 
normalisation methods were of similar appearance PQN was employed due to 
potential weakness of sum normalisation: the inability to account for presence or 
absence of a large signal(s) in certain samples without affecting normalised 
intensities of other signals of that sample, in this case the much reduced presence 
of glucose signals in N122. 
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a)  
b)  
Key:  Tumour and  Normal 
Figure 6.11 PCA scores plot of PC 1 coloured according to tissue type for aqueous 
extract samples using a) constant sum normalisation (0.311, 0.171) and b) PQN 
(0.311, 0.174); R2X and Q2X values, respectively, in parentheses.  
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a)  
b)    
Figure 6.12 Loadings plot of PC 1 for aqueous extract samples using a) constant 
sum normalisation and b) PQN. 
 
Quotients of spectra relative to the median (reference) spectrum varied between 
0.74 and 1.25 with a value of 0.97 for N122. After multiple test correction the same 
conclusion regarding difference between mean integral values of sample types 
applied to 22 of the 24 bin regions tested including 10 of the 11 bin regions 
previously identified as significantly different (Table 6.5). Alanine had a p-value 
>0.05 when constant sum normalisation was used but upon implementation of PQN 
it could be concluded a significantly greater concentration was present in Tumour 
samples, however, the reverse was applicable to CH=CH of fatty acid chains 
(5.294-5.374 ppm) with the level no longer being significantly greater in Tumour 
samples. 
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Due to the small sample set of 12 pairs, N122 and T122 were removed from analysis 
because one paired sample could greatly influence univariate analysis results. PQ 
normalised data was retested for normality of distribution and pair-wise testing 
applied as previously. Ten bin region mean integral values that were significantly 
different between sample types when samples N and T 122 were included remained 
so with only 2.246-2.275 ppm, the signal assigned to lipids, no longer significantly 
different (Table 6.5). Seven additional bin regions were concluded to be significantly 
different and contained an unidentified resonance (2.948-2.978 ppm), creatine 
(3.021-3.050 ppm and 3.922-3.947 ppm), GPC and PCho (3.216-3.241 ppm), taurine 
(3.254-3.284 ppm) and glycerophospholipid (4.154-4.169 ppm and 4.364-
4.394 ppm). Levels were increased in Tumour compared to Normal samples for all 
bins. Metabolic reasoning for the findings will be discussed. 
 
 
 
Table 6.5 Summary of data regarding mean integral difference between tissue types for different normalisation methods and after exclusion 
of a sample using PQN; sum normalised data, also shown in Table 6.3, has been included to aid comparison. Non = non-normal, ND = no 
difference, N = Normal, T = Tumour and ↑ = significant increase.  
Identified Bin 
[centre] (ppm) 
Bin Range 
Tested (ppm) 
Major Metabolite Data Distribution Corrected p-value Mean Integral 
Conclusion 
Sum PQN Exc 122 Sum PQN Exc 122 Sum PQN Exc 122 
0.879-0.890 [0.885] 
0.879-0.934 CH3 of fatty acid chain Non Non Non 0.119 0.284 0.328 ND ND ND 
0.890-0.920 [0.905] 
1.136-1.165 [1.151] 1.126-1.165 Unidentified Normal Non Non 0.075 0.176 0.052 ND ND ND 
1.188-1.217 [1.203] 1.188-1.217 3-hydroxybutyrate Normal Normal Normal 0.116 0.214 0.219 ND ND ND 
1.276-1.286 [1.281] 
1.276-1.315 CH2 of fatty acid chain Non Non Non 0.063 0.181 0.208 ND ND ND 1.286-1.297 [1.292] 
1.297-1.315 [1.306] 
1.315-1.344 [1.329] 1.315-1.344 Lactate Normal Normal Normal 0.018 0.032 0.032 ↑T ↑T ↑T 
1.483-1.507 [1.495] 1.439-1.507 Alanine Normal Normal Normal 0.052 0.033 0.032 ND ↑T ↑T 
2.153-2.182 [2.168] 2.153-2.182 Glutamate Normal Normal Non 0.035 0.043 0.032 ↑T ↑T ↑T 
2.246-2.275 [2.261] 2.246-2.275 Lipid Normal Normal Non 0.024 0.043 0.052 ↑N ↑N ND 
2.346-2.371 [2.359] 2.346-2.371 Glutamate Normal Normal Normal 0.016 0.030 0.012 ↑T ↑T ↑T 
2.447-2.472 [2.459] 2.447-2.472 Glutamine Non Non Non 0.035 0.033 0.032 ↑T ↑T ↑T 
2.948-2.978 [2.963] 2.948-2.978 Unidentified Non Normal Non 0.096 0.092 0.032 ND ND ↑T 
3.021-3.050 [3.035] 3.021-3.050 Creatine Non Non Normal 0.190 0.181 0.049 ND ND ↑T 
3.216-3.241 [3.229] 3.216-3.241 GPC and PCho Non Non Non 0.181 0.144 0.032 ND ND ↑T 
3.254-3.284 [3.269] 3.254-3.284 Taurine Non Non Non 0.132 0.181 0.049 ND ND ↑T 
1
6
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Table 6.5 Continued. 
Identified Bin 
[centre] (ppm) 
Bin Range 
Tested (ppm) 
Major Metabolite Data Distribution Corrected p-value Mean Integral 
Conclusion 
Sum PQN Exc 122 Sum PQN Exc 122 Sum PQN Exc 122 
3.405-3.435 [3.420] 3.405-3.435 Taurine Normal Normal Non 0.782 0.730 0.298 ND ND ND 
3.922-3.947 [3.935] 3.922-3.947 Creatine Non Non Normal 0.190 0.176 0.049 ND ND ↑T 
3.958-3.968 [3.963] 
3.958-3.997 Unidentified Normal Normal Normal 0.016 0.030 0.012 ↑T ↑T ↑T 
3.968-3.997 [3.983] 
4.085-4.098 [4.092] 
4.085-4.144 Lactate Normal Normal Normal 0.000 0.024 0.024 ↑T ↑T ↑T 4.098-4.128 [4.113] 
4.128-4.144 [4.136] 
4.154-4.183 [4.169] 4.154-4.183 Glycerophospholipid Non Non Non 0.172 0.181 0.049 ND ND ↑T 
4.364-4.394 [4.379] 4.364-4.394 Glycerophospholipid Normal Normal Normal 0.179 0.181 0.049 ND ND ↑T 
4.499-4.529 [4.514] 4.499-4.529 Unidentified Non Non Normal 0.044 0.050* 0.024 ↑T ↑T ↑T 
4.628-4.648 [4.638] 4.628-4.678 β-glucose Normal Non Non 0.024 0.032 0.024 ↑N ↑N ↑N 
5.224-5.253 [5.239] 5.224-5.253 α-glucose Non Non Non 0.024 0.030 0.024 ↑N ↑N ↑N 
5.315-5.344 [5.330] 5.294-5.374 
CH=CH of fatty acid 
chain 
Normal Non Non 0.044 0.092 0.074 ↑N ND ND 
*p-value <0.05 when more than three decimal places retained.
1
6
2
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The creatine level was significantly elevated in Tumour samples when samples N 
and T 122 were not included in analysis (Table 6.5). HR-MAS of tissue showed raised 
creatine levels in head and neck squamous cell carcinoma compared to normal 
adjacent tissue.(205) This observation was supported by reduction of creatine kinase 
in oral squamous cell carcinoma.(206) The enzyme catalyses the reversible process of 
phosphorylation of creatine to creatine phosphate so a reduction in the enzyme 
level would inhibit the process in this direction thus creatine, as the reverse 
direction product, would be expected to be present in a greater quantity.(207) 
 
The same conclusion as for creatine was made regarding the bin at 3.254-3.284 ppm 
that contained taurine. Taurine has been shown to be increased in breast tumour 
samples compared to non-tumour samples.(135,141) Taurine has been postulated as 
being an antioxidant(208,209) and marker of increased cell proliferation.(135) Glucose 
was also present in the downfield bin (3.405-3.435 ppm) that contained taurine. 
This observation could explain why a significant difference in mean integrals was not 
observed for this bin; increased glucose in Normal samples could be counteracted 
by up regulation of taurine in Tumour samples. 
 
Altered choline metabolism is indicative of cancer but the role of choline-containing 
metabolites is poorly understood.(119,210) In this study the mean integral level for the 
bin 3.216-3.241 ppm containing GPC and PCho (Table 6.5) was significantly 
increased in Tumour samples when samples N and T 122 were not included in the 
analysis. GPC has a higher chemical shift than PCho.(118,188,211) Elevations in total 
choline metabolites(210,212) and PCho(134,210,212) have been observed though both an 
increase(141) and decrease(213) in GPC have been reported and consensus cannot be 
achieved regarding the GPC to PCho ratio. Breast cancer tissue and cells have 
exhibited a decrease in the ratio(141,213) and Stewart et al.(210) cite this ratio change as 
indicative of cancer whereas Moestue et al.(214) argue the opposite. It has been 
postulated that the micro-environment of the tumour affects choline 
metabolism(212) such that in vivo tumours could evolve further mechanisms 
compared to in vitro tumours.(215) Due to the aforementioned region containing two 
overlapping signals assessment of the mean values between the tissue sample types 
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for GPC and PCho cannot be performed. Figure 6.13a shows N122 and N7428 to 
have very similar levels of the greater intensity signal (GPC) but different amounts of 
the lower intensity signal (PCho) whilst for T7388 it is difficult to establish the two 
separate signals. Figure 6.13b shows more clearly the composition of the signals 
within the region for the majority of samples but it cannot be ascertained whether 
the ratio trend of the two signals is different between Normal and Tumour samples 
nor can it be established whether the increased Tumour sample mean integral of 
the region was due to an integral value change in both signals or just one. 
 
Betaine production and phosphatidylcholine (PDC) synthesis are the two major 
pathways of intracellular choline metabolism.(212) Betaine is further synthesised to 
glycine(119) and subsequently, in order, to glutathione, glutamate and glutamine,(199) 
the last two of which were identified in spectra and raised in Tumour samples. PCho 
is an intermediary of PDC production and GPC and free fatty acids are degradation 
products of PDC.(119) PDC, a glycerophospholipid, is the most abundant membrane-
forming phospholipid in cells.(119,216) 
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                  a) 
 
                 b) 
Figure 6.13 ACD normalised view of 1H-NMR spectrum section of aqueous extracts 
including 3.216-3.241 ppm region, which contains GPC (most downfield signal) and 
PCho signals. a) Vertical integral range to include all samples and b) lower vertical 
integral range to emphasise the majority of samples. Spectral line of sample: red = 
Normal, black = Tumour. 
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The signals tentatively assigned as glycerophospholipids(187) in bins 4.154-4.183 ppm 
and 4.364-4.394 ppm were elevated for Tumour samples when samples N and T 122 
were excluded. Given increased choline metabolites and GPC in tumour tissue and 
the relationship with glycerophospholipids an explanation is provided for the 
aforementioned observation. 
 
6.1.1.1.3 Analysis Excluding Lactate 
 
Lactate is prevalent in Tumour samples (Figure 6.1) and can strongly influence 
positions of samples in scores space. Scaling can be used to reduce the disparity in 
influence signals of different intensities have. Pareto has been used in these 
analyses as the de facto scaling method but MVA is still strongly influenced by large 
intensity bins. Non-normalised data from lactate containing bins (1.314-1.374 ppm 
and 4.085-4.144 ppm) was removed before PQN was employed.  
 
The scores (Figure 6.14) and loadings plots (Figure 6.15) for PC 2 versus PC 1 of the 
three component model (R2X(cum) = 0.584 and Q2X(cum) = 0.251) were very similar 
in appearance (vertical reflection excluded) to those for which lactate was included 
(Figure 6.4 and Figure 6.5, respectively). 
 
Scores and loadings plots (data not shown) associated with the one component 
PLS-DA model (R2X = 0.217, R2Y = 0.541 and Q2Y = 0.362) were very similar to the 
equivalent that included lactate (Figure 6.8 and Figure 6.9, respectively). 
 
Further information in relation to metabolites differing between Tumour and 
Normal samples was not gained upon exclusion of lactate from MVA.  
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Key:  Tumour and  Normal 
Figure 6.14 PCA scores plot coloured according to tissue type for aqueous extract 
samples excluding lactate regions showing the first two model components. R2X = 
0.251 and 0.212, Q2X = 0.039 and 0.041 for PC 1 and PC 2, respectively. 
 
 
Figure 6.15 PCA loadings plot corresponding to the model displayed in Figure 6.14. 
 
6.1.1.1.4 Analysis of Aromatic Region Only 
 
Figure 6.1a shows the spectrum of aqueous extracts is dominated by the aliphatic 
region and signals in the aromatic region are of much lower intensity. Beckonert et 
al.(135) reported differences between Tumour and Normal samples in the aromatic 
region of aqueous extracts of breast cancer tissue. In this study visual differences 
were observed but no bins were identified by MVA when considering the whole 
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spectrum. To circumvent the scaling issue referred to in Section 6.1.1.1.3 only the 
aromatic region (5.446-9.362 ppm) was analysed.  
 
The majority of Tumour and Normal samples were separated along PC 1 (Figure 
6.16) in the two PC model (R2X(cum) = 0.331 and Q2X(cum) = 0.007) with the same 
two Normal samples, N007 and N122, located amongst the majority of Tumour 
samples as per inclusion of the aliphatic region (Figure 6.4). The loadings plot (Figure 
6.17) indicated levels of many metabolites were raised in the aforementioned 
grouping of samples with a corresponding decrease in formate (8.452 ppm) and a 
singlet at 7.675 ppm tentatively assigned as pyridoxine.(191) Four Tumour samples 
were isolated from the majority of Tumour samples, occupying similar PC 1 scores 
space to Normal samples. The reverse was true regarding levels of metabolites for 
this grouping. 
 
 
Key:  Tumour and  Normal 
Figure 6.16 PCA scores plot coloured according to tissue type for the sum 
normalised aromatic region of aqueous extracts.  
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Figure 6.17 PCA loadings plot corresponding to the model displayed in Figure 6.16. 
 
Metabolite levels were investigated within bins that possessed the greatest 
modulus PC 1 loadings values in Figure 6.17. Bins with a modulus p[1] value equal to 
or greater than 0.105 were analysed: inspection of spectra showed the bin centred 
at 7.709 ppm contained distinguishable signals for only four samples, this was 
deemed an insufficient number upon which conclusions could be based. Bins with a 
p[1] value at least equal to that of the aforementioned bin were investigated to 
ensure a signal(s) was present for numerous samples before univariate analysis was 
performed and all bins identified conformed. In total 14 bin regions were used in 
analysis. Box plots in Figure 6.18 provide an overview of paired sample data whilst 
Table 6.6 displays the bins identified as having potentially different mean integrals 
and conclusion regarding whether the difference was statistically significant. 
Adenosine 3',5'-diphosphate,(103) pyridoxine(191) and UDP-GlcNAc and UDP-
GalNAc(189,190) have been tentatively assigned. 
 
When all 24 paired samples were included no bin mean integral values were 
significantly different between Tumour and Normal samples once adjustment for 
multiple testing was performed. The box plots showed N122 to be more extreme 
than 1.5 times the interquartile range beyond the upper quartile on four occasions. 
Previously, when the whole spectrum was considered analysis was performed that 
excluded the sample, and the paired Tumour sample, because the same observation 
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was noted on multiple occasions (Figure 6.6) and was attributed to the sample 
containing a very low level of glucose. The paired 122 samples were also excluded in 
aromatic region only analysis and results incorporated into Table 6.6. Resultantly, 
UDP-GlcNAc and UDP-GalNAc in the regions 5.973-6.015 ppm and 6.108-6.124 ppm 
and unidentified signals in 8.178-8.200 ppm and 8.200-8.229 ppm regions were 
significantly increased in Tumour samples. 
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a)  b)  
c)  d)  
e)  f)  
g)  h)  
  
Figure 6.18 Box plots of aromatic region integrals for Normal (N, red filled box) 
and Tumour (T, black filled box) paired samples. * = samples more extreme than 
1.5 times the interquartile range beyond the upper or lower quartile, coloured as 
per filled box with sample label. Refer to Table 6.6 for assignments of spectral 
regions. 
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i)  j)  
k)  l)  
m)  n)  
 
Figure 6.18 Continued. 
 
 
Table 6.6 Summary of data regarding mean integral difference between tissue types before and after exclusion of samples from aromatic 
region bins identified in Figure 6.17. Non = non-normal; ND = no difference; N = Normal; T = Tumour; ↑ = significant increase. 
Identified Bin 
[centre] (ppm) 
Bin Range 
Tested (ppm) 
Major Metabolite 
Data Distribution  
p-value Mean Integral 
Conclusion Uncorrected Corrected 
All Exc 122 All Exc 122 All Exc 122 All Exc 122 
5.973-5.985 [5.978] 
5.973-6.015 UDP-GlcNAc and UDP-GalNAc Non Non 0.071 0.013 0.168 0.046 ND ↑T 
5.985-6.015 [6.000] 
6.108-6.124 [6.116] 6.108-6.124 UDP-GlcNAc and UDP-GalNAc Non Non 0.012 0.003 0.168 0.042 ND ↑T 
6.124-6.146 [6.134] 
6.124-6.175 Adenosine 3',5'-diphosphate Non Non 0.071 0.033 0.168 0.077 ND ND 
6.146-6.175 [6.160] 
6.900-6.925 [6.912] 6.900-6.925 Tyrosine Normal Normal 0.146 0.081 0.252 0.126 ND ND 
7.172-7.195 [7.183] 
7.172-7.225 Tyrosine Normal Normal 0.224 0.090 0.285 0.126 ND ND 
7.195-7.225 [7.209] 
7.329-7.345 [7.336] 7.329-7.345 Phenylalanine Normal Normal 0.586 0.381 0.631 0.410 ND ND 
7.422-7.451 [7.436] 7.422-7.451 Phenylalanine Normal Normal 0.077 0.026 0.168 0.073 ND ND 
7.661-7.690 [7.675] 7.661-7.690 Pyridoxine Non Non 0.638 0.424 0.638 0.424 ND ND 
7.946-7.972 [7.958] 
7.946-7.995 UDP-GlcNAc and UDP-GalNAc Non Non 0.182 0.050 0.255 0.100 ND ND 
7.972-7.995 [7.983] 
8.178-8.200 [8.188] 8.178-8.200 Unknown Non Normal 0.028 0.006 0.168 0.042 ND ↑T 
8.200-8.229 [8.214] 8.200-8.229 Unknown Non Non 0.071 0.010 0.168 0.046 ND ↑T 
8.251-8.280 [8.265] 8.251-8.280 Adenosine 3',5'-diphosphate Non Non 0.347 0.182 0.405 0.212 ND ND 
8.438-8.468 [8.452] 8.438-8.468 Formate Non Non 0.084 0.062 0.168 0.109 ND ND 
8.619-8.647 [8.632] 8.619-8.647 Adenosine 3',5'-diphosphate Normal Normal 0.162 0.105 0.252 0.133 ND ND 
1
7
3
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From glucose, fructose 6-phosphate can be produced via glycolysis, which in turn 
can react with glutamine to produce glutamate and glucosamine 6-phosphate.(217) 
The former product has been identified as raised in Tumour samples previously in 
this study whilst the latter is a constituent of UDP-GalNAc. UDP-GalNAc can be 
reversibly catalysed to UDP-GlcNAc. Another UDP-GalNAc moiety, acetyl CoA, can 
be made from pyruvate or by fatty acid oxidation.(189) Reduced glucose and 
increased glycolysis product levels, such as lactate, in Tumour samples was 
concluded earlier in this work therefore increased levels of UDP-GlcNAc and 
UDP-GalNAc, derived from glycolysis, in Tumour samples complements the previous 
conclusion.  
 
O-linked β-N-acetylglucosamine glycosylation (O-GlcNAcylation) is the glycosylation 
of proteins with O-linked β-N-acetylglucosamine (O-GlcNAc).(190) Several tumour-
associated proteins have been identified as glycosylated O-GlcNAc proteins and 
levels in breast tumour tissue are increased compared to corresponding adjacent 
tissue.(218) Gu et al.(218) have reasoned that a raised level of UDPGlcNAc and 
subsequently GlcNAcylation might be one of the reasons why the Warburg effect is 
present for tumours. 
 
It can be speculated as to why the UDP-GlcNAc and UDP-GalNAc signals between 
7.946 ppm and 7.995 ppm were not significantly raised in Tumour samples: 
underlying signals could be present that do not follow the same trend or due to the 
low signal intensity noise could reduce the magnitude of difference between sample 
types. 
 
Box plots (Figure 6.18) for 8.178-8.200 ppm and 8.200-8.229 ppm bins show sample 
N122 was more extreme than 1.5 times the interquartile range beyond the upper 
quartile as it was for two of the three UDP-GlcNAc and UDP-GalNAc containing 
regions. It can be tentatively speculated that signals could be from metabolites 
related to glycolysis. 
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6.1.1.2 Evaluation of Breast Cancer Severity 
 
6.1.1.2.1 Analysis of Whole Spectrum 
 
Further to discriminating between Tumour and Normal samples, breast cancer 
grade was investigated in an attempt to reveal metabolic markers of disease 
severity. 
 
PCA of PQ normalised data produced a one component model (R2X = 0.387 and 
Q2X= 0.174) when Tumour samples alone were included. Scores and loadings plots 
are shown in Figure 6.19 and Figure 6.20, respectively. 
 
 
Key: grade =  1,  2 and   3 
Figure 6.19 PCA scores plot for aqueous extract Tumour samples. Samples 
coloured according to tumour grade. 
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Figure 6.20 PCA loadings plot corresponding to the model displayed in Figure 6.19. 
 
No distinction in scores space based on tumour grade was observed. Although 
many studies have identified metabolic differences between tumour and non-
tumour breast tissue samples very few have reported differences between tumour 
grades. This could be due to composition of the tissue because the composition is 
linked with levels of metabolites.(136,141) For tumours of the same grade the cancer 
cell percentage has been reported to vary from 0% to over 50%. Histopathological 
analysis was not possible for this study but if a similar observation was present for 
all grades this could explain why no separation between samples based on grade 
was present. Hilvo et al.,(219) using LC-MS, showed phospholipids were increased in 
grade 3 samples compared to those in the combined grade 1 and 2 group but 
triglycerides were unchanged and no change was observed for either lipid species 
between grade 1 and 2 samples. In one of the first tissue MAS studies Cheng et 
al.(137) indicated lactate and PCho increased in grade 3 compared to grade 2 
samples through an elevation in the lactate:choline and PCho:choline ratios. For 
this study, although lactate (1.329 and 4.112 ppm) and PCho and GPC (3.228 ppm) 
containing bins were shown to be highly discriminatory between samples with 
levels significantly higher in Tumour samples, correlation was not present with 
tumour grade.  
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Although metabolites were not identified that were reflective of tumour grade 
investigation ensued to determine whether there was a connection between 
Tumour sample grade and the paired Normal sample. For example, whether both 
paired samples were in the same scores space relative to other samples of the same 
type or whether positioning in scores space of Normal samples was dependent on 
the grade of the Tumour counterpart. Figure 6.21 shows the scores plot whilst the 
loadings plot (data not shown) was the same as Figure 6.5 (model statistics related 
to this figure apply). Samples T116, N6876 and N132 were included to show 
positions relative to other samples despite not having a paired sample. 
 
 
Key: shape -  Tumour and  Normal; grade =  1,  2 and   3 
Figure 6.21 PCA scores plot for aqueous extract samples. Tumour samples 
coloured according to tumour grade and Normal samples coloured according to 
the grade of Tumour counterpart. R2X = 0.311 and 0.184, Q2X = 0.171 and 0.151 for 
PC 1 and PC 2, respectively. 
 
No pattern is apparent in scores space between paired Tumour and Normal 
samples. Normal samples do not show a metabolite profile that is related to Tumour 
sample grade and through non-clustering of Normal samples coloured the same in 
Figure 6.21, grade of the paired Tumour sample cannot be estimated, i.e. a raised or 
reduced metabolite(s) level in Normal samples does not indicate corresponding 
Tumour sample grade. Additionally, using PLS-DA, models were not able to be 
generated for the data used in the above two PCA models. 
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6.1.1.2.2 Analysis Excluding Lactate 
 
Lactate has been shown to be significantly increased in Tumour samples compared 
to Normal samples but different grades of Tumour samples have not been 
distinguished when lactate signals have been included. It was hypothesised that 
exclusion of lactate (1.314-1.374 ppm and 4.085-4.144 ppm) could reveal influential 
metabolites of smaller intensities. 
 
PCA generated a three component model (R2X(cum) = 0.683 and Q2X(cum) = 0.215) 
but separation based on grade was not observed (data not shown; PC 1 similar to 
Figure 6.19 and Figure 6.20 for scores and loadings plots, respectively). A PLS-DA 
model was not able to be created nor a PCA model incorporating Tumour and 
Normal samples. 
 
6.1.1.2.3 Analysis of Aromatic Region Only 
 
For reasons previously stated the aromatic region alone was analysed. PCA 
produced a one component model (R2X = 0.274 and Q2X= 0.071) when only Tumour 
samples were included. No separation based on tumour grade was observable 
(Figure 6.22). Nearly all of the bins identified when Tumour and Normal samples 
were analysed displayed the greatest modulus p[1] values in the loadings plot (data 
not shown). Two of the most prominent bins were centred at 6.000 ppm and 
7.958 ppm; both contained UDP-GlcNAc and UDP-GalNAc. The two metabolites 
have been associated with breast cancer progression.(135,218) Beckonert et al.(135) 
used self organising map (SOM) plots to visualise tissue extract data and these 
indicated UDP-GlcNAc and UDP-GalNAc were highest in grade 3 samples and lowest 
in control with grade 2 having an intermediate level though the observation was 
much closer to that of the former. Quantification and hence statistical significance 
of differences was not performed by the authors. 
 
Application of PLS-DA was made and a one PC model (R2X = 0.148, R2Y = 0.378 and 
Q2Y = 0.070) was built. Group 1 samples were separated from group 2 and 3 
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samples; there was no separation between groups 2 and 3 (Figure 6.23). The 
loadings plot (data not shown) indicated the unidentified signal at 8.188 ppm was 
elevated in grade 1 samples and UDP-GlcNAc and UDP-GalNAc (5.978 ppm, 
6.000 ppm and 7.598 ppm), adenosine 3',5'-diphosphate (6.134 ppm, 6.160 ppm 
8.265 ppm and 8.632 ppm), pyridoxine (7.675 ppm) and formate (8.452 ppm) were 
raised in grade 2 and 3 samples. The six metabolites were identified in the loadings 
plot (Figure 6.17) as strongly contributing to Tumour and Normal samples’ scores 
positions.  
 
PLS-DA was repeated using two classes: grade 1 and grades 2 and 3 combined. The 
scores and loadings plots of the one PC model (R2X = 0.152, R2Y = 0.727 and 
Q2Y = 0.264) were not shown due to the similarity when three classes were used.  
 
 
Key: grade =  1,  2 and   3 
Figure 6.22 PCA scores plot of the aromatic region for aqueous extract samples of 
Tumour samples. Coloured according to tumour grade. 
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Key: grade =  1,  2 and   3 
Figure 6.23 PLS-DA scores plot of the aromatic region for aqueous extract samples 
of Tumour samples. Classed according to tumour grade. 
 
Univariate analysis was performed to determine whether levels of metabolites were 
significantly different between grade 1 and grades 2 and 3 combined. Box plots 
(Figure 6.24) provided an overview of data from the two classes and Table 6.7 
concluded whether any difference was statistically significant. Before correction for 
multiple testing adenosine 3',5'-diphosphate (8.619-8.647 ppm) was significantly 
increased in grade 2 and 3 samples compared to grade 1 samples but after 
correction the difference was no longer statistically significant. There was no 
difference between classes for all other bin integral values tested.  
 
‘Leave-one-out’ cross-validation was performed to test whether PLS-DA overfitted 
the data (Table 6.8). Although seven of nine (78%) grade 2 or 3 samples were 
correctly predicted with five of those having a Y-predicted value of over 0.70, only 
one of four (25%) grade one samples were correctly predicted and the Y-predicted 
value for that sample was only 0.557. Figure 6.25 shows many permuted models for 
the ‘grades 2 and 3 combined’ class to have higher R2Y and Q2Y values than the 
original model. The intercept values of the regression lines for R2Y and Q2Y are 
0.586 and -0.058, respectively. The R2Y value is much greater than 0.4 so it is 
indicated that the model has overfitted the data thus furthering the implication 
from ‘leave-one-out’ cross validation. The permutation testing plot for the control 
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class is not shown but with R2Y and Q2Y intercept values of 0.582 and -0.053, 
respectively, the same conclusion was made. Being unable to validate the model 
would explain why no significant differences between classes were observed. Using 
PQN a PCA model was not able to be built when all samples were included.  
 
It is concluded that there is no evidence to suggest a difference between 
metabolite levels of samples with different tumour grades. 
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a)  b)  
c)  d)  
e)  f)  
g)  h)  
  
Figure 6.24 Box plots of aromatic region integrals for grade 1 (green filled box) and 
grade 2 and 3 combined (pink filled box) Tumour samples. * = samples more 
extreme than 1.5 times the interquartile range beyond the upper quartile, 
coloured as per filled box, with sample label. 
 
 
 
Table 6.7 Summary of Tumour sample data regarding mean integral differences of aromatic region bins between grade 1 and grades 2 and 3 
combined. 
Identified Bin [centre] 
(ppm) 
Bin Range 
Tested (ppm) 
Major Metabolite Data 
Distribution  
p-value Mean Integral 
Conclusion Uncorrected Corrected   
5.973-5.985 [5.978] 
5.973-6.015 UDP-GlcNAc and UDP-GalNAc Non-normal 0.106 0.243 No difference 
5.985-6.015 [6.000] 
6.124-6.146 [6.134] 
6.124-6.175 Adenosine 3',5'-diphosphate Normal 0.139 0.243 No difference 
6.146-6.175 [6.160] 
7.661-7.690 [7.675] 7.661-7.690 Pyridoxine Non-normal 0.260 0.320 No difference 
8.178-8.200 [8.188] 8.178-8.200 Unknown Normal 0.320 0.320 No difference 
8.251-8.280 [8.265] 8.251-8.280 Adenosine 3',5'-diphosphate Normal 0.057 0.200 No difference 
8.438-8.468 [8.452] 8.438-8.468 Formate Normal 0.284 0.320 No difference 
8.619-8.647 [8.632] 8.619-8.647 Adenosine 3',5'-diphosphate Normal 0.028 0.196 No difference 
 
1
8
3
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Table 6.8 ‘Leave one out’ cross-validation of the PLS-DA model in Figure 6.23. 
Sample 
Excluded 
Number of 
Components 
R2X(cum) R2Y(cum) Q2Y(cum) 
Y-Predicted* 
1 2 or 3 
T7178 3 0.506 0.918 0.338 -0.107 1.107 
T7388 3 0.493 0.926 0.293 0.292 0.708 
T7428 1 0.157 0.739 0.260 0.274 0.726 
T6758 1 0.165 0.732 0.271 -0.085 1.085 
T7242 1 0.172 0.768 0.411 0.728 0.272 
T122 1 0.175 0.673 0.325 0.304 0.696 
T007 3 0.499 0.899 0.118 0.296 0.704 
T023 1 0.179 0.701 0.208 -0.089 1.089 
T014 1 0.153 0.784 0.272 0.505 0.495 
T015 1 0.169 0.716 0.228 0.346 0.654 
T116 1 0.153 0.812 0.211 0.323 0.677 
T040 1 0.157 0.750 0.249 0.400 0.600 
T093 3 0.506 0.917 0.193 0.557 0.443 
*A sample was regarded as belonging to a grade by having a Y-predicted value >0.50. 
Incorrect classification is represented by red shading and correct by pink, orange or green, 
corresponding to a Y-predicted value of <0.60, 0.60-0.70 or >0.70, respectively. 
 
 
Key:  R2Y and  Q2Y 
Figure 6.25 Permutation testing plots for the ‘grades 2 and 3 combined’ class in 
the PLS-DA model shown in Figure 6.23. The R2Y and Q2Y intercept values of the 
regression lines are 0.586 and -0.058, respectively. 
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6.1.1.3 Investigation of Processing Time 
 
The time that tissue samples are not in the frozen state must be kept to a minimum 
both at the time of collection and processing.(51) Regarding the latter, a number of 
steps were taken to ensure the extraction procedure adhered to this and was 
consistent. The samples were still frozen upon first contact with organic extraction 
solvents as stipulated by Beckonert et al.(51) but one variable that could not be 
controlled was the time required to ensure as much as possible of the sample was 
homogenised in a suitable timeframe due to variation in size and composition. 
Enzymatic changes can occur rapidly and levels of certain metabolites can alter on a 
millisecond timescale.(51) 
 
To test the effect of variable homogenisation time a large sample (T6758) was 
processed as normal. Immediately after the sample was placed on ice following all 
solvent addition steps non-homogenised tissue was removed and the extraction 
procedure repeated. The processing steps between the end of homogenising and 
tissue removal was approximately two minutes.  
 
Both samples were included in PCA. The samples were positioned very closely in 
scores space both in PC 2 versus PC 1 plot (data not shown; very similar to Figure 
6.4) and PC 3 versus PC 2 plot (Figure 6.26). For the three PC model R2X(cum) was 
0.604 and Q2X(cum) equalled 0.324. T6758L was not used in any other analysis. 
 
The closeness in scores space indicates the time taken for homogenisation due to 
variance in sample size and consistency does not impact strongly on the aqueous 
extraction profile and consistency of homogenisation is a more important factor. 
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Key:  Tumour and  Normal 
Figure 6.26 PCA scores plot coloured according to tissue type for aqueous extract 
samples showing the second and third model components. R2X = 0.179 and 0.127, 
and Q2X = 0.172 and 0.084 for PC 2 and PC 3, respectively. ‘L’ at the end of the 
tissue sample code denotes the sample with the longer processing time. 
 
6.1.2 Lipophilic Extract Analysis 
 
Regions pertaining to the solvent signals of methanol (3.321-3.450 ppm) and 
chloroform (7.403-7.594 ppm) were removed and PCA of sum normalised data 
performed initially. These signals are shown on a typical spectrum in Figure 6.27. A 
variety of sources were used to identify metabolite signals.(103,135,142,220-223)  
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Figure 6.27 1H-NMR spectrum of tissue lipophilic extracts from a Normal sample. 
a) Whole spectrum, b) expansion of 3.1-6.5 ppm region. The x-axis is chemical shift 
in ppm. DAGPLs = diacylglycerophospholipids  
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6.1.2.1 Evaluation of Breast Cancer Occurrence 
 
PCA was performed and a two PC model (R2X(cum) = 0.821 and Q2X(cum) = 0.735) 
was generated with scores and loadings plots shown in Figure 6.28 and Figure 6.29, 
respectively. 
 
 
Key:  Tumour and  Normal 
Figure 6.28 PCA scores plot for lipophilic extract samples using 0.02 ppm variable 
bins coloured according to tissue type. Samples most remote from the majority 
are labelled.  
 
 
Figure 6.29 PCA loadings plot corresponding to the model displayed in Figure 6.28. 
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Table 6.9 shows the bins that had a positive or negative p[1] value greater than 0.15 
and were the most influential regarding separation of samples along PC1. One 
Normal and four Tumour samples were clearly separated from the other 23 samples 
in this component. The high R2X value of 0.607 indicated the PC captured a large 
amount of the total variance of the data.  
 
Table 6.9 Identity of lipids causing separation of samples in Figure 6.28. 
Bin Centre 
(ppm) 
Lipid 
Lipid Level in Five Most 
Separated Samples in 
PC 1 Scores Space 
0.895 CH3 fatty acid ↓ 
1.019 C-19 CH3 cholesterol ↑ 
1.275 
Bulk CH2 fatty acid ↓ 
1.299 
1.323 
1.353 
1.630 β-CH2 fatty acid ↓ 
2.027 Allylic CH2 fatty acid ↓ 
2.350 α-CH2 fatty acid ↓ 
3.215 Choline phospholipids ↑ 
 
With only four Tumour samples separated from the majority of Normal samples 
little information could be gained about potential metabolic differences between 
cancerous and non-cancerous tissue. A number of strategies to resolve this were 
employed including PQN, removal of select samples, removal of heavily influential 
bins and use of smaller bin size. 
 
Employing PQN rather than sum normalisation on the same pre-normalised data 
generated a two PC model with R2X(cum) = 0.938 and Q2X(cum) = 0.914. The scores 
plot is shown in Figure 6.30 and loadings plot in Figure 6.31. 
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Key:  Tumour and  Normal 
Figure 6.30 PCA scores plot for lipophilic extract samples using PQN coloured 
according to tissue type. Samples most remote from the majority are labelled. 
 
 
Figure 6.31 PCA loadings plot corresponding to the model displayed in Figure 6.30. 
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the five separated samples were less prominent using PQN. In conclusion, PQN 
alone did not enhance knowledge of potential metabolic changes between tissue 
types compared to sum normalisation but unless specified otherwise PQN data was 
used in further work due to its potential advantages.(69) 
 
The next approach was to remove Tumour samples 040, 7178, 7388 and 7428 and 
Normal sample 6876. The first two PCs of the six component model 
(R2X(cum) = 0.968, Q2X(cum) = 0.877) are exhibited in the scores plot shown in 
Figure 6.32. The complementary loadings plot was very similar to Figure 6.29, for 
which no samples were removed, so is not shown. Approximately, an amplification 
of the centre of the scores plot shown in Figure 6.30, i.e. where 23 of the 28 
samples were located before any were excluded, is exhibited in Figure 6.32. 
Removal of five samples still resulted in the same bins influencing the position of 
samples in scores space and similar relative positions of the remaining samples.  
 
 
Key:  Tumour and  Normal 
Figure 6.32 PCA scores plot showing the first two model components for lipophilic 
extract samples using PQN excluding the five samples with largest scores values in 
Figure 6.28. Coloured according to tissue type. R2X = 0.649 and 0.227, and Q2X = 
0.528 and 0.270 for PC 1 and PC 2, respectively. 
 
The spectrum, as shown in Figure 6.27, contains a large resonance from bulk 
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Excluding the aforementioned large resonance (1.200-1.458 ppm), which accounted 
for 59-71% of the total spectral integral, would increase the influence of all other 
signals when repeating analysis. The loadings plot of the two PC model (R2X(cum) = 
0.886 and Q2X(cum) = 0.855) in Figure 6.33 shows an amplification of the p[1] values 
of bins compared to the same bins in Figure 6.31, for which the 1.200-1.458 ppm 
region was not excluded. The complementary scores plots were similar: data not 
shown for exclusion of bulk methylene resonance. 
 
 
Figure 6.33 PCA loadings plot for lipophilic extract samples using PQN excluding 
1.200-1.458 ppm.  
 
Removal of the bulk methylene region provided little extra information on 
influential bins. To allow assessment of small intensity signals all of the large signals 
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the lipophilic extracts spectrum has been attributed to triglycerides.(135) The five 
labelled samples in Figure 6.28 possessed the five greatest amounts of small signals 
(4.9-10.3%) thus providing numerical evidence as to why scores plots indicated the 
five samples contained lesser amounts of triglyceride signals.  
 
The same five samples were still separate from the majority in PC 1 though T014 
was additionally present in similar scores space (Figure 6.34). The complementary 
-0.20
-0.10
-0.00
0.10
0.20
0.30
0.40
-0.10 -0.05 -0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40
p
[2
]
p[1]
0.2360.247587081943092. 3260414 43950. 191. 6.6 3674
0.694
0.7197 50.7470. 69
0.79.80.8110.8210.831
0.8410.851
0.861
0.873
0.895
0.925
0.950
0.975
0.997
1.0191.0421. 51. 661.07. 911.102. 11.1 21.132.1421.162
1.1831.195
1.472
1.5021.531.550.561.570
1.580
1.590
1.600 1.610
1.630
1.660
1.690
1.718
.7471.77479881.81.8431 63. 74 .895
1. 1692. 36
.947.9571.9671.9771.987
1.997 2.007
2.027
2.057
2.087
2.117
2.1462.1712.186
2. 982. 1
2.242 22. 42.285. 9. 05
2.315
2.327
2.350
2.380
2.4
2.435
2.454. 76
2.506
.5360.6 4..2 62. 6.7 6. 3748
2.7582.768
2.787
2.8172.8382. 59
2.889
2.919
2.948.3. 03 0.038.. 83.1033 12.1. 23.16. 93.215
3.245
73.2 6303. 63. 643.494
.3 455.5653.5 5
3.595 .6. 533.673916
768 8..8
3.89. 1
3 9 5
.984.0074.037.4 .4. 224.132
4.142 4.152
4.163
4.184
4.214
4.243
4.2684.2834. 0
4.322
4.351
4.380
4.4 2
4.4. 504.476
4.499
4.5254.5554.584. 26 599.0 15. 804789015.1 25 526. 755.5. 9.215.2. 364
5.258
5.280
5.301
5.313
5.323
5.333
5.353
5.383
5.413
5.442
5.465.4895.5199. 9. 24. 0.6 35. 805.. 28126 .3.7 046. 747. 387.
7. 6
. 38. 97 3.659.
07 0.
8.89. 55
SIMCA-P+ 12.0.1 - 2012-12-29 18:47:49 (UTC+0) 
193 
 
loadings plot of the two PC model (R2X(cum) = 0.637 and Q2X(cum) = 0.402) is 
displayed in Figure 6.35. 
  
 
Key:  Tumour and  Normal 
Figure 6.34 PCA scores plot for lipophilic extract samples excluding large signals. 
Coloured according to tissue type. Samples most remote from the majority are 
labelled. 
 
 
Figure 6.35 PCA loadings plot corresponding to the model displayed in Figure 6.34. 
 
Tumour samples 014, 040, 7178, 7388 and 7428 exhibited raised levels of signals in 
bins centred at 3.103, 3.595, 4.007 and 4.037 ppm. Signals in the first bin were 
attributed to –CH2NH2 head group of ethanolamine phospholipids, the second bin to 
–CH2N– head group of choline phospholipids and the third and fourth bins to both 
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glycerol C-3 methylene proton of diacylglycerophospholipids (DAGPLs) and –OCH2 
head group of ethanolamine phospholipids.(220) N6876 contained greater levels of 
C-18 and C-19 CH3 cholesterol at 0.694 and 1.019 ppm,
(220) respectively, and an 
unidentified metabolite at 1.843 ppm. C-18 CH3 cholesterol has been shown to be 
raised in grade 3 versus non-tumour breast cancer tissue.(135) Assessment 
concerning sample grade will be discussed in section 6.1.2.2.2. Assignment of signals 
that were decreased in the aforementioned six samples was unable to be made. 
PLS-DA scores plot (Figure 6.36; one PC model, R2X = 0.395, R2Y = 0.324 and 
Q2Y = 0.196) identified the same five Tumour samples as separate from the majority 
of samples but N6876 was no longer distinctly positioned in scores space, being 
closer to the majority of samples rather than the five separated Tumour samples. 
The four bins previously discussed as increased in the five Tumour samples were 
again highlighted in the loadings plot (not shown) and likewise those bins associated 
with a decreased level. 
 
 
Key:  Tumour and  Normal 
Figure 6.36 PLS-DA scores plot for lipophilic extract samples excluding large 
signals. Classed according to tissue type. Samples labelled as per Figure 6.34. 
 
Similar results for the majority of samples in terms of PCA scores space separation 
were observed when including and excluding large signals. A previous study(135) 
concluded self-organising map (SOM) plots showed similar results when sum 
normalisation was performed for the whole spectrum and non-triglyceride regions, 
which accounted for less than 1% of the total spectral integral. Although N6876 
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contained a greater amount of low intensity signals along with five Tumour samples 
than the majority, the composition of these signals was shown to be different 
between the samples in question. 
 
The six labelled samples in Figure 6.34 were excluded from PCA to further 
investigate potential separation between the other 22 samples. A one component 
model (R2X = 0.262 and Q2X = 0.134) was generated but the scores plot (Figure 6.37) 
did not show separation between Tumour and Normal samples. However, it is 
interesting to note that nine of the 14 Normal samples had the greatest t[1] values 
with six clearly separated from Tumour samples. The loadings plot (Figure 6.38) 
indicated levels of C-18 CH3 cholesterol (0.694 ppm), –CH2N– head group of choline 
phospholipids (3.595 ppm) and glycerol C-3 methylene proton of DAGPLs and –OCH2 
head group of ethanolamine phospholipids in the bin centred at 4.000 ppm were 
reduced in the nine aforementioned Normal samples. This observation will be 
investigated in context of breast cancer grade in Section 6.1.2.2.2. A PLS-DA model 
was not able to be generated. 
 
 
Key:  Tumour and  Normal 
Figure 6.37 PCA scores plot for lipophilic extract samples excluding large signals 
and the (labelled) six samples most remote from the majority in Figure 6.34. 
Coloured according to tissue type. 
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Figure 6.38 PCA loadings plot corresponding to the model displayed in Figure 6.34. 
 
Composition of the same lipid species can affect signal positions in spectra, for 
example bulk CH2 of fatty acid resonance appears further upfield with increased 
HDL lipoproteins, the reverse is applicable to increased VLDL lipoproteins.(128,224) It 
was postulated that use of small bins may provide information into lipid 
composition. 0.001 ppm fixed bins were employed but a similar outcome ensued in 
terms of position of samples in the scores plot (Figure 6.39). Smaller bins allowed 
further insight into which part of the CH2 resonance discriminated samples primarily 
in PC 2 (Figure 6.40).  
 
The bin centred at 1.275 ppm, range 1.261-1.291 ppm, discriminated between 
samples in PC 2 when 0.02 ppm variable bins were used but use of 0.001 ppm fixed 
bins showed many bins in the 1.26 ppm region caused the trend and bins in the 
1.27-1.28 ppm region aided separation along PC 1. Spectral investigation showed 
samples with a high PC 2 scores value generally displayed the maximum intensity 
part of the resonance at the highest upfield chemical shift. Tumour and Normal 
samples are not separated based on this observation. As previously, part of the CH2 
resonance around 1.32 ppm and choline phospholipids had high p[1] modulus 
values. There is potential to indicate predominant density, either high or low, of 
lipoproteins relative to other samples in the data set by using small bins though 
peak shifting, for instance due to difference in pH and small variation in 
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temperature between samples,(225) needs to be fully accounted for and 
deconvolution of the signal is advocated to accurately determine the amount of 
different density lipoproteins.(224) 
 
 
Key:  Tumour and  Normal 
Figure 6.39 PCA scores plot for lipophilic extract samples using 0.001 ppm fixed 
bins. Coloured according to tissue type. Samples most remote from the majority 
are labelled.  
 
 
Figure 6.40 PCA loadings plot corresponding to the model displayed in Figure 6.39. 
Selected bins are labelled. 
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6.1.2.2 Evaluation of Breast Cancer Severity 
 
6.1.2.2.1 Analysis of Whole Spectrum 
 
In an analogous manner to aqueous extracts, breast cancer grade was investigated 
in an attempt to reveal metabolic markers of disease severity. 
 
PCA of PQ normalised data produced a two component model (R2X(cum) = 0.964 
and Q2X(cum) = 0.945) when Tumour samples alone were included: scores plot 
shown in Figure 6.41 but loadings plot not shown due to similarity with Figure 6.31, 
for which Normal samples were included. 
 
 
Key: grade =  1,  2 and   3 
Figure 6.41 PCA scores plot for lipophilic extract Tumour samples. Samples 
coloured according to tumour grade. Samples most remote from the majority are 
labelled.  
 
The four Tumour samples that were most remote from the majority along PC 1 
when Normal samples were included in analysis were still separated. That two grade 
3 samples (T023 and T7242) had high positive scores values indicated no separation 
based on tumour grade. One sample was ER, PR and DCIS positive and HER negative, 
which follows the status of descriptors for almost all samples for which data was 
recorded. The other sample was also ER and PR positive but status of DCIS and HER 
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was not recorded. Based on these four tumour descriptors there is no reason to 
explain the positioning of the two samples. Exclusive of these two samples tentative 
separation could be viewed, with the progressive nature of tumour severity being a 
possible reason for distinction within grade 2 samples, but grounds for exclusion of 
the two grade 3 samples in question do not exist. 
 
As per aqueous extracts, investigation ensued to determine whether there was a 
connection between Tumour sample grade and the paired Normal sample. Figure 
6.42 shows the scores plot; model statistics apply from previous work related to 
Figure 6.30 as does the loadings plot shown in Figure 6.31. Samples N6758 and 
N6876 were included to show positions relative to other samples despite not having 
a paired sample. 
 
 
Key: shape -  Tumour and  Normal; grade =  1,  2 and   3 
Figure 6.42 PCA scores plot for lipophilic extract samples. Tumour samples 
coloured according to tumour grade and Normal samples coloured according to 
the Tumour counterpart. 
 
No pattern is apparent in scores space between paired Tumour and Normal samples 
though for each of 007, 023 and 7242 the paired samples are located in close 
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free (Normal) tissue does not show a metabolite profile that is related to Tumour 
sample grade. 
 
6.1.2.2.2 Analysis of Spectra Excluding Large Signals 
 
Using PCA a one PC model (R2X = 0.499 and Q2X = 0.367) was built for the 13 
Tumour samples. Figure 6.43 shows the scores plot whilst the loadings plot has been 
omitted due to similarity with Figure 6.38. T014 belongs to grade 2 class and is more 
distant from grade 1 samples than when the whole spectrum was used (Figure 6.41) 
but the two grade 3 samples are still positioned in scores space that is populated by 
grade 1 samples. 
 
If a relationship between Normal samples and grade of Tumour samples was 
present it would be expected that groups of Normal samples in scores space would 
be present dependent on the grade of the paired Tumour sample irrespective of the 
positioning of the Tumour sample. Figure 6.44 does not show this observation 
indicating the relationship is not present. Samples N6758 and N6876 were included 
to show positions relative to other samples despite not having a paired sample. The 
scores plot in Figure 6.35 applies and associated model statistics. 
 
As shown by Figure 6.37, the nine samples with greatest positive t[1] values when 
the six samples most remote from the majority were removed were Normal 
samples but grade of the corresponding Tumour sample (Figure 6.45) is not related 
to this observation. Four, two and three samples are associated with grades 1, 2 and 
3, respectively. The scores plot also shows more clearly than Figure 6.44 that 
positioning of grade 1 Tumour samples and counterpart Normal samples does not 
appear to be related. 
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Key: grade =  1,  2 and   3 
Figure 6.43 PCA scores plot for lipophilic extract Tumour samples excluding large 
signals. Samples coloured according to tumour grade. 
 
 
Key: shape -  Tumour and  Normal; grade =  1,  2 and   3 
Figure 6.44 PCA scores plot for lipophilic extract samples excluding large signals. 
Tumour samples coloured according to tumour grade and Normal samples 
coloured according to the Tumour counterpart.  
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Key: shape -  Tumour and  Normal; grade =  1,  2 and   3 
Figure 6.45 PCA scores plot for lipophilic extract samples excluding large signals 
and the (labelled) six samples most remote from the majority in Figure 6.44. 
Tumour samples coloured according to tumour grade and Normal samples 
coloured according to the Tumour counterpart. 
 
PLS-DA models were not able to be built for data used in the above three analyses. 
PCA of either whole spectra or small intensity signals did not provide information on 
metabolite changes that were related to breast cancer severity as assessed through 
tumour grade.  
 
6.2 Conclusions 
 
For proliferation cancer cells require large quantities of lipids and macromolecules, 
which are mostly synthesised from intermediates of glycolysis and glutaminolysis. 
Analysis of aqueous extracts from breast tissue biopsies revealed a number of 
metabolites were significantly up- or down-regulated between Normal and Tumour 
samples. In accordance with the Warburg effect, glucose was decreased and lactate 
and alanine increased in Tumour samples. Glutamine, glutamate, GPC, PCho, 
glycerophospholipids, taurine, creatine and as yet unidentified signals were raised in 
Tumour samples. Glycolysis derived UDP-GlcNAc and UDP-GalNAc were identified as 
raised in Tumour samples through investigation of the aromatic region only. PCA of 
lipophilic extracts revealed a small number of samples, both Normal and Tumour, 
contained lower amounts of triglycerides and upon removal of these prominent 
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signals increased levels predominantly of head groups of various phospholipids 
were observed in Tumour samples in the aforementioned sub-group. Normal and 
Tumour samples, however, could not be discriminated either inclusive or exclusive 
of the sub-group of samples.  
 
Breast cancer severity as assessed through tumour grade did not correlate with 
differences in levels of metabolites in analyses of either aqueous or lipophilic 
extracts. Normal samples did not reveal the propensity of complementary Tumour 
samples in terms of grade nor was there correlation between metabolite levels of 
paired samples. 
 
Results from both aqueous and lipophilic extracts showed the importance of 
normalisation and scaling methods. 
 
The hospital site of sample collection, as inferred throughout by no separation of 
samples based on length of code identifiers (which was different for the two 
hospital sites) was not relevant to the findings of this study. This also applied to the 
source of samples, either BCCTB or direct, collected from the same site. 
 
This is the first study, to the author’s knowledge, that has used de facto pattern 
recognition techniques, i.e. PCA and PLS-DA, for analysis of both aqueous and 
lipophilic aqueous extracts of breast tissue. The sample cohort is very well defined 
in terms of menopausal status and subtype, grade and DCIS status of the tumour; 
due to heterogeneity of the disease reducing factors that can affect the outcome of 
results is very important especially in small sample number metabolomics studies. 
Conclusions made here with regards to relatively homogeneous breast cancer could 
be supposed to other statuses of the disease, due to certain common features, as 
hypotheses to be verified or disproved.  
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Chapter 7. Conclusions 
 
1H-NMR based metabolomics has successfully been applied to the field of breast 
cancer. GC analysis of amino acid concentrations has also been implemented. 
 
7.1 Identification of Breast Cancer Status using Plasma and Urine  
 
Metabolomics analysis of plasma or urine was unable to identify differences 
between patients with breast cancer and those who exhibited non-cancerous breast 
abnormalities.  
 
Glucose, lactate and lipids were the most abundant metabolites in plasma. Exclusion 
of glucose due to levels being highly affected by diet did not result in improved 
separation between samples based on a number of descriptors. 
 
Known potential confounding factors reported in the patients’ medical records were 
accounted for as much as possible. Individually, none were shown to be the major 
contributor to positioning of samples in multivariate space. When differences in 
BMI, age and smoking status were minimised together (for the whole spectrum) 
tentative separation was observed between case and control samples based on 
increased levels of lipids and lactate and a decreased level of glucose for the former. 
A larger number of samples that conformed to strict criteria for all three of the 
variables would be needed to validate the observation.  
 
Analysis of urine from the same cohort revealed that many patients consumed 
acetaminophen that was not recorded in their medical records. Neither exclusion of 
the signals pertaining to acetaminophen and acetaminophen by-products nor the 
exclusion of samples containing the signals revealed information to determine case 
from control samples. 
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Unlike plasma, minimising BMI, age and smoking status did not reveal metabolites 
that potentially distinguished between those afflicted with breast cancer and non-
afflicted patients. 
 
Amino acid (AA) concentrations were quantified using GC for plasma aliquots 
obtained from the same cohort as for the NMR analysis. Of the 26 AAs extracted 
using a commercially available system only nine were used in analysis due to 
presence at insufficient concentration for quantification or unsatisfactory 
reproducibility of the other AAs. Significant differences in the AA levels were not 
present between case and control samples. 
 
7.2 Identification of Breast Cancer Tumour Descriptors using Plasma 
and Urine  
 
Amongst those afflicted by breast cancer, the grade of tumour was not able to be 
distinguished using either plasma or urine. This was true of all tumour types and the 
preponderant type, invasive ductal carcinomas. Samples were not differentiated 
based on ER or PR scores or HER2 status. For urine, whereby all three descriptors 
were combined, tumour subtype was not responsible for the positioning of samples 
in scores space. 
 
Using GC for quantification of AAs, tentative separation was observed between 
certain tumour grades. A validated PLS-DA model indicated concentrations of the 
seven AAs present in all samples (ALA, GLY, VAL, LEU, ISO, PRO and PHE) were 
greater in grade 2 samples compared to grade 1 samples. Univariate analysis 
revealed that PRO was decreased in the latter grade. However, a grade two sample 
had much a greater concentration of PRO and upon removal the difference was no 
longer significant. It must be stressed that there was no justification for this action 
because the concentrations in all three replicates were comparable but highlights 
the influence that one sample can have on small data sets.  
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7.3 SHY Analysis of Plasma and Urine Data Related to Breast Cancer  
 
Tentative correlations were revealed between full resolution plasma and urine data 
when SHY was applied that otherwise would not have been identified.  
 
Pearson’s analysis was susceptible to outlying samples. Broad, unique singlets in the 
urine range 8.123-8.579 ppm for a case sample caused positive correlation with two 
plasma regions. The origin of the urine signals was not able to be established. For 
control samples, many areas of positive correlation were present that were related 
to the signal at 3.15 ppm in plasma. The signal was attributed to DMSO2, a common 
dietary supplement, and one sample contained a substantially greater amount than 
any other. However, it was revealed that for case samples glycerol in plasma was 
positively correlated to (an) unidentified urine species within the range 4.259-
4.296 ppm and was confirmed by the more rigorous Spearman’s analysis. 
 
Spearman’s analysis also revealed that the aforementioned urine area was 
negatively correlated with the upfield section of lipid signals. This indicates a 
negative correlation between glycerol and lipids. It was speculatively hypothesised 
that levels of HDL, which exhibits the greatest upfield shift and contains lesser 
amounts of triglycerides compared to LDL and VLDL, were related to glycerol due to 
the connectivity between glycerol and glycerides and hence triglycerides. Negative 
association has been observed between triglycerides and HDL-cholesterol in CVD 
but patients’ medical records do not contain information related to this affliction. 
 
7.4 Identification of Breast Cancer Status and Tumour Descriptors 
using Tissue Extracts 
 
Due to the heterogeneity of breast cancer reducing factors that can affect the 
outcome of results is very important especially in small sample number 
metabolomics studies. The sample cohort is very well defined in terms of 
menopausal status, DCIS presence and subtype and grade of the tumour.  
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7.4.1 Aqueous Extracts  
 
Analysis of aqueous extracts from breast tissue biopsies revealed a number of 
metabolites that were significantly up-regulated or down-regulated in Tumour 
samples compared to Normal samples. Decreased glucose and increased lactate was 
present in Tumour samples, which is in accordance with the Warburg effect. The 
different levels were clearly visible from inspection of spectra. Alanine, glutamine, 
glutamate, GPC, PCho, glycerophospholipids, taurine, creatine and as yet 
unidentified signals were raised in Tumour samples. 
 
For proliferation, cancer cells require large quantities of lipids and macromolecules, 
which are mostly synthesised from intermediates of glycolysis and glutaminolysis; 
many metabolites are connected with the TCA cycle. 
 
Due to the small size of signals in the aromatic region compared to those in the 
aliphatic region, changes in signal intensity were not apparent in loadings space. 
Upon MVA of the aromatic region alone UDP-GlcNAc, UDP-GalNAc and unknown 
signals in the range 8.178-8.229 ppm were identified as elevated in Tumour 
samples. Glucose can undergo a series of reactions to form a moiety of UDP-GalNAc, 
which can be reversibly catalysed to UDP-GlcNAc. Acetyl CoA, another moiety, can 
be made from pyruvate, which is abundant due to increased glycolysis in Tumour 
cells. 
 
Grade of tumour could not be distinguished by levels of metabolites and there was 
no indicator of prediction from Normal samples of the grade of the paired Tumour 
sample. 
 
7.4.2 Lipophilic Extracts 
 
Five samples, four Tumour and one Normal, were distinct from other samples and 
dominated scores space. This was attributed to containing lower levels of α-, β-, 
allylic and bulk CH2 fatty acid and bulk methylene fatty acid whilst levels of choline 
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phospholipids were increased. Removing the five samples did not discriminate 
between Normal and Tumour samples. Neither removal of the bulk CH2 fatty acid 
region, which contributed to over half of the spectrum integral, or all of the large 
signals that accounted for approximately 90% of the spectrum integral separated 
Tumour from Normal samples. The same samples were still isolated and the Tumour 
ones were shown to contain increased levels of head groups of various 
phospholipids.  
 
Grade of tumour could not be distinguished by levels of metabolites and the grade 
of Tumour samples could not be indicated from the paired Normal samples. 
 
7.5 Further Work 
 
Verification of the findings that indicated a difference between groups of samples is 
required in a larger cohort, which is more representative of the patient population 
and reduces the impact of individual samples on the statistical significance of 
results. 
 
Confounding factors can obscure potential differences between classes of samples. 
A larger cohort could provide greater numbers of samples that are matched 
according to various parameters known to influence metabolomics studies or 
maintain similar numbers that are sourced from a more defined cohort. 
 
Breast cancer is a heterogeneous disease so determining whether the findings from 
the tissue extracts analysis, which used a well defined cohort in terms of tumour 
status, applied to other types of tumour would provide information on the extent to 
which the various types are different.  
 
In addition to collecting tumour and adjacent normal tissue samples, if less-invasive 
samples were obtained from the same patients, such as plasma and urine, SHY 
could be performed on multiple sample types. If covariances were identified 
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between extracts of tissue samples and biofluid samples the need to collect the 
tissue sample would be reduced. In addition to benefits to the patient, sample 
integrity would be easier to maintain because tissue samples require immediate 
snap-freezing and the processing steps for metabolomics studies are more involved. 
In this study, SHY revealed covariances between plasma and urine that included 
lipids and non-lipids, which indicated that there could be increased value for 
investigation into covariances between different biofluids and both lipophilic and 
aqueous tissue extracts. For SHY analysis of control samples, identification of the 
unknown urine metabolite that was shown to correlate with glycerol and lipids in 
plasma could aid interpretation of the metabolic pathways connecting the species. 
 
MS has greater sensitivity than NMR spectroscopy(45,52) but metabolite identification 
is not as universal.(52,53) Use of the former technique could reveal further differences 
in metabolite levels with SHY being employed to determine whether correlations 
were present between the two platforms, which could reveal information related to 
metabolic pathways.  
 
Due to SHY being in its infancy a reduction in the number of spurious covariances 
and the processing power required whilst retaining non-spurious covariances could 
result from establishing the optimum number of data points to be used.  
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Chapter 8. Experimental Methods 
 
8.1 NMR Sample Preparation 
 
Chemicals were purchased from Sigma-Aldrich Company Ltd. (Poole, Dorset, UK), 
unless otherwise stated. NMR tubes (S-5-500-7, Norell) were purchased from GPE 
Scientific Ltd. (Leighton Buzzard, Bedfordshire, UK). 
 
8.1.1 Samples for 1H-NMR Analysis 
 
8.1.1.1 Plasma Samples (Chapter 2) 
 
Samples were stored at -80oC before defrosting at room temperature. Samples were 
centrifuged (Hettich Mikro 120 (C1204) Centrifuge, angle rotor A1242) at 11,992 g 
for 5 minutes. 350 µl of plasma supernatant was added to 408 µl of deuterium oxide 
(D2O). The mixture was vortexed for 8 s before transferring 600 µl to a 5 mm NMR 
tube. Samples not analysed immediately were stored at 4oC for a maximum of 
1.5 hours. 
 
8.1.1.2 Urine Samples (Chapter 3) 
 
Samples were stored at -80oC before defrosting at room temperature. Samples 
were centrifuged (Hettich Mikro 120 (C1204) Centrifuge, angle rotor A1242) at 
11,992 g for 5 minutes. 460 µl of urine supernatant was added to 230 µl of 
phosphate buffer. 100 ml of stock phosphate buffer solution (pH 7.43) contained 
2.885 g sodium phosphate monobasic (Na2HPO4), 0.525 g sodium phosphate dibasic 
(NaH2PO4), 0.0172 g (1 mM) trimethylsilyl propanoic acid (TSP) and 0.0195 g (3 mM) 
sodium azide (NaN3) in 20 ml of D2O and 80 cm
3 of ribonuclease (RNase) free water. 
The phosphate buffer was shaken thoroughly and placed in a sonicator, 
interspersed by shaking, until salts dissolved. The urine/phosphate buffer mixture 
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was vortexed for 8 s before transferring 600 µl to a 5 mm NMR tube. Samples not 
analysed immediately were stored at 4oC for a maximum of 1.5 hours. 
 
8.1.1.3 Tissue Extracts (Chapter 6) 
 
8.1.1.3.1 Separating Aqueous and Lipophilic Components 
 
Samples were stored at -80oC and surrounded by dry-ice during transferral 
(<2 minutes) to the processing laboratory. The frozen weight was recorded and the 
sample returned to the dry-ice. For samples >41 mg, 4 ml g-1 of methanol and 
0.85 ml g-1 of water were added. The volume to weight ratio was increased for 
samples ≤41 mg to provide a minimum of 200 µl and the same scaling factor applied 
to subsequent volumes of extraction solvents. Following homogenisation (Omni 
Tissue Homogeniser; Camlab, Over, Cambridgeshire, UK) at 35,000 rpm using a 
stainless steel probe and glass vial, the sample was vortexed for 5 s. 2 ml g-1 of 
chloroform was added and vortexed for 5 s. A further 2 ml g-1 of chloroform and 
2 ml g-1 of water were added and vortexed for 5 s. The sample was left on ice for 
15 minutes before centrifugation at 1,023 g for 15 minutes. The solutions separated 
into an upper methanol/water phase (with polar metabolites) and a lower 
chloroform phase (with lipophilic compounds) with protein and cellular debris 
between the two layers. The upper layer was removed and was snap frozen using 
N2. The lower layer was removed and transferred to a glass vial. 
 
8.1.1.3.2 Processing of the Aqueous Component 
 
Methanol and water were removed from the upper layer using a speed vacuum 
concentrator and the extracts stored at -80oC. The extracts were resuspended in 
680 µl of a 0.17% weight to volume solution of the sodium salt of TSP in D2O, 
vortexed for 5 sec and centrifuged at 11,992 g for 5 minutes. 600 µl was transferred 
to a 5 mm NMR tube. All samples were analysed immediately. 
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8.1.1.3.3 Processing of the Lipophilic Component 
 
Chloroform was removed from the lower layer under a stream of N2 and the 
extracts resuspended in 430 µl of deuterated chloroform (CDCl3; 99.8%), containing 
0.03% volume to volume of tetramethylsilane (TMS), and 215 µl of deuterated 
methanol (CD3OD; 99.8%; Eurisotop, Gif-sur-Yvette, Paris, France). The solution was 
stored at 4oC for a maximum of three days before centrifugation at 1,023 g for 5 
minutes and transferral of 600 µl to a 5 mm NMR tube. All samples were analysed 
immediately. 
 
8.2 NMR Data Collection 
 
All 1H-NMR spectra were acquired on a Varian Unity Inova 500 spectrometer (Varian 
Inc., Palo Alto, California, USA) operating at 499.97 MHz proton frequency, at 20oC. 
Samples were loaded into the probe and left for 5 minutes to allow temperature 
equilibration. 
 
8.2.1 CPMG Experiment (Chapter 2) 
 
The CPMG pulse sequence [RD – 90o – (τ – 180o – τ)n – acq] was used to obtain 
metabolic profiles for all plasma samples. The relaxation delay (RD) was 2 s, during 
which the water resonance was selectively saturated, τ was 1.5 ms and n was 150. 
For each spectrum 512 transients were collected into 16,384 pairs of data points 
with a spectral width of 8,000.00 Hz.  
 
8.2.2 1D NOESY Experiment (Chapter 3) 
 
The 1D NOESY pulse sequence [RD – 90o – t1 – 90
o – tm – 90
o – acq] was used to 
obtain metabolic profiles for all urine samples. The RD was 2 s, tm was 1.5 ms and t1 
was 3 µs. For each spectrum 512 transients were collected into 16,384 pairs of data 
points with a spectral width of 8,000.00 Hz.  
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8.2.3 Presaturation Experiment (Chapter 6) 
 
The presaturation (PRESAT) pulse sequence was used to obtain metabolic profiles 
for all tissue extracts. For each aqueous and lipophilic spectrum 512 and 256 
transients, respectively, were collected into 16,384 pairs of data points with a 
spectral width of 6,000.15 Hz. The RD was 0.5 s. 
 
8.3 NMR Spectral Processing 
 
All spectral data were processed using ACD Labs software 12.01 (Advanced 
Chemistry Development, Inc., (ACD/Labs), Toronto, Canada). An exponential line 
broadening was applied to each free induction decay (FID) prior to zero filling to 
65,536 points and Fourier transformation. The resulting spectra were phased, 
baseline corrected and referenced. Details of parameters are listed in Table 8.1 
 
Table 8.1 NMR spectral processing parameters 
Samples Pulse 
Sequence 
Line 
Broadening 
(Hz) 
Reference 
Compound Chemical Shift 
(ppm) 
Plasma CPMG 0.5 α-glucose 5.23(142) 
Urine 1D NOESY 0.5 TSP 0.000(142) 
Aqueous tissue 
extracts 
PRESAT 0.5 TSP 0.000(142) 
Lipophilic tissue 
extracts 
PRESAT 0.5 TMS 0.000(226) 
 
8.3.1 Additional NMR Data Processing for Multivariate Statistical Analysis 
 
8.3.1.1 Binning and Dark Regions 
 
Normalisation to constant sum and spectral binning was performed using ACD Labs 
software 12.01. All datasets were integrated into bins of 0.02 ppm width 
implementing 50% ‘looseness’, which allowed bin width to vary between 0.01 and 
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0.03 ppm. The software used an algorithm that simultaneously adjusted starting 
and final points of two adjacent bins to minimise the overall height of their borders 
resulting in bin divisions being more likely to occur at the edges of peaks. The 
lipophilic extract dataset was also binned using 0.001 ppm fixed widths. 
  
Prior to binning over a spectral range (Table 8.2), several dark regions were created 
for spectra from plasma (Table 8.3), urine (Table 8.4), aqueous tissue extracts (Table 
8.5) and lipophilic tissue extracts (Table 8.6) to exclude signals, such as from the 
water region, contaminants and certain metabolites, from subsequent MVA. 
 
Table 8.2 Spectral range for which binning was performed. 
Sample Range (ppm) 
Plasma 0.000-10.000 
Urine 0.150-10.000 
Aqueous tissue extracts 
0.210-10.000 
5.446-9.362  
Lipophilic tissue extracts 0.230-10.000 
 
Table 8.3 Dark regions used for the plasma spectra (Chapter 2).  
Dark Region 
(ppm) 
Excluded  Comment 
4.20-5.70 Water region  Variable water suppression 
efficiency 
3.18-3.94 Glucose Excluded later to remove 
influence from statistical 
models 
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Table 8.4 Dark regions used for the breast cancer urine spectra (Chapter 3). 
Dark Region 
(ppm) 
Excluded  Comment 
4.500-6.200 Water region and urea Variable water suppression 
efficiency 
2.143-2.200 
3.588-3.664 
3.883-3.926 
7.120-7.166 
7.300-7.386 
7.434-7.481  
Acetaminophen and acetaminophen 
by-products 
Excluded later to remove 
influence from statistical 
models 
3.034-3.064 
4.043-4.073 
Creatinine Excluded later to remove 
influence from statistical 
models 
3.954-3.984  
7.530-7.590 
7.611-7.662 
7.815-7.867 
Hippurate Excluded later to remove 
influence from statistical 
models 
 
Table 8.5 Dark regions used for the breast cancer aqueous tissue extracts spectra 
(Chapter 6). 
Dark Region 
(ppm) 
Excluded  Comment 
2.520-2.750  Citrate Possible contaminant from 
collection tube 
3.341-3.371  Methanol Extraction solvent 
4.750-5.000 Water region Variable water suppression 
efficiency 
1.314-1.374 
4.085-4.144 
Lactate Excluded later to remove 
influence from statistical 
models 
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Table 8.6 Dark regions used for the breast cancer lipophilic tissue extracts spectra 
(Chapter 6). 
Dark Region 
(ppm) 
Excluded  Comment 
3.321-3.450  Methanol Extraction solvent 
7.403-7.594  Chloroform Extraction solvent 
1.200-1.458 Bulk CH2 fatty acid Excluded later to remove 
influence from statistical 
models 
0.796-0.961 CH3 fatty acid 
Excluded later to remove 
influence from statistical 
models 
1.117-1.787 Bulk CH2 and β-CH2 fatty acids 
1.932-2.191 Allylic CH2 fatty acid 
2.268-2.446 α-CH2 fatty acid 
2.701-2.964 Diallylic CH2 fatty acid 
3.147-3.450 Methanol and choline phospholipids 
4.083-4.758 glycerol C-1 methylene protons of 
diacylglycerophospholipids 
5.056-5.606 Olefinic CH fatty acid and glycerol C-2 
proton of diacylglycerophospholipids 
7.210-7.725 Chloroform containing region 
 
8.3.1.2 Probabilistic Quotient Normalisation 
 
Urine (Chapter 3), full resolution plasma and urine (Chapter 4), and aqueous and 
lipophilic tissue extracts (Chapter 6) data sets were PQ normalised.  
 
Constant sum normalised data was exported from ACD Labs software 12.01 into 
Excel 2007 (Microsoft, Redmond, Washington, USA). For all “control” spectra the 
median of every variable (bin/data point) was calculated; this acted as the reference 
spectrum.(69) For each test spectrum quotients were calculated for every variable 
relative to the reference spectrum. The median of these quotients, excluding noise 
regions (regions included in the calculations are shown in Table 8.7), was calculated 
per test spectrum and all variables of the test spectrum were divided by this 
median. If regions were subsequently excluded from MVA, new constant sum 
normalised data was obtained and the PQN steps repeated. 
217 
 
Table 8.7 Regions included for the calculation of the median quotient of test 
spectra. 
Samples Urine Plasma (full 
resolution)   
Urine (full 
resolution)   
Aqueous 
tissue 
extracts 
Lipophilic 
tissue extracts 
Region 
(ppm) 
0.494-4.500 0.807-1.053 0.493-3.588 0.725-2.520 0.559-3.321 
6.200-9.162 1.173-1.385 3.664-3.883 2.750-3.341 3.450-3.752 
9.261-9.301 1.452-1.495 3.926-4.500 3.371-4.750 3.828-5.766 
9.344-9.374 1.851-1.921 6.200-7.120 5.164-6.175 5.892-6.043 
9.668-9.726 1.965-2.165 7.166-7.300 6.507-6.544 6.249-6.371 
9.957-10.000 2.188-2.295 7.386-7.434 6.764-8.045 7.011-7.403 
 2.317-2.480 7.481-9.000 8.098-8.730 7.594-7.748 
 3.022-3.978 9.022-9.162 8.812-8.872 8.107-8.137 
 4.035-4.149 9.261-9.301 8.926-8.953  
 6.861-6.910 9.344-9.375 9.136-9.165  
 7.021-7.051 9.666-9.726 9.323-9.352  
 7.162-7.206    
 7.721-7.748    
 8.440-8.459    
 
8.4 Multivariate Statistical Analysis 
 
All multivariate statistical analyses were performed using SIMCA-P+ software, 
version 12.0.1.0 (Umetrics, Umeå, Sweden). This software was used to scale (Pareto 
unless otherwise stated) and mean centre the data. 
 
PCA was performed to view any intrinsic clustering in the samples, which can be 
seen in the scores (t) plots. The loadings (p) plots were used to identify regions of 
the spectra (bins) responsible for any clustering or outliers in the scores plot. 
 
PLS-DA was performed to improve distinction of separation between groups of 
interest and to produce models from which classes of samples not used in that 
model could be predicted. Scores plots allowed observation of class discrimination 
and w* plots were used to identify the bins accounting for the discrimination.  
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The quality of each model was assessed by the goodness of fit (R2X) and the ability 
to predict the class membership of new sample (Q2X for PCA and Q2Y for PLS-DA) . 
In addition, for PLS-DA the proportion of the classification data (Y) accounted for 
(R2Y) was also considered. The predictive ability of the PLS-DA models was assessed 
by ‘leave-one-out’ cross-validation. Further validation was performed using 
permutation testing whereby the classes of samples were randomised and a PLS-DA 
model built. The R2Y and Q2Y values should be less than those generated for the 
original model, which were based on the real classifications. The maximum number 
of permutations permissible by the software was performed, 999.  
 
8.5 Univariate Statistical Analysis 
 
Univariate tests of statistical significance were performed on any bins that were 
considered influential in a trend of interest. The integral values of bins were tested 
for normality using the Shapiro-Wilk test. If the data distribution was normal and 
the variances of the two groups were equal the Student’s t-test was performed. If 
the variances were not equal the Welch-Aspin test was used, a modification of the 
Student’s t-test. For non-normal data the non-parametric Mann-Whitney U test was 
used instead. For both, the mean integral values were compared between groups 
and a p-value obtained for the statistical significance of the difference between 
groups. For tissue extracts data, samples belonged to the same patients when the 
two groups being tested were Tumour and Normal. Therefore, the data were paired 
and required the use of the paired-samples t-test or the Wilcoxon test for normal or 
non-normal data, respectively. All tests of normality and significance were 
performed in IBM SPSS Statistics 20.0 (IBM Corporation, Armonk, New York, USA). 
Resulting p-values were adjusted for multiple comparisons using the FDR correction 
in R software, version 2.7.0 (R Foundation for Statistical Computing, Vienna, 
Austria). 
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8.6 SHY Analysis of Breast Cancer Plasma and Urine (Chapter 4) 
 
PQ normalised case and control sample matrices were analysed separately. The 
Pearson’s and Spearman’s correlation coefficients and their statistical significances 
(through p-values) were calculated for every column in the plasma matrix against 
every column in the urine matrix using the “corr(x,y)” function in MatLab, version 
7.12.0.635 (R2011a) (The MathWorks, Inc., Natick, Massachusetts, USA). In the 
resulting correlation matrix any correlations with p-value >0.001 were set to zero to 
reduce spurious correlations. The correlation matrix was plotted using the 
“imagesc” function.  
 
A personal computer (Evesham Technology, Evesham, Worcestershire, UK; 
processor speed = 3.0 GHz, RAM = 2 GB, processor type = Intel(R) Pentium(R) 4 CPU) 
was used in an attempt to produce a correlation matrix generated from every data 
point of full resolution data (37,815 data points per spectrum) but the processing 
requirements surpassed the capabilities of the personal computer. Approximately a 
square 6,000 matrix was the maximum correlation matrix size that could be 
generated. A higher specification personal computer (Dell Inc., Round Rock, Texas, 
USA; processor speed = 2.93 GHz, RAM = 16 GB, processor type = Intel(R) Core(TM) 
i7 CPU) was used but a square 37,815 correlation matrix was not able to be 
generated. The data points pertaining to the region 4.500-6.200 ppm, which 
contained water and additionally urea for urine, were excluded resulting in 30,852 
data points per spectrum but generation of a correlation matrix was not possible. 
Removing data points that had a value of zero for all samples resulted in 9,060 and 
27,450 data points per spectrum for plasma and urine, respectively (Table 8.7, third 
and fourth columns), and allowed generation of a correlation matrix. 
 
Integrals of the data points were plotted in OriginPro 8 SR4, version 8.9051 
(OriginLab Corporation, Northampton, Massachusetts, USA).  
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8.7 GC Analysis of Breast Cancer Plasma (Chapter 5) 
 
The EZ:Faast (Phenomenex, Macclesfield, UK) system was used to extract and 
derivatise AAs from breast cancer plasma samples. The sample preparation 
procedure listed in the information booklet that accompanied the system was 
followed. The solid phase extraction step was performed via a sorbent packed tip 
that bound AAs but allowed interfering compounds to flow through. AAs on the 
sorbent were extruded into the sample vial and derivatised with a reagent in 
aqueous solution. Derivatised AAs concomitantly migrated to the organic layer and 
were additionally separated from interfering compounds. An aliquot (2 µl) from the 
organic layer was analysed by GC with FID using an Autosystem XL gas 
chromatograph (Perkin-Elmer, Waltham, Massachusetts, USA). A ZB-AAA 10 m x 
0.25 mm column (Phenomenex, Macclesfield, UK) was used in constant flow mode 
with a split ratio of 1:15 at 250oC, a helium flow rate of 1.5 ml min-1 and a 
temperature increase of 32oC min-1 between 110oC and 320oC. 
 
Using the EZ:Faast system, calibration standard sets used for AA quantification were 
made and consisted of three samples containing all 26 AAs that could be quantified 
at increasing concentration (50, 100 and 200 nmol ml-1). Up to three injections of 
the same standard set were performed within a 24 hour period (the maximum 
storage time at room temperature recommended by the manufacturers). After 
every 10 test samples a standard set was run. Three injections of every test sample 
were performed within a 24 hour period. 
 
Multivariate and univariate statistical analysis was performed as described in 
Section 8.4 and 8.5 with the exceptions that data were not normalised and UV 
scaling was performed rather than Pareto.  
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Appendices 
 
Appendix 1: Arterial Disease 
 
Initial work focussed on arterial disease, as discussed below, but due to samples 
(plasma, urine and carotid or femoral plaques) being unavailable for a substantial 
period of time that would be collected specifically for metabolomics studies, 
investigation into metabolic markers related to breast cancer ensued. 
 
A1.1   Introduction 
 
Atherosclerosis is a disease of large and medium-sized arteries. It is the most 
important contributor to CVD(227) and heavily affects the burden of myocardial 
infarction (MI; heart attack) and stroke. Published work provides various, but high, 
figures for the seriousness of the problem. In Westernised societies atherosclerosis 
is the main cause of morbidity and mortality, (228) contributing to about 50% of all 
deaths.(229,230) CVD is the most common, and second most common, cause of death 
in European men and women respectively, who are under 65 years of age(231) and 
the disease is expected to become the leading cause of death worldwide in the 
twenty-first century.(227,231,232) It is estimated that CVDs affect 57 million Americans, 
and each year causes 954,000 deaths and costs $259 billion.(230) Imaging techniques 
commonly employed clinically are biased towards the detection of severe, flow-
limiting stenoses (narrowing of blood vessels) and are relatively poor at detecting 
early disease.(233) Consequently, the first presentation of arterial disease is often an 
acute event such as myocardial infarction or stroke.(233) 
 
The effect of atherosclerosis depends on where it occurs: in the arteries that 
perfuse the brain it can cause stroke and transient ischaemic attacks (TIA) whereas 
in the heart it can lead to myocardial infarction and heart failure.(234) Stroke is often 
preceded by TIA(234) whereby reduced supply of blood and oxygen occurs to the 
brain temporarily so the symptoms soon go unlike for stroke. It is sometimes called 
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a mini stroke. Renal impairment, hypertension, abdominal aortic aneurysms and 
critical ischaemia (CI) can occur if atherosclerosis affects other arteries.(235) 
Peripheral arterial disease (PAD) normally occurs in legs with symptoms most 
common in calf muscles with some patients being affected in the thigh and buttock 
regions.(236) There are various categories associated with progression of the disease. 
Intermittent claudication is a less severe form with the symptoms being aching or 
pain in the legs reproducibly brought on by walking and relieved by rest.(237) CI is 
more severe with pain at rest. Ulceration and gangrene can occur and if 
revascularisation surgery is not performed in time amputation is required.(236) Over 
£200 million is the estimated annual cost to the UK of CI.(236) Patients suffering from 
PAD have more than twice the risk of exhibiting coronary heart disease (CHD) 
events, such as MI, but only 25% of patients are undergoing treatment.(238) 
 
A1.2   Previous Metabolomics Studies of Arterial Related Diseases 
 
There have been a number of metabolomics studies into arterial disease and 
associated factors.(145,239-243) Many potential markers have been identified in relation 
to blood pressure in urine by 1H NMR: formate, sodium and alanine are positively 
correlated with blood pressure, with hippurate showing the inverse association.(145) 
4-hydroxyproline was identified as the metabolite of interest in plasma of patients 
with non-ST-elevation acute coronary syndrome (NSTEACS) using GC-MS.(240) ST is 
the segment between S and T time points in an electrocardiogram (ECG). An 
elevated ST segment is associated with acute MI.(244) The authors have suggested 
the decrease in plasma hydroxyproline levels in NSTEACS versus control may reflect 
a status of low collagen synthesis and turnover. Analysis of gas chromatography 
coupled to time-of-flight mass spectrometry (GC-TOF-MS) serum data identified 
pseudouridine, 2-oxoglutaric acid, 2-hydroxy, 2-methylpropanoic acid, erythritol, 
and 2,4,6-trihydroxypyrimidine as showing significant differences in levels between 
patients with systolic heart failure and controls.(239) 2-oxoglutarate is a major 
intermediate of the TCA cycle and a change in several other constituents of the TCA 
cycle has been shown in plasma using LC-MS: 6 of the 23 most-changed metabolites 
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after exercise in patients with inducible ischaemia are involved in the Krebs 
cycle.(241) The same study also showed the six most discordant metabolites between 
cases and controls are citric acid, γ-aminobutyric acid, uric acid, MET193, MET 200 
and MET288. One of the first metabolomics human studies had shown that 
metabolomics can diagnose the presence and severity of CHD(242) but a later study 
proved the results were due to a confounding factor, statin treatment, which 
caused decreases in cholesterol, low-density lipoprotein (LDL) and triglycerides, thus 
affecting the lipid peak contributions in the spectra.(243) Most arterial disease studies 
have focussed on coronary related problems with many fewer concerned with 
PAD.(245) 
 
A1.3   NMR Analysis of Plasma  
 
The following chapter will describe 1H NMR analysis of plasma obtained from 75 
patients who conformed to a control group or one of two arterial disease groups 
(Table A.1); one group exhibited coronary problems whilst the other consisted of 
patients suffering from claudication. 
 
Prior to detailed analysis of the NMR spectra it was immediately apparent that 
citrate was present as a contaminant: two large doublets centred at 2.52 and 
2.65 ppm.(246,247) The most likely source of the ‘contamination’ was sample 
collection vessels that used citrate as an anti-coagulant. Vacuettes coated with 
lithium heparin have become the usual vessels for blood collection but previously 
citrate and ethylenediaminetetraacetic acid (EDTA) had been used extensively 
especially for “bio-bank” samples.(246) The region 2.461-2.741 ppm containing the 
citrate resonances was excluded from subsequent analysis. 
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Table A1.1 Summary of patients’ demographics. 
         Descriptor 
 
Group 
Total Male 
Female 
Non-Diabetic 
Diabetic 
Non-Smoker 
Smoker 
Claudication 26 
18 
13 
7 
6 
5 
4 
1 
8 
8 
4 
4 
0 
0 
0 
Coronary 23 
18 
14 
11 
3 
4 
3 
1 
5 
5 
3 
2 
0 
0 
0 
Control 26 
19 
17 
15 
2 
2 
1 
1 
7 
4 
2 
2 
3 
1 
2 
 
A1.3.1   Reference Compound Investigation 
 
A number of different metabolites have been used to reference 1H-NMR spectra, 
including lactate, alanine, acetate and glucose(71,246,248,249) rather than TSP,(48,250) 
which has been used traditionally, but spectra and results showing comparison are 
not readily available. Signals referenced to TSP can exhibit sizeable chemical shift 
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variation between samples.(251) Additionally, in plasma, due to binding with albumin, 
TSP cannot be used to quantify the concentration of other compounds,(252) which is 
its secondary use. Using a CPMG pulse sequence heavy molecules are filtered out so 
TSP bound to albumin is not detected and because the ratio of unbound to bound 
TSP changes, variable levels of TSP result in CPMG spectra. The chemical shift of 
metabolite signals was investigated when spectra were referenced to different 
compounds (Table A1.2). 
 
Table A1.2 Maximum chemical shift of signals using various reference compounds.  
Reference Compound 
Chemical Shift (ppm) 
Reference Signal(103) 
Maximum Variation of 
Other Signals* 
TSP 0.000 0.011 
Lactate (CH3) 1.317 0.004 
Alanine (CH3) 1.463 0.006 
Acetate (CH3) 1.910 0.004 
Glucose (H1’ α) 5.223 0.004 
*Not including those in the table. 
 
The maximum chemical shift variation of peaks was greater when referenced to TSP 
than to any of the other compounds. Most signals exhibited no more than 
0.001 ppm variation when referenced using lactate, acetate or glucose. 
 
Excluding TSP, when alanine was used as the reference compound the chemical shift 
range of other metabolites varied the most and when referenced to other 
compounds the alanine signal exhibited greater chemical shift range than lactate, 
acetate or glucose. 
 
Of the 75 samples included in the analysis the one that exhibited the greatest 
upfield chemical shift of signals when referenced to TSP contained a greater 
quantity of unbound TSP. Data acquisition was not possible for two prepared 
plasma samples (not included in Table A1.1) and due to volume loss during the 
refreezing cycle insufficient quantity was available. Further deuterium oxide 
(D2O)/TSP solution was added to provide the standard volume for data acquisition 
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(Section A1.5.2). The data were not included in MVA. Upfield chemical shift of 
signals was also displayed by the two samples (Figure A1.1a). Conversely, when 
referenced to acetate, alanine, glucose or lactate, the three samples showed greater 
downfield shift of TSP (Figure A1.1b) but not of other signals. These observations 
can be explained by protein interactions causing chemical shift variation:(251) the 
greater the amount of protein binding relative to the amount of TSP, the greater the 
downfield chemical shift of signals when referenced to TSP and vice-versa.  
 
Of the reference compounds investigated acetate, glucose and lactate were 
superior to alanine and TSP. Signal overlap with underlying lipid resonances can 
occur for the lactate doublet at 1.317 ppm although this problem does not occur for 
the quartet at 4.103 ppm. The H1’ α-glucose doublet at 5.223 ppm will be used for 
referencing in future blood vessel disease work because it is readily resolved and of 
the alternative reference compounds to TSP has found common use.(246,249) 
 
a)  b)  
Figure A1.1 Chemical shift of spectra showing a) lactate signal referenced to TSP 
and b) TSP signal referenced to lactate. Sample included in MVA with the greatest 
amount of TSP shown in bold red and the two excluded refrozen samples shown in 
bold blue and green. 
 
A1.3.2 Metabolomics Investigation 
 
A1.3.2.1 Analysis of Disease Type Groups 
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PCA was performed with samples assessed according to disease type category 
(claudication, coronary or control). Scores and loadings plots of the five PC model 
(R2X(cum) = 0.693 and Q2X(cum) = 0.456) are shown in Figure A1.2 and Figure A1.3 
respectively. 
 
 
Key:  coronary,  claudication and  control samples. 
Figure A1.2 PCA scores plot for CPMG plasma data showing the first two model 
components. R2X = 0.291 and 0.177, and Q2X = 0.196 and 0.138 for PC 1 and PC 2, 
respectively.    
 
 
Figure A1.3 PCA loadings plot corresponding to the model displayed in Figure A1.2. 
 
No separation was present in scores space between the three groups of samples. 
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4.121 ppm) and glucose (all bins that had a p[1] value less than -0.005; centred 
between 3.201-3.921 ppm, inclusive) containing bins dominated the loadings plot 
therefore the different sample groups were not represented by levels of the two 
metabolites. PC 5 versus PC 3 scores plot showed very tentative separation between 
the three sample groups based primarily in PC 3 (Figure A1.4). The loadings plot 
(Figure A1.5) indicated lipids (0.881 and 1.281 ppm) were highest and lactate lowest 
in coronary samples that were broadly identified by the red ellipse whilst for 
claudication samples broadly identified by the blue ellipse the reverse was implied; 
levels of the metabolites were of intermediate values for the control group. 
However, there were quite a few coronary samples positioned in scores space 
primarily populated by claudication samples and two of the samples with greatest 
t[3] values belonged to  the claudication group. Additionally, the R2X and Q2X values 
were low for both PCs (Figure A1.4 legend). 
 
A one component model (data not shown; R2X = 0.267, R2Y = 0.075 and Q2Y = 0.006) 
was generated using PLS-DA but with such a low Q2Y value little credence can be 
attributed to the findings. Separation in scores space similar to that in PC 3 of the 
PCA model was observed but based on glucose and lactate with the former raised in 
claudication samples and the latter raised in coronary samples. 
 
Levels of lactate(253) and glucose(66) in biofluids can be highly dependent on diet. Due 
to the impracticality of restricting patients’ food and fluid intake prior to sample 
donation, the time of their last meal varied and drink types and quantities 
consumed were not recorded. Glucose (3.181-3.941 ppm) and lactate 
(1.301-1.341 ppm and 4.061-4.141 ppm) containing bins were excluded to allow 
other metabolites that are less influenced by diet to determine scores space 
positions of samples. 
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Key:  coronary,  claudication and  control samples. 
Figure A1.4 PCA scores plot for CPMG plasma data showing PC 5 v. PC 3. R2X = 
0.091 and 0.061, and Q2X = 0.065 and 0.091 for PC 3 and PC 5, respectively. Ellipses 
coloured according to the key indicate areas occupied by many samples of the 
respective groups and are for display only. 
 
 
Figure A1.5 PCA loadings plot corresponding to the model displayed in Figure A1.4. 
 
Figure A1.6 and Figure A1.7 show the scores and loadings plots, respectively, of PC 1 
and PC 2 upon removal of glucose and lactate regions. Separation of the three 
groups was not present in these components or when other components of the four 
PC model (R2X(cum) = 0.601 and Q2X(cum) = 0.423) were visualised (data not 
shown).  
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Key:  coronary,  claudication and  control samples. 
Figure A1.6 PCA scores plot for CPMG plasma data excluding glucose and lactate 
regions showing the first two model components. R2X = 0.309 and 0.129, Q2X = 
0.262 and 0.093 for PC 1 and PC 2, respectively. 
 
 
Figure A1.7 PCA loadings plot corresponding to the model displayed in Figure A1.6. 
 
Lipids are important in determining the position of samples in scores space as are 
the bins, amongst others, centred at 2.041 ppm, the resonance arising from acetyl 
groups of glycoprotein, and 0.961 ppm, which contains the majority of the leucine 
triplet and upfield peak of valine doublet. PLS-DA produced a non-discriminatory, in 
terms of the three disease type groups, one PC model (data not shown; R2X = 0.213, 
R2Y = 0.084 and Q2Y = 0.002) that had a very low Q2Y value. 
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Although both are related to blood vessels, coronary and claudication afflictions are 
distinct so analysis was performed using all combinations of two disease type 
groups to investigate whether there were metabolic differences that were 
previously obscured when analysing all three groups. A summary of the models is 
shown in Table A1.3. 
 
Table A1.3 Summary of models for all combinations of two disease type groups. 
Groups Included 
PCA PLS-DA 
Number 
of PCs 
R2X 
(cum) 
Q2X 
(cum) 
Number 
of PCs 
R2X 
(cum) 
R2Y 
(cum) 
Q2Y 
(cum) 
Coronary and control 3 0.544 0.384 0 / / / 
Claudication and control 3 0.553 0.378 2 0.408 0.399 0.087 
Coronary and  claudication 4 0.630 0.445 0 / / / 
 
No separation between groups was observed in PCA for any combination of two 
disease type groups (data not shown). Only the combination of claudication and 
control groups generated a PLS-DA model (scores plot shown in Figure A1.8 and 
loadings plot in Figure A1.9). 
 
 
Key:  claudication and  control samples. 
Figure A1.8 PLS-DA scores plot for CPMG plasma data excluding glucose and 
lactate regions of claudication and control samples. 
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Figure A1.9 PLS-DA loadings plot corresponding to the model displayed in Figure 
A1.8. 
 
The model was tested by cross-validation through exclusion of one-third of samples 
that were randomly assigned and their class predicted from the resultant model 
with the process performed three times to ensure the operation was applied to 
every sample. Of the 52 samples, 28 (54%) were predicted correctly (Y-predicted 
value >0.50) with 9, 6 and 13 having Y-predicted values of <0.60, 0.60-0.70 and 
>0.70, respectively, and 24 incorrectly predicted. Not many more samples were 
correctly predicted than would be expected by chance hence the PLS-DA model in 
Figure A1.8 was surmised to have poorly fitted the data leading to the conclusion 
that there was no difference in metabolite levels in claudication and control samples 
when all samples were assessed. Permutation testing (plots not shown) also 
indicated the model was poor due to the high number of permuted models that had 
R2Y and Q2Y values in excess of the values for the original model. 
 
A number of confounding factors are known such as race,(254) sex(40,255) and diabetic 
state.(256,257) All samples were obtained from white European patients but the other 
two factors were not consistent for all samples (Table A1.1). Of the 75 samples, 55 
were from males of whom 44 did not have diabetes. Analysis based on disease type 
group was performed for the reduced numbers in the sample cohort (“male, non-
diabetic”). 
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A three PC model (R2X(cum) = 0.562 and Q2X(cum) = 0.369) was generated using 
PCA. The scores plot is shown in Figure A1.10 but the loadings plot is not shown due 
to the similarity (vertical mirror image excepted) with Figure A1.7, for which all 
samples were included. Control samples tended to be positioned in low PC 2 scores 
space with coronary and claudication samples possessing greater, either positive or 
negative, t[2] values. The contribution to the predicted variation (Q2X) was low in 
the second component, being only 0.017, and no separation was present in the first 
component. Using PLS-DA, a model was unable to be made. The three combinations 
of two disease type groups were analysed but separation was not present between 
any of the groups (data not shown; summary of models displayed in Table A1.4).  
 
 
Key:  coronary,  claudication and  control samples. 
Figure A1.10 PCA scores plot for CPMG plasma data excluding glucose and lactate 
regions of “male, non-diabetic” samples showing the first two model components. 
R2X = 0.337 and 0.126, Q2X = 0.293 and 0.017 for PC 1 and PC 2, respectively.  
 
Table A1.4 Summary of models including only “male, non-diabetic” samples for all 
combinations of two disease type groups. 
Groups Included 
PCA PLS-DA 
PCs R2X(cum) Q2X(cum) PCs 
Coronary and control 1 0.379 0.325 0 
Claudication and control 2 0.482 0.300 0 
Coronary and  claudication 3 0.598 0.345 0 
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Smoking is another factor that can influence metabolomic profiles(255) and previous 
studies have excluded patients who smoke.(258) Excluding current smokers from the 
“male, non-diabetic” cohort reduced the sample number to 33. Analysis as 
previously reported was performed. No separation between disease type groups of 
the “male, non-diabetic, non-smoker” cohort was observed; scores and loadings 
plots are not shown due to similarity with those produced using “male, non-
diabetic” samples. Table A1.5 provides a summary of the models. 
 
Table A1.5 Summary of models including only “male, non-diabetic, non-smoker” 
samples for all combinations of two disease type groups. 
Groups Included 
PCA PLS-DA 
PCs R2X(cum) Q2X(cum) PCs 
Coronary, claudication and control 2 0.493 0.344 0 
Coronary and control 1 0.414 0.352 0 
Claudication and control 1 0.403 0.318 0 
Coronary and  claudication 2 0.502 0.304 0 
 
A final approach to analysis of disease type was to remove all samples that were not 
part of the “male, non-diabetic, never smoked” cohort. Smoking is a risk factor for 
blood vessel disease and although the risk for PAD decreases with time of 
abstinence, former smokers still have a greater risk than those who have never 
smoked.(259) Additionally, the risk increases with total cigarettes smoked(259) so the 
metabolic profile could be affected by previous smoking. Despite providing a well-
defined cohort, including samples only from “male, non-diabetic, never smoked” 
patients substantially reduced the data to be analysed: of the 14 samples, three, five 
and six were coronary, claudication and control, respectively. 
  
Figure A1.11 shows the PCA scores plot of the one component model (R2X = 0.365 
and Q2X = 0.214) for “male, non-diabetic, never smoked” samples indicating no 
separation was present between the three disease type groups. The loadings plot is 
not displayed due to similarity with PC 1 of Figure A1.7, for which all samples were 
included. Due to the small number of coronary, claudication and control samples 
analysis was not performed between any two of the disease type groups.  
235 
 
 
Key:  coronary,  claudication and  control samples. 
Figure A1.11 PCA scores plot for CPMG plasma data excluding glucose and lactate 
regions of “male, non-diabetic, never smoked” samples.  
 
Irrespective of how defined the cohort was through elimination of potential 
confounding factors in a step-wise manner, coronary, claudication and control 
samples could not be distinguished according to their metabolic profile. 
 
A1.3.2.2   Analysis of Other Sample Descriptors 
 
In addition to disease type, sex and smoking and diabetic statuses many other 
sample descriptors were recorded (Table A1.6). Whether these affected the 
positioning of samples in scores space and their potential relevance to disease type 
groups was investigated.  
 
For scores plots, samples were coloured according to data classified either by 
percentile or value classification (Table A1.6). Where values are commonly used in 
the medical profession to describe defined parts of the category, value classification 
for this study has been used, as for ankle brachial index (ABI) (Table A1.7) and body 
mass index (BMI) [weight (kg)/height (m2)] (Table A1.8). For percentile classification, 
as near as possible 20% of samples were in classes 1 to 5. Cholesterol, glucose, 
glycated haemoglobin, HDL, LDL and triglyceride values were recorded to one 
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decimal place so multiple values could occur resulting in non-exact percentile 
distributions.  
 
Table A1.6 Sample categories investigated with classification used in analysis. 
Category Data Classification 
ABI Percentile and Value 
Age Percentile 
BMI Percentile and Value 
Cholesterol Percentile 
Glucose Percentile 
Glycated Haemoglobin Percentile 
HDL Percentile 
LDL Percentile 
Triglycerides Percentile 
Percentile classification: as near as possible 20% of samples in classes 1 to 5 with 1 having 
the lowest level and 5 the highest level. 
 
Table A1.7 ABI classification for this study with corresponding indication of 
medical condition.(260) 
ABI Value Value Classification Indication of Medical Condition 
0.50-0.79 1 Moderate arterial disease 
0.80-0.89 2 Some arterial disease 
0.90-0.99 3 Acceptable 
1.00-1.19 4 Normal 
1.20+ 5 Abnormal blood vessel hardening 
 
Table A1.8 BMI classification for this study with corresponding weight 
category.(254) 
BMI Value Value Classification Weight Category 
<18.50 1 Underweight 
18.50-24.99 2 Normal 
25.00-29.99 3 Overweight 
>30.00 4 Obese 
Units: BMI = kg m-2. 
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Some separation was observed between triglyceride percentiles in PC 2 versus PC 1 
and PC 4 versus PC 2 scores plots (Figure A1.12 a and b, respectively) when all 
samples (data available for 72 samples) were included (four component model, 
R2X(cum) = 0.604 and Q2X(cum) = 0.417). Most of the class 5 samples (highest 20% 
of values) are clearly separated from samples with lower triglyceride values. 
Loadings plots (data not shown for PC 2 versus PC 1 due to similarity with Figure 
A1.7; PC 4 versus PC 2 shown in Figure A1.13) indicate class 5 samples have the 
highest lipid levels and generally a lower lipid level is associated with lower class 
value. Triglycerides are a type of lipid so connection between the two would be 
expected: NMR spectroscopy based metabolomics can provide an indication of the 
relative amount of triglyceride in blood plasma for larger data sets. In smaller data 
sets, i.e. “male, non-diabetic, non smoker” samples, a similar trend could not be 
observed. This provides an example of the need for balance between a well-defined 
cohort and suitable sample numbers.  
 
Previously, disease type groups had been tentatively separated (Figure A1.4) with 
lipids being important to the discrimination (Figure A1.5); triglyceride percentile 
classes were incorporated into the scores plot (Figure A1.14). It can be observed 
that all control samples (diamonds) except one are within the ellipse (brown) drawn 
to show positioning of many control samples whilst the t[3] range for coronary 
(triangles) and claudication (squares) samples is much greater despite all three 
disease type groups containing samples from the most extreme percentile classes. 
Speculatively, this could infer that patients who are not afflicted by coronary or 
claudication complications can regulate their metabolic profile better than some 
patients with similar lipid/triglyceride levels who are afflicted with blood vessel 
disease. 
 
Classes of other categories (Table A1.6) did not determine sample positioning in any 
PC combination of scores space and were not associated with disease type groups. 
PC 2 versus PC 1 scores plots for all samples and “male, non-diabetic, non-smoker” 
samples of the various categories are referred to in Table A1.9 along with 
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summaries of models. PLS-DA models, where generated, were not shown because 
Q2Y values were too small for the models to be considered reliable. 
 
a)  
b)  
Key: shape -  coronary,  claudication and  control samples, 
colour - class  1,  2,  3,  4 and  5.  
Figure A1.12 PCA scores plot for CPMG plasma data excluding glucose and lactate 
regions showing a) PC 2 versus PC 1 and b) PC 4 versus PC 2. Coloured according to 
percentile classification of triglyceride level (Table A1.6). R2X = 0.309, 0.129 and 
0.069, and Q2X = 0.268, 0.076 and 0.035 for PC 1, PC 2 and PC 4, respectively. 
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Figure A1.13 PCA loadings plot corresponding to the model displayed in Figure 
A1.12b). 
 
 
Key: shape -  coronary,  claudication and  control samples, 
colour - class  1,  2,  3,  4,  5 and  no data.  
Figure A1.14 PCA scores plot for plasma data including glucose and lactate regions 
showing PC 5 versus PC 3. Coloured according to percentile classification of 
triglyceride level (Table A1.6). R2X = 0.091 and 0.061, Q2X = 0.065 and 0.091 for PC 
3 and PC 5, respectively. Red, turquoise and brown coloured ellipses indicate areas 
occupied by many samples of coronary, claudication and control groups, 
respectively, and are for display only. 
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Table A1.9 Summary of models created using various sample descriptors (categories) as the class identifier. M, ND, NS   “male, non-diabetic, 
non-smoker” samples.  
Category Samples 
Included 
Number of 
Samples 
Figure PCA PLS-DA 
PCs R2X 
(cum) 
Q2X 
(cum) 
R2X of 
PC 2/PC 1 
Q2X of 
PC 2/PC 1 
PCs R2X 
(cum) 
R2Y 
(cum) 
Q2Y 
(cum) 
ABI All 70 Figure A1.15 a) and c) 3 0.549 0.425 0.330/0.128 0.290/0.110 0 / / / 
M, ND, NS 31 Figure A1.15 b) and d) 1 0.396 0.339 0.000/0.396 0.000/0.339 0 / / / 
BMI All 75 Figure A1.16 a) and c) 4 0.601 0.423 0.309/0.129 0.262/0.093 0 / / / 
M, ND, NS 33 Figure A1.16 b) and d) 2 0.493 0.344 0.370/0.124 0.309/0.050 0 / / / 
Age All 75 Plots not shown 4 0.601 0.423 0.309/0.129 0.262/0.093 2 0.424 0.116 0.008 
M, ND, NS 33 Plots not shown 2 0.493 0.344 0.370/0.124 0.309/0.050 0 / / / 
Cholesterol All 73 Plots not shown 4 0.604 0.397 0.309/0.130 0.266/0.097 0 / / / 
M, ND, NS 31 Plots not shown 2 0.500 0.348 0.374/0.126 0.314/0.049 0 / / / 
Glucose All 74 Plots not shown 4 0.602 0.396 0.308/0.130 0.267/0.088 1 0.278 0.050 0.003 
M, ND, NS 32 Plots not shown 2 0.496 0.348 0.370/0.126 0.312/0.052 0 / / / 
Glycated 
Haemoglobin 
All 72 Plots not shown 3 0.542 0.402 0.313/0.129 0.276/0.070 0 / / / 
M, ND, NS 32 Plots not shown 2 0.496 0.348 0.370/0.126 0.312/0.052 0 / / / 
HDL All 74 Plots not shown 4 0.602 0.396 0.308/0.130 0.267/0.088 0 / / / 
M, ND, NS 32 Plots not shown 2 0.496 0.348 0.370/0.126 0.312/0.052 0 / / / 
LDL All 70 Plots not shown 4 0.601 0.406 0.312/0.122 0.276/0.050 0 / / / 
M, ND, NS 30 Plots not shown 2 0.504 0.355 0.374/0.130 0.309/0.066 1 0.371 0.087 0.007 
2
4
0
 
 
 
a)  b)  
c)  d)  
Key: shape -  coronary,  claudication and  control, 
colour - class: a) and b)  1,  2,  3,  4 and  5, c) and d)  1,  2,  3,  4 and  5 
Figure A1.15 ABI: PCA scores plots for plasma data excluding glucose and lactate regions showing PC 2 versus PC 1 for a) and c) all samples 
and b) and d) “male, non-diabetic, non-smoker” samples. Coloured according to a) and b) percentile classification (Table A1.6) and c) and d) 
value classification (Table A1.7). 
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a)  b)  
c)  d)  
Key: shape -  coronary,  claudication and  control samples, 
colour – class: a) and b)  1,  2,  3,  4 and  5, c) and d)  1,  2,  3,  4 and  5  
Figure A1.16 BMI: PCA scores plots for plasma data excluding glucose and lactate regions showing PC 2 v. PC 1 for a) and c) all samples and 
b) and d) “male, non-diabetic, non-smoker” samples. Coloured according to a) and b) percentile classification (Table A1.6) and c) and d) 
value classification (Table A1.8). 
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A1.4   Conclusions 
 
The degree of chemical shift variation between samples is dependent on the 
reference compound. TSP, which has traditionally been used, has been shown to be 
inferior to acetate, glucose and lactate. Due to the readily resolvable nature of H1’ of  
α-glucose this was selected as the reference compound for all further work. 
 
Plasma spectra were dominated by diet dependent metabolites, namely glucose 
and lactate, and distinction between coronary, claudication and control samples 
was not present in the higher PCs. Tentative separation was visible in lower PCs 
based on lipid levels with the indication that levels were highest in coronary samples 
and lowest in claudication samples. Upon removal of glucose and lactate, separation 
between the three disease type groups was not visible. Through removal of 
samples, certain known confounding factors were accounted for such as sex, 
smoking and presence of diabetes. Samples from the optimum cohort in terms of 
retaining sufficient sample numbers, which was the “male, non-diabetic, non-
smoker” cohort, did not provide further information regarding differences between 
the groups. Consideration has to be made between reducing confounding factors 
whilst providing a suitable number of samples for analysis.  
 
Clinical laboratory recorded triglyceride levels corresponded to relative lipid levels 
as shown by scores and loadings plots for larger data sets therefore NMR 
spectroscopy based metabolomics could provide an indication of the relative 
amount of triglyceride levels in blood plasma. It was tentatively implied that for 
patients whose triglyceride levels were similar those not afflicted by coronary or 
claudication complications could regulate their metabolic profile better than some 
patients who were afflicted with blood vessel disease. 
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A1.5   Experimental Methods 
 
A1.5.1   NMR Sample Preparation 
 
Chemicals were purchased from Sigma-Aldrich Company Ltd. (Poole, Dorset, UK). 
NMR tubes (S-5-500-7, Norell) were purchased from GPE Scientific Ltd. (Leighton 
Buzzard, Bedfordshire, UK). 
 
A1.5.2   Samples for 1H-NMR Analysis 
 
Samples were stored at -80oC before defrosting at room temperature. Samples were 
centrifuged (Hettich Mikro 120 (C1204) Centrifuge, angle rotor E2384) at 12,009 g 
for 5 minutes. 350 µl of plasma supernatant was added to 408 µl of a 0.17% weight 
by volume solution of TSP in D2O. The mixture was vortexed for 8 s before 
transferring 600 µl to a 5 mm NMR tube. Samples not analysed immediately were 
stored at 4oC for a maximum of 1.5 hours. 
 
A1.5.3   NMR Analysis 
 
All 1H-NMR spectra were acquired on a Varian Unity Inova 500 spectrometer 
(Varian Inc., Palo Alto, California, USA) operating at 499.97 MHz proton frequency, 
at 20oC. Samples were loaded into the probe and left for 5 minutes to allow 
temperature equilibration. 
 
A1.5.3.1   CPMG Experiment 
 
The CPMG pulse sequence [RD – 90o – (τ – 180o – τ)n – acq] was used to obtain 
metabolic profiles for all plasma samples. The relaxation delay (RD) was 2 s, during 
which the water resonance was selectively saturated, τ was 1.5 ms and n was 150. 
For each spectrum 512 transients were collected into 16,384 pairs of data points 
with a spectral width of 8,000.00 Hz.  
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A1.5.4   NMR Spectral Processing 
 
All spectral data were processed using ACD Labs software 12.01 (Advanced 
Chemistry Development, Inc., (ACD/Labs), Toronto, Canada). An exponential line 
broadening of 1.applied to each FID prior to zero filling to 65,536 points and Fourier 
transformation. The resulting spectra were phased, baseline corrected and 
referenced (Table A1.10). 
 
Table A1.10 Reference Compounds Used  
Reference Compound Chemical Shift (ppm) 
TSP 0.000(142) 
Lactate 1.317(103) 
Alanine 1.463(103) 
Acetate 1.910(103) 
α-glucose 5.223(103) 
 
A1.5.5   Additional NMR Data Processing for Multivariate Statistical Analysis 
 
A1.5.5.1   Binning and Dark Regions 
 
Spectral binning was performed using ACD Labs software 12.01. The data set was 
integrated into fixed bins of 0.04 ppm.  
  
Prior to binning over the spectral range 0.141-0.998, several dark regions were 
created for spectra to exclude signals from subsequent multivariate analysis (Table 
A1.11). 
 
Table A1.11 Dark regions used for spectra.  
Dark Region (ppm) Excluded  Comment 
2.461-2.741 Citrate Possible contaminant from collection tube 
4.421-5.421 Water region Variable water suppression efficiency 
1.301-1.341  
4.061-4.141 
Lactate 
Excluded later to remove influence from 
statistical models 
3.181-3.941 Glucose 
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A1.5.6   Multivariate Statistical Analysis 
 
All multivariate statistical analyses were performed using SIMCA-P+ software, 
version 12.0.1.0 (Umetrics, Umeå, Sweden). This software was used to scale and 
mean centre the data. 
 
PCA and PLS-DA was performed. The predictive ability of the PLS-DA models was 
assessed by exclusion of a third of the samples and their class memberships 
predicted using models built from the remaining samples, where the samples were 
randomly allocated into three exclusion groups using a random number generator 
(Microsoft Excel 2007). Further validation was performed using permutation testing 
whereby the classes of samples were randomised and a PLS-DA model built. The R2Y 
and Q2Y values should be less than those generated for the original model, which 
were based on the real classifications. The maximum number of permutations 
permissible by the software was performed, 999.  
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Appendix 2: Gas Chromatography 
 
 
Figure A2.1 Calibration curve gradient of glycine (GLY) for all runs of standards 
against run order.  
 
 
Figure A2.2 Plot of IS area/total AA area against run order of 200 nmol ml-1 
standards that had different elapsed times between first and last runs: a) 
Standard VII, 6 h 30 min, b) Standard X, 23 h 55 min and c) Standard XI, 23 h 55 
min. 
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Figure A2.2 Continued. 
 
 
 
 
 
 
 
r² = 0.70 
6.60E-02 
6.70E-02 
6.80E-02 
6.90E-02 
7.00E-02 
7.10E-02 
7.20E-02 
7.30E-02 
7.40E-02 
7.50E-02 
1 2 3 
IS
 A
re
a/
To
ta
l A
A
 A
re
a 
x1
0
-2
 
Run Order of Standard X 
 
r² = 0.47 
6.60E-02 
6.70E-02 
6.80E-02 
6.90E-02 
7.00E-02 
7.10E-02 
7.20E-02 
7.30E-02 
7.40E-02 
1 2 3 
IS
 A
re
a/
To
ta
l A
A
 A
re
a 
x1
0
-2
 
Run Order of Standard XI 
b) 
c) 
249 
 
Table A2.1 Structure and retention times of AAs identifiable by GC analysis of 
plasma. 
AA Retention 
Time (minutes) 
Structure 
Full Name Abbreviation 
Alanine ALA 1.59 
 
Sarcosine SAR 1.65 
 
Glycine GLY 1.69 
 
α-Aminobutyric acid ABA 1.79 
 
Valine VAL 1.88 
 
β-Aminoisobutyric acid β-AIB 1.96 
 
Norvaline (internal 
standard) 
IS 2.00 
 
Leucine LEU 2.08 
 
allo-Isoleucine α-ILE 2.11 
 
 
250 
 
Table A2.1 Continued. 
Isoleucine ILE 2.14 
 
Threonine THR 2.34 
 
Serine SER 2.38 
 
Proline PRO 2.45 
 
Asparagine ASN 2.54 
 
Aspartic acid ASP 3.05 
 
Methionine MET 3.09 
 
Hydroxyproline HYP 3.22 
 
Glutamic acid GLU 3.39 
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Table A2.1 Continued. 
Phenylalanine PHE 3.43 
 
α-Aminoadipic acid AAA 3.68 
 
Glutamine GLN 4.01 
 
Ornithine ORN 4.37 
 
Lysine LYS 4.62 
 
Histidine HIS 4.80 
 
Tyrosine TYR 5.07 
 
Tryptophan TRP 5.36 
 
Cystine C-C 6.01 
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